University of Missouri, St. Louis

IRL @ UMSL
Dissertations

UMSL Graduate Works

6-15-2011

Development of New Strategies for Expeditious
Oligosaccharide Synthesis
Sophon Kaeothip
University of Missouri-St. Louis, sophonkaeothip@yahoo.com

Follow this and additional works at: https://irl.umsl.edu/dissertation
Part of the Chemistry Commons
Recommended Citation
Kaeothip, Sophon, "Development of New Strategies for Expeditious Oligosaccharide Synthesis" (2011). Dissertations. 432.
https://irl.umsl.edu/dissertation/432

This Dissertation is brought to you for free and open access by the UMSL Graduate Works at IRL @ UMSL. It has been accepted for inclusion in
Dissertations by an authorized administrator of IRL @ UMSL. For more information, please contact marvinh@umsl.edu.

Development of New Strategies for Expeditious
Oligosaccharide Synthesis

by
Sophon Kaeothip

A dissertation submitted in partial fulfillment
of the requirements for the degree of
Doctor of Philosophy (Chemistry)

University of Missouri - St. Louis
December 2010

Dissertation Committee
Prof. Alexei V. Demchenko, Ph. D. (Chairperson)
Prof. James S. Chickos, Ph. D.
Prof. Michael R. Nichols, Ph. D.
Prof. Rudolph E. K. Winter, Ph. D.

Abstract
Development of New Strategies for Expeditious Oligosaccharide Synthesis

Sophon Kaeothip
Doctor of Philosophy
University of Missouri - St. Louis
Prof. Alexei V. Demchenko, Chairperson

The important role that carbohydrates play in biology and medicine has been the
major incentive for devising new methods for chemical and enzymatic glycosylation. The
chemical approach to oligosaccharides involves multiple synthetic steps and the
development of new strategies that allow for streamlining the synthesis of these complex
biomolecules is a significant area of research.
The aim of this doctoral dissertation is to develop new reagents and efficient
methodologies for oligosaccharide synthesis. It was found that siver(I) tetrafluoroborate
can be used as a powerful activator of various glycosyl donors for oligosaccharide
synthesis. This study evolved into the development of a very effective orthogonal
strategy which allowed for the synthesis of a variety of oligosaccharide sequences with
moderate stereoselectivity.

Further studies showed that the improvement of

stereoselectivity of glycosylation can be achieved in two different modes. First, we
found that electron withdrawing protecting groups on the glycosyl acceptor can help to
obtain excellent α-stereoselectivity. Second, the stereoselectivity of glycosidation of
thioglycosides in the presence of bromine depends greatly on the anomeric orientation of

II

the leaving group. The mechanistic studies of this phenomenon were conducted using
high field NMR and the developed methodology was applied to the synthesis of a range
of therapeutically attractive carbohydrate-amino acid conjugates.
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CHAPTER I

Introduction

_________________________________________________________________

1

1.1

Introduction.

Complex

carbohydrates,

chemical

glycosylation,

and

conventional oligosaccharide synthesis
Carbohydrates are the most abundant biomolecules on Earth, nevertheless, their
chemistry and biology has been a “Cinderella” field. Our current knowledge about the key
roles of these fascinating natural compounds is not yet complete. However, thanks to the
explosive growth of the field of glycobiology in recent years, we already know that
carbohydrates are involved in a broad range of vital biological processes, fertilization,
anti-inflammation, immunoresponse, joint lubrication, antigenic determination, are only a
few to mention.1-4 Carbohydrates are also responsible for many damaging processes in
our cells - bacterial and viral infections, development and growth of tumors, metastasis,
tissue rejection, etc.5 This area of science has stimulated major scientific efforts in the
beginning of 21st century primarily due to the fact that many of these processes are
directly associated with deadly diseases, such as AIDS, cancer, meningitis, septicemia,
hepatitis, and malaria.
The elucidation of the exact mechanisms of the disease progression would be
significantly facilitated if we had comprehensive knowledge of the structure,
conformation, and properties of the associated carbohydrate molecules. Although
glycoscientists have learned to selectively cleave, isolate, purify, and characterize certain
classes of naturally occurring glycostructures, the availability of pure natural isolates in
sufficient quantities remains low. In order to ensure the availability of pure complex
carbohydrates, their chemical or enzymatic synthesis is of prime importance. It is well
appreciated that a reliable and efficient synthesis could lead to useful glycostructures for
structural studies and determination of their biological roles. In addition, the synthetic
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approach can provide significant quantities and natural carbohydrates or their unnatural
mimetics that are often required for investigating their therapeutic and diagnostic
applications. Pharmaceutical and biotechnology companies have already demonstrated an
interest in producing complex oligosaccharides or glycoconjugates, however, examples
including heparin and its analogs,6,7 oligosaccharide antibiotics,8,9 carbohydrate-based
vaccines,10-14 and other therapeutic agents15-17 are still rare. Therefore, the development of
stereoselective methods and efficient strategies for the synthesis of complex
carbohydrates is critical to the emerging areas of glycosciences.
The monomeric units in complex carbohydrates are connected via glycosidic
linkages. The glycosidic linkage is obtained by means of the glycosylation reaction,
arguably the most important and challenging reaction in carbohydrate chemistry. A
typical chemical glycosylation is based on the nucleophilic displacement of a leaving
group (LG) on the glycosyl donor by a hydroxyl moiety of the glycosyl acceptor (Scheme
1). The remaining hydroxyls of both units are temporarily masked with protecting groups.
In spite of significant progress made in the area of glycoside synthesis, the necessity to
form either a 1,2-cis or a 1,2-trans-glycosidic bond with complete stereoselectivity
remains the main reason chemical O-glycosylation is ranked among the most challenging
problems of modern synthetic chemistry. The achievement of high yields and complete
stereocontrol is difficult due to the complexity of the glycosylation process that often
proceeds along with a variety of side reactions. Various factors such as temperature,
pressure, structure, conformation, solvent, promoter, steric hindrance, or leaving group
can affect the stereoselectivity of glycosylation. Some of these factors influence the
stereoselectivity dramatically, others only to certain extent;18,19 undoubtedly, the
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neighboring substituent at C-2 is one of the major players. If the use of a base-labile
ester-protecting groups is permitted, 1,2-trans glycosides can be prepared with the
assistance of a neighboring participating group.20,21 These glycosylations proceed
primarily via a bicyclic acyloxonium ion intermediate that can only accept the top face
nucleophilic attack resulting in the stereoselective formation of a 1,2-trans glycoside.
Many traditional glycosyl donors such as halides, thioglycosides, or O-imidates provide
excellent stereoselectivity and high yields. However, if the use of an acyl participating
group is impractical or impossible, the synthesis of 1,2-trans glycosides becomes
cumbersome, which has stimulated the development of a number of alternative
approaches.

Scheme 1.1 Traditional linear oligosaccharide synthesis.
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Another important factor affecting the outcome of glycosylations is the nature of
the anomeric leaving group. As a result, a large number of glycosyl donors have been
developed.22,23 In addition to traditionally used chlorides or bromides,24,25 more recent
glycosyl donors such as Schmidt’s O-trichloroacetimidates,26 Mukaiyama’s fluorides,27,28
alkyl/aryl thioglycosides pioneered by Ferrier, Nicolaou and Garegg,29,30 Fraser-Reid’s
O-pentenyl glycosides,31,32 and Danishefsky’s glycal-epoxide system33 have become
valuable alternatives to the classic approaches.34
Moreover, a single-step glycosylation is not the only challenge researchers
working on oligosaccharide synthesis face. Traditional linear approaches for the synthesis
of oligosaccharides involve extensive protecting group manipulations between each
glycosylation step.35 Such additional manipulations increase the number of total synthetic
steps and decrease the efficiency of the oligosaccharide assembly as reflected in dramatic
drop in yield. This called for revisiting existing linear strategies for oligosaccharide
synthesis and some significant improvements have already emerged.

1.2

Expeditious oligosaccharide synthesis: selective and chemoselective concepts
More recent strategies for oligosaccharide synthesis are typically based on the

selective activation of one leaving group over another.35,36 These expeditious approaches
significantly shorten oligosaccharide assembly by minimizing the need for protecting
group manipulations between glycosylation steps. Nicolaou’s selective activation,27
Fraser-Reid’s armed-disarmed approach,37 Danishefsky’s glycal assembly,33 Ogawa’s
orthogonal technique,38,39 Roy’s40 and Boons’41 active-latent concept, Wong’s and Ley’s
programmable strategies,42-45 are only few to mention.
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One of the most conceptually attractive and practically efficient procedures,
Fraser-Reid’s armed-disarmed approach, is based on the principle of chemoselectivity.
According to this principle, a benzylated (electronically activated, armed) glycosyl donor
is chemoselectively activated over the acylated (electronically deactivated, disarmed)
glycosyl acceptor bearing the same type of leaving group (Scheme 2).46,47 The
availability of a suitable mild promoter is essential to effectively differentiate the
reactivity levels of the armed and disarmed species. At this stage, a 1,2-cis-linked
disaccharide is preferentially obtained due to the general use of the ether-type arming
substituent, a non-participating group. The obtained disaccharide can then be used for
1,2-trans glycosylation directly in the presence of a more potent promoter that can
activate the disarmed leaving group. Initially developed for O-pentenyl glycosides,32,47
this approach works with many other classes of stable glycosyl donors.35 The armeddisarmed strategy thus offers an efficient tool for the synthesis of oligosaccharides with
cis-trans glycosylation patterns. While the synthesis of cis-cis-linked derivatives is also
possible (after additional reprotection OAc→OBn), the classic armed-disarmed strategy
is not applicable to the synthesis of other oligosaccharide patterns, which significantly
limited its versatility. This resulted in a number of improvement and various reactivity
levels as well as inverse procedures that expand the scope of the armed-disarmed
approach.

6

Scheme 1.2 Chemoselective activation strategy.

In principle, the use of the selective activation concept offers a more flexible
oligosaccharide sequencing because this approach does not rely on the nature of the
protecting groups. Instead, it requires a few leaving groups (LGa, LGb, LGc, etc) that can
be sequentially activated. Unfortunately, this relatively simple concept is limited to the
number of available leavings groups compatible with the principle of sequential
activation. This in part can be addressed by related semi-orthogonal and orthogonal
strategies (vide infra).

Scheme 1.3 Selective activation strategy.

This chapter is dedicated to a thorough overview of strategies making use of the
principle of selective activation of one leaving group of another. The accumulated
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knowledge has eventually translated into more advanced semi-orthogonal and orthogonal
strategies that are also discussed below.

1.3

Selective activation
1.3.1

Glycosyl bromides and chlorides

The application of glycosyl bromides and chlorides as an effective glycosyl donor
in the glycosylation reaction was first introduced by Michael followed by more versatile
approach developed by Koenigs and Knorr.48 Being relatively unstable, glycosyl chloride
and bromide can only be selectively activated over other, more stable leaving groups,
such as thio, seleno and n-pentenyl glycosides. The first application of glycosyl bromide
in selective glycosylation strategy was reported by Zen49 in the synthesis of isomaltose,
isomaltotetraose and isomaltooctaose. Zen demonstrated that glycosyl bromide can be
selectively activated over a thioglycoside acceptor in presence of silver carbonate
(AgCO3). This principle is illustrated by a two-step synthesis reported by Lonn (Scheme
1.4).50,51 Accordingly, fucosyl bromide 1.1 was selectively activated over the S-ethyl
leaving group of glycosyl acceptor 1.2. The resulting disaccharide 1.3 is then coupled
directly with glycosyl acceptor 1.4. This was achieved in the presence of MeOTf and led
to the formation of trisaccharide 1.5. This example clearly illustrated the advantage of the
selective activation strategy over the traditional approach that would imply additional
protecting/leaving group manipulations after the first coupling step.
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Scheme 1.4 Selective activation of glycosyl bromide over thioglycoside.

Stronger promoters for bromide activation, such as AgOTf, can be also
successfully employed as required.52,53 For example, as reported by Oscarson et al., the
synthesis of a tetrasaccharide of Vibro cholerae O139 began with AgOTf-promoted
activation of bromide 1.6 over S-ethyl glycosyl acceptor 1.7 (Scheme 1.5).54 The
resulting disaccharide 1.8 was then subjected to a two-step deprotection sequence, which
brings the elements of a conventional strategy. The resulting diol 1.10 is then
glycosylated with glycosyl bromide 1.11 to afford tetrasaccharide 1.12. All three
glycosidic linkages were constructed using selective activation strategy although some
interim protecting group manipulations were necessary.
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Scheme 1.5 Selective activation approach to the synthesis of a tetrasaccharide repeating
unit of V. cholerae O139.

Kovac et al. showed that glycosyl bromide and chloride can be selectively
activated with AgOTf in presence of anomeric actetate.55 Pinto et al. described selective
activation of glycosyl bromide donors over phenyl selenoglycoside acceptors, which was
realized in the presence of AgOTf and γ-collidine.56 Selective activation of glycosyl
bromide over n-pentenyl glycoside acceptor in presence of AgOTf was demonstrated in
the

synthesis

of

an

glycophosphatidylinositol.58

analog57

elicitor-active
Mukaiyama

and

and

in

Kobashi

the

synthesis

introduced

of
tri(1-

pyrrolidino)phosphine oxide as an activator for glycosyl bromide suitable for conducting
selective activations.59 The activation takes place via glycosyl phosphonium bromide
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intermediate. Scheme 1.6 illustrates the activation of glycosyl bromide 1.13 over
thioglycoside 1.14 and glycosyl fluoride 1.15 leading to the respective disaccharides 1.16
and 1.17 in good yields.

Scheme 1.6 Tri(1-pyrrolidineo)phosphine oxide as the activator of glycosyl bromides in
selective activations.

Glycosyl chlorides can be also selectively activated with AgOTf in presence of
thioglycosides. An example of this activation was employed in the synthesis of
dodecasaccharide described by Ito and co-worker.60,61 Selective activation of glycosyl
chloride over glycosyl fluoride was also employed as depicted in Scheme 7.62,63 Thus,
sialyl chloride donor 1.18 was activated over sialyl fluoride acceptor 1.19 to afford a
2→8-linked disialoside in 49% yield.
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Scheme 1.7 Selective activation of glycosyl chloride over glycosyl fluoride.

Glycosyl iodides were also developed as an extension of the glycosyl chlorides
and the glycosyl bromide.64 The first glycosyl iodide was reported in 1910 by Fischer,65
but it was mainly due to the efforts by Gervay-Hague et al. that glycosyl iodides found
broad application in glycoside and oligosaccharide synthesis, including that via selective
activation.66,67 The glycosidation of glycosyl iodide 1.21 with glycosyl acetate acceptor
1.22 under neutral conditions (TBAI/DIPEA) gave disaccharide 1.23 with complete αstereoselectivity (Scheme 1.8). Another example of glycosyl iodide utility is selective
activations was reported by Oscarson.68 Glycosyl iodide donor 1.21 was activated over
thioglycoside acceptor 1.24 in the presence of triphenylphosphine oxide (Ph3PO) to
afford the corresponding disaccharide 1.25 with complete α-stereoselectivity.
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Scheme 1.8 Selective activation of glycosyl iodide 1.21 over glycosyl acetate 1.22 and
thioglycoside 1.24.

1.3.2

Glycosyl fluorides

Glycosyl fluorides were introduced by Mukaiyama et al. as glycosyl donors that
can be activated with fluorophilic activator SnCl2-AgClO4.69 Since then, glycosyl
fluorides have become useful building blocks for oligosaccharide synthesis because they
can be used both as glycosyl donors and glycosyl acceptors. It was established that the
glycosyl fluorides are typically stable under basic as well as weakly acidic conditions
required for protecting group manipulations. Glycosyl fluorides are also able to withstand
typical conditions required for the activation of other anomeric halides (vide supra).
Nicolaou and his co-workers extensively studied the application glycosyl fluorides in
oligosaccharide and natural product synthesis.70,71 It was proven that glycosyl fluorides
can be activated in the presence of thioglycosides with a combination of AgClO4 and
SnCl2. An example of the total synthesis of the tumor-associated Lex family of
glycosphingolipids is depicted in Scheme 1.9.72
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Scheme 1.9 Selective activation utilizing glycosyl fluoride as glycosyl donor.

As depicted in Scheme 1.10, a similar concept was applied to the synthesis of a
tetrasaccharide containing two consecutive sialic acid units, which were also connected
by selective activation (vide supra). Thus, the activation of glycosyl donor 1.20 over
thioglycoside acceptor 1.32 was achieved in presence of AgOTf/SnCl2 and resulted in the
formation of tetrasaccharide 1.33.62,63
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Scheme 1.10 Selective activation utilizing glycosyl fluoride as glycosyl donor.
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In 2002, Mukaiyama et al. reported that a catalytic amount of protic acid, such as
TfOH, HClO4 or C4F9SO3H is also suitable for the activation of fluoride donors over
thioglycoside acceptors.73 Danishefsky demonstrated that glycals also can tolerate
activation of glycosyl fluorides in the presence of Sn(OTf)2.74,75 Nicolaou and co-workers
have described a related glycosylation strategy based on two-stage activation concept,
whereby thioglycoside is first converted into a glycosyl fluoride, which is then used as a
glycosyl donor for coupling with a thioglycoside acceptor.71,76-80

1.3.3

O-Linked glycosyl donors

1.3.3.1 Hemiacetals (1-OH derivatives)
The direct glycosidation of 1-hydroxyl sugar is undoubtedly the most direct
method of glycosylation. Reported by Fischer in 1901, this general approach has
undergone a few stages of modifications and conceptual adjustments, and today, the
dehydrative approach is arguably the most commonly used in application to
oligosaccharide synthesis. In 1976, Leroux and Perlin developed the direct dehydrative
glycosylation using triflic anhydride in the presence of a sterically hindered base, γcollidine, and Bu4NBr81,82 The reaction proceeded via a stepwise activation of glycosyl
donor 1.34 via the formation of the anomeric triflate followed by glycosyl bromide
intermediates. Resultantly, glycosylation of glycosyl acceptor 1.35 bearing an anomeric
acetate group afforded disaccharide 1.36 in 60% yield (Scheme 1.11a).
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Scheme 1.11 Selective activation of hemiacetal over glycosyl acetate (a) and
thioglycoside (b).

In last few years, Gin and co-workers have developed a sulfonium-based
electrophile activation of hemiacetal donor with treatment of Ph2SO and Tf2O. The in situ
formation of the highly reactive sulfonium bistriflate provided the formation of the
activated anomeric oxosulfonium intermediate. Van der Marel et al. then utilized the
diphenyl

sulfoxide

protocol

for

selective

glycosylation

of

hemiacetal

with

thioglycosides.83,84 Thus, Ph2SO/Tf2O-mediated dehydrative condensation of 1-hydroxyl
donor 1.37 with thioglycoside 1.38 afforded disaccharide 1.39 in 91%. This approach was
then extended to the synthesis of heparin oligosaccharide (vide infra).84

1.3.3.2 Acyl and carbonyl derivatives
Advantages of the glycosyl ester donors in the carbohydrate synthesis are their
easy preparation and relative chemical stability. The most representative anomeric
functional group in this area is the acetyl group. In general, Lewis acids (SnCl4, FeCl3,
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BF3.OEt2, TsOH) are used as promoters to activate glycosyl esters. To date, several
glycosyl esters have been developed as efficient glycosyl donors, particularly for the
synthesis of thioglycosides and glycosylation of simple alcohols. However, a number of
applications to oligosaccharide synthesis via selective activation have also emerged.
Below is a brief survey of relevant applications. Mukaiyama et al. utilized a
preactivation-based glycosidation of glycosyl acetate 1.40 using iodotrimethylsilane
followed by the addition of thioglycoside glycosyl acceptor 1.41 and phosphine oxide
(Scheme 1.12a).85 This glycosylation provided disaccharide 1.42 in good yields and
high α-selectivity.

Scheme 1.12 Selective activation of glycosyl acetate 1.40 (a), carbonate 1.43 (b), and
ortho-alkynylbenzoate 1.46 (c) over thioglycoside acceptors.
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A example from work reported by Mukaiyama et al. involves selective activation
of anomeric carbonate 1.43 over thioglycosyl acceptor 1.44 in the presence of
TrB(C6F5)4).86,87 As depicted in Scheme 1.12b, the requisite disaccharide 1.45 was
isolated in a nearly quantitative yield. Recently, Yu et al. introduced orthoalkynylbenzoates as efficient glycosyl donors, which can be activated with catalytic
amount of Ph3PAuOTf.88 The utility of glycosyl donor 1.46 was demonstrated selective
activation of thioglycoside acceptor 1.47 to afford the disaccharide 1.48 (Scheme 1.12c).

1.3.3.3 O-Imidates
Glycosyl trichloroacetimidates, that over the years have become the most
commonly used glycosyl donors, were introduced by Schmidt and co-workers. These are
relatively unstable derivatives, and their glycosidation can be readily promoted by the
catalytic amount of a mild Lewis acid. The selective activation of trichloroacetimidates
over other glycosyl donors can be straightforwardly executed with TMSOTf89 or BF3OEt2.90 For example, as a part of the synthesis of glycolipid of Mycobacterium
smegmatis, TMSOTf-promoted coupling of trichloroacetimidate 1.49 and thioglycoside
acceptor 1.50 afforded β(1→4) linked trisaccharide 1.51 in 71% yield (Scheme 1.13a).89
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Scheme 1.13 Glycosyl trichloroacetimidates in oligosaccharide synthesis via selective
activation over thioglycoside 1.50 (a), n-pentenyl glycoside 1.53 (b) and propargyl
glycoside 1.56 (c).

The use of TESOTf for selective activation was also demonstrated in the
glycosidation of glycosyl trichloroacetimidate donor with selenoglycoside acceptor, as
described by Pinto et al.56 A number of syntheses involving the activation of
trichloroacetimidates over O-pentenyl glycosides also emerged.91-93 For example, towards
the synthesis of proteoglycan linkage region, trichloroacetimidate glycosyl donor 1.52
was selectively activated over with n-pentenyl glycosyl acceptor 1.53 in the presence of
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TESOTf. As depicted in Scheme 1.13b, disaccharide 1.54 was isolated in 89% yield.92
Recently, Mukhopadhyay et al. showed that H2SO4-silica can be used as an activator to
selectively activate trichloroacetimidate disaccharide donor 1.55 over propargyl glycosyl
acceptor 1.56 leading to trisaccharide 1.57 in 91%.94
Similar glycosyl donors, (N-phenyl)trifluroacetimidates introduced by Yu and coworkers95 can also be selectively activated over a range of glycosyl acceptors bearing
stable anomeric leaving groups. For example, as reported by Seeberger et al.96 activation
of (N-phenyl)trifluoroacetimidate donor 1.58 over n-pentenyl glycosyl acceptor 1.59 was
accomplished in the presence of TMSOTf (Scheme 1.14a). The resulting tetrasaccharide
1.60 was isolated in 80% yield and served as a precursor towards the synthesis of the
repeating unit of Bacillus Anthracis cell wall polysaccharide.96

Scheme 1.14 Selective activation of (N-phenyl)trifluroacetimidate 58 over n-pentenyl
glycoside 59 (a) and sequential activation of trichloroacetimidate 61 followed by the
activation of (N-phenyl)trifluroacetimidate 62 (b).
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Iadonisi et al. demonstrated that the reactivity of glycosyl trichlro- and (Nphenyl)trifluoroacetimidates can be differentiated.97 It was found that a mild promoter,
such as Yb(OTf)3, allows for selective activation of glycosyl trichloroactimidate building
block 1.61 over glycosyl (N-phenyl)trifluoroacetimidate 1.62 (Scheme 1.14b). It should
be noted that since both glycosyl donor and glycosyl acceptor bear the same protecting
groups, the nature of this activation is clearly selective. The resulting disaccharide is then
coupled with glycosyl acceptor 1.63 in a one-pot manner. This was affected by using
additional quantities of the promoter and led to the formation of trisaccharide 1.64 in
40% yield over 2 steps.
Mukaiyama and co-workers reported selective activation of cyclic imidate donor,
6-nitro-2-benzothiazoate 1.65 over thioglycoside 1.66 or glycosyl fluoride acceptor
1.15.98 As depicted in Scheme 1.15, these HB(C6F5)4-catalyzed selective activations
resulted in the formation of disaccharides 1.67 and 1.68, respectively, in good yields.

Scheme 1.15. Selective activation of 6-nitro-2-benzothiazoate 1.65 over thioglycoside
1.66 and glycosyl fluoride 1.15.
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1.3.3.4 O-P derivatives
Several glycosyl donors possessing a phosphorus atom in the leaving group at the
anomeric center have also been investigated. Diethyl and dibenzyl glycosyl phosphites
independently introduced by Schmidt and Wong, respectively, have found a wide
application in glycoside and oligosaccharide synthesis. The activation of glycosyl
phosphite requires only catalytic of TMSOTf (usually 10-20%), which allows for
potential application in selective activations over a broad range of leaving groups,
similarly to that of O-imidates (vide supra). Thus, the selective activation of glycosyl
phosphites over thioglycoside acceptors affected in the presence of TMSOTf was also
reported.99,100 For example, Nagorny demonstrated that the coupling of sialyl phosphite
donor 1.69 and thioglycoside acceptor 1.70 was accomplished using TMSOTf as a
promoter. The resultant trisaccharide product was obtained as a 3.5:1 mixture of anomers,
which was acetylated and purified to furnish trisaccharide 1.71 as a pure α-anomer.100
Danishefsky demonstrated that the coupling of glycosyl phosphites with glycals can be
affected in the presence of TMSOTf.101
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Scheme 1.16 Selective activation of glycosyl phosphite over thioglycoside (a) and
phosphorodiamidate (b).

Further expansion emerged with the development of glycosyl diphenyl
phosphates,102

glycosyl

diphenylphosphineimidates,103

and

glycosyl

phosphoroamidates.104 Towards the synthesis of ganglioside GM3, sialyl phosphite 1.72
could be selectively activated over phosphorodiamidate acceptor 1.73 in the presence of
TMSOTf, BF3-OEt2 or TfOH.105 As depicted in Scheme 1.16b, the disaccharide 1.74 was
isolated in excellent yield after fine-tuning of the reaction conditions.
In 2001, Seeberger and co-workers reinvented the use of glycosyl phosphates as
glycosyl donors.106,107 TMSOTf, TBSOTf, or BF3.OEt2 were all proved to be suitable
promoters for the activation of glycosyl phosphates, also in oligosaccharide synthesis via
selective activations. For example, selective activation of glycosyl phosphate 1.75 over
thioglycoside acceptor 1.76 in the presence of TMSOTf resulted in the formation of
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disaccharide 1.77 in 96% yield (Scheme 1.17). Similarly, glycosyl phosphate 1.78 was
activated over n-pentenyl glycosyl acceptor 1.79 that resulted in the formation of
disaccharide 1.80 in 82% yield.

Scheme 1.17 Glycosyl phosphate in selective activation reported by Seeberger et al.

Along similar lines, Mukaiyama et al. glycosyl diphenylphosphinites as a
glycosyl donors.85 It was noted that this donor can be selectively activated over
thioglycoside and glycosyl fluoride acceptors in the presence of MeI.

1.3.3.5 Transglycosylation (n-pentenyl, propargyl, hetaryl)
The use of n-pentenyl glycoside as glycosyl donors, was introduced by FraserReid in 1988.108 The activation of the leaving group is based on an electrophilic reagent,
most commonly in the presence of IDCP, NIS/TfOH or NIS/TESOTf. Since these are
essentially the same activation conditions as those for the activation of more common
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thioglycosides, the use of n-pentenyl glycosides as glycosyl donors in selective
activations is rare. For example, it was found that n-pentenyl glycoside 1.81 could be
selectively activated with IDCP over disarmed thioglycoside 1.82 (Scheme 1.18a).109
This coupling needs the additional enforcement by the electronic effects as only armed npentenyl glycoside could be activated over disarmed thioglycoside. Lopez et al.
demonstrated that n-pentenyl glycosides can be selectively activated over glycosyl
fluoride acceptors (vise infra).110 More recently, Hotha et al. paired n-pentenyl glycoside
with propargyl glycosides for selective glycosylation.111 It was observed that n-pentenyl
glycoside 1.84 could be activated over propargylated glycosyl acceptor 1.85 in the
presence of NIS/TMSOTf (Scheme 1.18b). Resultantly, disaccharide 1.86 was obtained
in 68% yield propargyl disaccharide in moderate yield.

Scheme 18. Application of n-pentenyl glycosyl donors in selective glycosylation
strategy.
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The utility of 3-methoxy-2-pyridyl glycoside as a glycosyl donor in selective
glycosylations was described by Hanessian et al.112 As depicted in Scheme 1.19a, 3methoxy-2-pyridyl glycosyl donor 1.87 was selectively activated over thioglycoside
acceptor 1.88 in the presence of Cu(OTf)2 and the resulting disaccharide 1.89 was
obtained in 75% yield. Very recently, Hotha described that propargyl glycoside 1.90 can
be selectively activated over n-pentenyl glycoside 1.91 in the presence of AuBr3 at
65°C.111 As depicted in Scheme 1.19b, disaccharide 1.92 was isolated in 65 % yield.
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Scheme 1.19 Application of 3-methoxy-2-pyridyl (a), and propargyl glycosides (b) in
selective activations.

Chenault et al. discovered that isopropenyl glycosides can be activated over npentenyl glycosides in the presence of TMSOTf.113 Jensen and co-workers reported a
glycosylation method employing methyl 2-hydroxy-3,5-dinitrobezoate glycosides
(methyl 3,5-dinitrosalicylate, DISAL) as a glycosyl donors.114 DISAL glycosyl donor
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was applied to the synthesis of starch-related linear hexasaccharide whereas DISAL
donor can be activated over thioglycoside acceptor in the presence of LiClO4 and Li2CO3
as the promoter system.115 Kim et al. discovered that 2-(benzyloxycarbonyl)benzyl
(BCB)

glycosides

are

perfectly

stable,

whereas

the

corresponding

2-

(hydroxycarbonyl)benzyl (HCB) counterparts can be activated in presence of Tf2O and
DTBMP.75

This

phenomenon

was

applied

to

selective

activation

of

2-

(hydroxycarbonyl)benzyl donor over 2-(benzyloxycarbonyl)benzyl acceptor. This
activation, however, was performed using pre-activation conditions under which HCB
was first treated with DTBMP (30 min), followed by the treatment with Tf2O. After that,
BCB glycosyl acceptor was added, therefore, formally this cannot be classified as the
selective activation.

1.3.4

S-linked glycosyl donors

1.3.4.1 Sulfoxides, thiocyanates, xanthates, etc.
Glycosyl sulfoxides prepared from the corresponding thioglycosides via
oxidation,116 can be glycosidated in the presence of trifluoromethanesulfonic
anhydride.117 In 1994, van Boom et al. reported that TMSOTf and triethylphosphite
(TEP) is an effective promoter system for the selective activation of phenylsulfenyl
glycosides over phenylthioglycoside acceptors.118 The synthesis of antigens Lea, Leb and
Lex utilizing the glycosyl sulfoxide method was reported by Kahne (Scheme 1.20).119
Herein, Tf2O in presence of 2,6-di-tert-butyl-4-methylpyridine (DTBMP) was used as
activator. Thus, glycosidation of sulfoxide 1.93 over thenylthio glycoside 1.94 resulted in
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the formation of disaccharide 1.95 in 86% yield. The latter was converted into a glycosyl
acceptor 1.96, which was subjected to another round of selective glycosylation with
glycosyl sulfoxides 1.97. The resulting trisaccharide 1.98 was obtained in 95% yield.
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Scheme 1.20 Utilizing sulfoxide glycoside in selective activation as a part of the
synthesis of Lea antigen.

Kochetkov and co-workers showed that glycosyl thiocyanates can be selectively
activated over the 6-O-trityl thioglycoside acceptor.120 As depicted in Scheme 1.21a,
thiocyanate 1.99 was selectively activated over thioglycoside 1.100 in the presence of
triphenylmethylium perchlorate (TrClO4) as an activator. The resulting disaccharide
1.101 was obtained in 82% yield. Fügedi et al. introduced glycosyl 1piperidinecarbodithioates as glycosyl donors that can be activated in the presence of
AgOTf or TMSOTf.121 As depicted in Scheme 1.21b, selective activation of 1piperidinecarbodithioate donor 1.102 over thioglycosides acceptor 1.103 was affected in

28

the presence of AgOTf and resulted in the formation of disaccharide 1.104. Along similar
lines,

condensation

of

pentafuranosyl

dithiocarbamate

with

5-nitro-2-pyridyl

thioglycoside in the presence of NIS/TfOH was described by Bogusiak and Szeja.122

Scheme 1.21 Selective glycosidation of thiocyanate (a) and 1-piperidinecarbodithioate
(b) over thioglycoside acceptors.

1.3.4.2 Thioimidates
The first wave of glycosyl thioimidates, compounds with a generic leaving group
SCR1=NR2,

included

benzothiazolyl,123

pyridin-2-yl,124-126

pyrimidin-2-yl,124,127

imidazolin-2-yl,124 and 1’-phenyl-1H-tetrazolyl.128 Although all of these derivatives have
been tested as glycosyl donors and promising results have been obtained, the application
of this class of compounds to selective activations emerged only much later. A few years
ago, Demchenko et al. found that S-benzoxazolyl (SBox) and S-thiazolinyl (STaz)
glycosides were sable toward many harsh reaction conditions associated with protective
group manipulations.129,130 In addition, these thioimidates could be glycosidated under a
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range of mild reaction conditions and provided excellent anomeric stereoselectivity –
important traits for both glycoside synthesis and oligosacccharide assembly. The
particular versatility of thioimidates derives from the different modes that can be used for
their activation. Activations can take place either directly via the anomeric sulfur or
remotely via the nitrogen.131,132 Further studies revealed that SBox and STaz glycosides
can be selectively activated over other classes of leaving groups. For example, AgBF4 –
promoted activation of SBox glycoside 1.105 over n-pentenyl glycoside acceptor 1.106
resulted in the formation of disaccharide 1.107 in 86% yield (Scheme 1.22a).133
Similarly, De Meo and Parker described that the SBox sialyl donor 1.108 can be activated
over SEt glycosyl acceptor 1.109 in the presence of AgOTf.134 As shown in Scheme
1.22b, the resulting disaccharide 1.110 was obtained in 89% yield.
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Scheme 1.22 SBox glycosides in selective activation strategy.
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STaz glycosyl donor 1.111 was glycosidated selectively over thioglycoside
acceptor 1.112 in the presence of AgBF4.133 As depicted in Scheme 1.23a, disaccharide
1.113 was isolated in 89% yield. SBox glycosyl donor 1.114 could be also selectively
activated over STaz acceptor 1.115 in the presence of Bi(OTf)3 to afford disaccharide
1.116 in 69% yield (Scheme 1.23b).132

Scheme 1.23 STaz glycosides as glycosyl donors and acceptors in selective activations.

1.3.4.3 S-Alkyl and aryl glycosides
Alkyl and aryl thioglycosides have been widely studied as versatile building block
for oligosaccharide synthesis due to their high chemical stability. They are also good
intermediates to be transformed into a range of other glycosyl donors and can act as
acceptors in glycosylation reactions, which make thioglycosides suitable for use in
chemoselective, selective and iterative glycosylations. As shown by Ogawa et al.,
selective activation of thioglycosides over glycosyl fluorides can be executed in the
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presence of NIS and AgOTf as a promoter system.38 In addition, other promoters
including NIS/TfOH,135 MeOTf,60,61 and DMTST136,137 are also capable of the selective
activation of thioglycosides over fluorides. For example, selective activation of
thioglycoside 1.117 over fluoride acceptor 1.118 led to the formation of trisaccharide
1.119 in 85% yield (Scheme 1.24a).137 Selective activation of thioglycoside 1.120 over Sthiazolinyl glycosyl acceptor 1.115 could be affected in the presence of NIS in
combination with a catalytic amount of TfOH.129 As shown in Scheme 1.24b, this
coupling resulted in the formation of disaccharide 1.116. STaz glycosides can be also
activated in the presence of the same activators, but this requires at least stoichiometric
amount of TfOH.

Scheme 1.24 Selective of thioglycosides over glycosyl fluoride (a), S-thiazolinyl (b),
and n-pentenyl (c) glycosyl acceptors.
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Boons reported that the glycosidation of thioglycoside 1.121 with di-O-trityl
pentenyl glycosyl acceptor 1.122 can be achieved in the presence of MeOTf.138 As shown
in Scheme 1.24c, trisaccharide 1.123 was obtained in 96% yield. The regioselectivity
observed is due to the observation reported by Kochetkov et al. that trityl ethers invert the
reactivity of alcohols towards glycosylation.139 Boons and co-workers also developed as
interesting concept for oligosaccharide synthesis by demonstrating that the increase of
steric hindrance around the active site of the leaving group has a dramatic effect on the
leaving group ability.140 Thus, it was shown that an S-ethyl glycoside can be selectively
activated over dicyclohexylmethyl thioglycoside in the presence of NIS/TMSOTf at low
temperature.
In the development of 4-acetoxy-2,2-dimethylbutanoate as a novel protecting
group for oligosaccharide synthesis, Ensley demonstrated that the activation of
thioglycosides over 1-O-acyl glycosyl acceptor can be performed in the presence of
NIS/AgOTf.141 It was also reported that glycals are stable under MeOTf-promoted
activation of thioglycosides.142 Recently, it was reported that S-tolyl rhamnopyranoside
1.124 can be selectively activated over propargyl glycosyl acceptor 1.125 in the presence
of NIS/H2SO4-silica.94 As shown in scheme 1.25, the resulting disaccharide 1.126
obtained in 87% yield, was converted to glycosyl acceptor 1.137. The latter was then
subjected to glycosylation with S-tolyl glycosyl donor 1.128 under the same reaction
conditions. This sequence resulted in the formation of trisaccharide 1.129 related to the
cytotoxic triterpenoid saponin in 83% yield.
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Scheme 1.25 Application of the selective activation of thioglycoside over propagyl in
the synthesis of trisaccharide 1.129.

1.3.5

Miscellaneous

glycosyl

donors

(orthoesters,

Se-glycosides,

glycal/epoxides)
Anomeric phenylselenides, introduced by Pinto et al. in 1991, are very effective
glycosyl donors.143 The phenylseleno leaving group behaves similarly to that of
thioglycosides with respect to their stability towards protecting group manipulations and
lability towards electrophilic reagents. Very differently though, selenoglycosides can be
activated with AgOTf and K2CO3, which allows for their selective activation in presence
of thioglycosides.56,143 In 2000, selenoglycosides are also more reactive towards MeOTf
or NIS/TfOH than their thioglycoside counterparts.144,145 Thus, Ley et al. reported
selective activation of phenylseleno glycoside 1.130 over thioglycoside acceptor 1.131 in
application to convergent synthesis of GPI anchor of Trypanosoma brucei (Scheme
1.26).144 This coupling was performed in the presence of MeOTf and resulted in the
formation of trisaccharide 1.132 in 75% yield. The latter was then converted into

34

glycosyl acceptor 1.133 which was glycosylated with selenoglycoside 1.134 again in the
presence of MeOTf. This second selective activation resulted in the formation of
pentasaccharide 1.135 in 75% yield. Recently, Fairbanks utilized electrochemistry for
activation selenoglycoside donors, although selective glycosylation of selenoglycoside
over thioglycoside acceptor gave low yields.146

Scheme 1.26 Convergent synthesis of pentasaccharides 1.135 using selective activation
of selenoglycosides over thioglycosides.
Yoshida et al. reported the use of telluroglycosides as glycosyl donors which can
be activated either electrochemically147,148 or in the presence of MeOTf, NIS/t-BuOCl, or
NBS/TMSOTf.149 The latter reaction conditions allowed for selective activation of
telluroglycosides over thioglycoside acceptors.
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Orthoesters have been used as useful glycosyl donors for 1,2-trans glycosylation
for decades. Their activation is typically achieved in the presence of Lewis acid or mild
electrophilic promoters, which permits their selective activation over a number of leaving
groups of different classes. For example, it was demonstrated that ethylthio orthoester
1.136 can be activated over conventional thioglycoside 1.137 using NIS/TfOH as an
activator (Scheme 1.27a).150 The resulting disaccharide 1.138 was isolated in 75% yield.
Lopez et al. reported a glycosylation approach in which n-pentenyl 1,2-orthoesters are
activated over glycosyl fluoride acceptor using NIS and Yb(OTf)3 as a promoter
system.110 Recently, Hotha et al. reported that n-pentenyl 1,2-orthoester 1.139 can be
selectively activated over propargyl glycoside acceptor 1.85 in the presence of
NIS/Yb(OTf)3 to afford disaccharide 1.140 in 62% yield (Scheme 1.27b).111 Along
similar lines, propagyl 1,2-orthoester 1.141 can be selectively activated over n-pentenyl
acceptor 1.142 in the presence with AuBr3 leading to trisaccharide 1.143 (Scheme 1.27c).
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Scheme 1.27 Selective activation of orthoesters in oligosaccharide synthesis.

Cyanoethylidene approach to 1,2-trans-glycosylation of tritylated acceptors has
been extensively studied by Kochetkov.151 As reported by Boons, this approach allows
for selective activation over n-pentenyl glycosyl acceptor in the presence of TrClO4.138,152
Backinowsky also reported that 1,2-O-(1-cyanoethylidene) glycoside can be activated
with TrClO4 in presence of thioglycoside acceptors described in synthesis of a “fullycarbohydrate” mannodendrimer.153
Danishefsky and his-coworkers developed a convenient method for the
preparation of the 1,2-anhydro sugars from glycals using dimethyldioxirane (DMDO)154
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as an effective epoxidation reagent.155 For example, 1,2-anhydro sugar 1.144 generated
from glycal 1.145 could be activated over glycal acceptor 1.146 in the presence of ZnCl2
in THF to afford 1,2-trans-linked disaccharide 1.147 in 81% (Scheme 1.28). The
epoxidation-glycosylation

sequence

can

be

then

reiterated

to

yield

larger

oligosaccharides, although similarly to other pre-activation type of couplings, this
approach cannot be classified as the formal oligosaccharide synthesis via selective
activations.

Scheme 1.28 Danishefsky’s glycal-epoxide method for oligosaccharide synthesis.

1.4

Multistep sequences based on selective activations
Multistep oligosaccharide synthesis have been developed using selective

activation strategy. In principle, the activation sequence can be continued providing
beyond previously discussed couplings of building blocks equipped with LGa and LGb.
The continuation requires the availability of a LGc, which would withstand activation
conditions for the LGb. However, these elongated multi-step sequences are not yet
routinely available (vide infra).62,63 This can be circumvented by performing additional
modifications between glycosylations that allow repetition of the sequence involving
repetitive LGa and LGb activations. An example applying such selective-activation
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strategy is the synthesis of heparin-like oligosaccharides reported by van der Marel and
co-workers (Scheme 1.29).84 The synthesis of pentasaccharide 1.157 began by utilizing
the diphenyl sulfoxide—triflic anhydride dehydrative protocol developed by Gin156 for
the activation of the hemiacetal donor 1.148 over thioglycoside acceptor 1.149. The
phenylthio moiety of the resulting disaccharide 1.150 was then directly coupled with
glycosyl acceptor 1.151 with the benzenesulfinyl piperidine (BSP)- triflic anhydride
system.157 The resulting trisaccharide 1.152 is then converted to the corresponding
hemiacetal derivative 1.153, which was selectively activated over thioglycoside acceptor
1.154 in the presence of diphenyl sulfoxide-triflic anhydride. The resulting
tetrasaccharide 1.155 isolated in 51% yield was glycosidated with glycosyl acceptor
1.156 in the presence of the BSP/Tf2O promoter system to furnish the target
pentasaccharide 1.157 in 53% yield.
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Scheme 1.29 Selective activation approach to the synthesis of heparin analogues.

An example with the involvement of three different leaving groups is depicted in
Scheme 1.30, in which trichloroacetimidoyl is used as a LGa, phenylselnyl as LGb, and Sethyl as LGc.158 Thus, activation of trichloroacetimidate 1.158 over selenoglycoside
acceptor 1.159 was achieved in the presence of TMSOTf. The resulting disaccharide
1.160 isolated in 90% was then coupled with thioglycoside acceptor 1.112 in the presence
of AgOTf and K2CO3 leading to trisacccharide 1.161 in 81% yield. In principle the
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thioethyl moiety can be activated further. A similar sequence using bromide as LGa,
Selenoglycoside as LGb and thioglycosides as LGc was also reported.56

Scheme 1.30 Selective activation utilizing three different leaving group.

Another relevant example is the use of the S-benzoxazolyl (SBox) moiety as LGa,
S-ethyl as LGb, and O-pentenyl as LGc depicted in Scheme 1.31.159,160 The SBox glycosyl
donor 1.114 was selectively activated over the SEt acceptor 1.82 in the presence of
AgOTf to produce disaccharide 1.162 in 99% yield. The latter disaccharide was
glycosidated with the n-pentenyl acceptor 1.163 in the presence of MeOTf to provide
trisaccharide 1.164 in 90% yield. Finally, the leaving n-pentenyl moiety of the
trisaccharide donor 1.164 was then activated with NIS/TMSOTf for the coupling with
glycosyl acceptor 1.165, resulting in the formation of tetrasaccharide 1.166 in 73% yield.
A similar example included the following three-step activation sequence performed in a
one-pot fashion: SBox as LGa, S-thiazolinyl (STaz) as LGb, and S-ethyl as LGc.161
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Scheme 1.31 Three-step SBox→ SEt → n-pent sequential selective activation.

Very recently, the synthesis of a β-(1→6)-linked hexasaccharide via the five-step
selective activation sequence was employing six different leaving groups as depicted in
Scheme 1.32.162 The synthesis began with the selective activation of thiocyanate donor
1.167 over STaz glycosyl acceptor 1.115 using Cu(OTf)2 as a promoter. The STaz
leaving group of disaccharide 1.116 was then directly activated over SBox acceptor 1.168
with benzyl bromide to give trisaccharide 1.169. The SBox moiety of 1.169 was then
selectively activated over the fluoride acceptor 1.170 in the in presence of MeOTf. The
resulting tetrasaccharide 1.170 was glycosidated with thioglycoside acceptor 1.137 in
presence of AgClO4/Cp2ZrCl2 to provide pentasaccharide 1.171. Finally, the S-ethyl
leaving group of 1.171 was selectively activated over the n-pentenyl acceptor 1.91 in the
presence of MeOTf as a promoter to furnish the hexasaccharide 1.172 in 72% yield.162

42

OBz
O

BzO
BzO

SCN

1.167
BzO
BzO

STaz

BzO

BzO
Cu)OTf)2
89%

OBz
O
O
BzO BzO
BzO
1.116

BzO
BzO

OBz
O

BzO
BzO

OBz
O

1.171

O

OH
O

BzO
BzO

STaz

SBox
BzO
1.168

BzO

67%
O
O
BzO BzO
BzO

OBz
O
O
BzO BzO
BzO

O
BzO BzO
BzO

BzO BzO
BzO

O

SEt
BzO

167
AgClO4/Cp2ZrCl2
84%

O
O
BzO BzO
BzO

O

OH
O

O
BzO BzO
BzO

O

OH
O

BzO
BzO

BzO F

O

O

1.170

O

O
BzO BzO
BzO

OH
O
BzO F

MeOTf
87%

O

O
BzO BzO
BzO

SBox

O
BzO BzO
BzO

OBz
O

BzO
BzO

O
BzO

O

BzO BzO
BzO
184
BzO
BzO

1.115

BnBr

O
BzO BzO
1.169
BzO

BzO
BzO

OH
O

BzO
BzO

O

O
SEt

BzO
BzO

O
BzO

BzO

O
BzO BzO
BzO

1.91

O
O

BzO BzO
BzO
1.172

O
O
BzO BzO
BzO

MeOTf
72%
O
O
BzO

Scheme 1.32 Selective activation utilizing six different leaving groups in the synthesis of
1,2-trans hexasaccharide 1.172.

1.5

Semi-orthogonal approach
The orthogonal approach makes use of two leaving groups LGa and LGb that can

be independently activated one over another and vice versa (vide infra). A semiorthogonal strategy is based on a similar principle, but it requires the additional
enforcement by electronic effects, similarly to that of the “armed-disarmed concept”.
Overall, this concept combines advantages of both selective and chemoselective
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activation; its utility, however, is limited as the protecting groups also often determine the
stereoselectivity as well.
Thus, it was demonstrated109 that either armed or disarmed thioglycoside can be
selectively activated over either armed or disarmed n-pentenyl glycosides in the presence
of MeOTf. However, only armed n-pentenyl could then be activated over a disarmed
thioglycoside acceptor using IDCP as a mild promoter. Thus, lactose S-ethyl donor 1.173
was selectively activated over the n-pentenyl moiety of glycosyl acceptor 1.142 in the
presence of MeOTf. The resulting trisaccharide was isolated in 98% yield as depicted in
Scheme 1.33. The n-pentenyl moiety of the latter was then subjected to
selective/chemoselective activation over S-ethyl acceptor 1.82 in the presence of IDCP
leading to tetrasaccharide 148 in 92% yield.

Scheme 1.33 Semi-orthoganality of thioglycoside and n-pentenyl leaving groups.
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This semi-orthogonal concept was recently extended to another suitable pair of
leaving groups, namely fluoride and n-pentenyl.110 While either armed or disarmed
glycosyl fluorides underwent smooth glycosylation with armed/disarmed n-pentenyl
glycoside in presence of Yb(OTf)3, only armed n-pentenyl glycosides could be activated
over disarmed glycosyl fluorides in presence of IDCP. As depicted in Scheme 1.34,
fluoride donor 1.176 was selectively activated over pentenyl glycosyl acceptor 1.177 in
the presence of Yb(OTf)3. The resulting n-pentenyl disaccharide was isolated in 68%
yield. Conversely, the activation of armed n-pentenyl glycoside 1.179 was achieved
selectively over fluoride acceptor 1.180 to afford disaccharide 1.181. No activation of
benzoylated n-pentenyl glycosides could be accomplished, whereas NIS/BF3-Et2O–
promoted selective activation resulted in a poor yield (25%).

Scheme 1.34 Semi-orthogonality of n-pentenyl glycoside and glycosyl fluoride.
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1.6

Orthogonal activation
The combination of two chemically distinct glycosylation reactions, in which one

of the leaving groups is activated while the other one remains intact, and vice versa, has
led to the discovery of the orthogonal strategy for oligosaccharide synthesis.38 This
unique, and virtually one of the most conceptually attractive techniques for expeditious
oligosaccharide synthesis, requires the use of two orthogonal classes of glycosyl
donors.163,164 As with the selective activation strategy, at the first step the glycosyl donor
bearing LGa is activated over the glycosyl acceptor bearing LGb. Uniquely to the
orthogonal strategy, however, the LGb is then activated over LGa of the new glycosyl
acceptor (Scheme 1.35). This activation sequence can then be reiterated to give
straightforward access to larger oligosaccharides. Ideally, the orthogonal approach allows
for an unlimited number of reiterations of the two orthogonal leaving groups LGa and
LGb, which is conceptually very attractive. In practice, however, the efficiency of
glycosidation is usually inversely correlated to the size of the glycosyl donor involved.
And since this approach presumes the elongation of glycosyl donors, the yields are
typically decreased dramatically at the later stage of the assembly.

Scheme 1.35 Orthogonal strategy for oligosaccharide synthesis.

1.6.1

Fluorides and thioglycosides.
46

The classic variation of the orthogonal activation route introduced by Ogawa et
al. involves building blocks bearing S-phenyl and fluoro leaving groups.38 Phenyl
thioglycoside donor 1.182 can be selectively activated over glycosyl fluoride acceptor
1.183 in the presence of NIS/AgOTf to afford the disaccharide 1.184 in 85% (Scheme
1.36). The fluoro leaving group of disaccharide 1.184 can then be activated over
thioglycoside acceptor 1.185 in the presence Cp2Hf2Cl2/AgOTf as a promoter system.
The resulting trisaccharide 1.186 is obtained in 72% yield. This selective activation
sequence can be then reiterated; to illustrate this, the trisaccharide donor 1.186 bearing Sphenyl was activated over the fluoride acceptor 1.183 to provide tetrasaccharide 1.187 in
66% yield.

Scheme 1.36. Orthogonal activation of phenylthio glycosides and fluorides.

1.6.2

Thioglycoside and thioimidate
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A combination of S-ethyl and S-thiazolinyl (STaz) leaving groups also represents
a promising orthogonal pair. STaz glycosides can be activated selectively with AgOTf,
whereas the ethyl thioglycoside can be activated with NIS and catalytic TfOH.129 This
finding was applied to the synthesis of a pentasaccharide derivative 1.192, as depicted in
Scheme 1.37.165 Thioglycoside donor 1.188 was first activated over the STaz acceptor
1.115 in the presence of NIS/cat. TfOH. The resulting disaccharide 1.189 isolated in 98%
yield was in turn activated over thioglycoside acceptor 1.137 with AgOTf to give
trisaccharide 1.190 in 93% yield. The sequence was then reiterated as follows.
Thioglycoside donor 1.190 was activated over STaz acceptor 1.115 in the presence of
NIS/cat. TfOH. The resulting tetrasaccharide 1.191 was selectively activated over
thioglycoside acceptor 1.137 by the addition of AgOTf to give pentasaccharide 1.192 in
59% yield.
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Scheme 1.37 Orthogonality of ethyl and thiazolinyl thioglycosides.

1.6.3

Thioimidate-only (SBox and STaz glycosides)

A related approach involving orthogonal activation of STaz and SBox glycosides
has also recently emerged.133 SBox glycosides can be selectively activated with
Cu(OTf)2165 or Bi(OTf)3132 over the STaz leaving group. As shown in Scheme 1.38, STaz
leaving group that is typically more stable than SBox towards a majority of thiophilic
activation conditions, can be also selectively activated over SBox in the presence of
relatively mild alkylation reagents, benzyl bromide or methyl iodide. Thorough
mechanistic studies showed that the selective activation is based on the different
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activation modes reactivity of these leaving groups. Thus, it was found that preferential
glycosidation of a certain thioimidate is not simply determined by the strength of
activating reagents; instead, the type of activation – direct (for SBox) vs. indirect (for
STaz) – comes to the fore and plays the key role. Thus, activation of STaz donor 1.193
over SBox acceptor 1.168 in the presence of BnBr at 55 °C afforded disaccharide 1.194
in 76% yield. The latter could be then activated over STaz acceptor in the presence of
Bi(OTf)3 at 0 °C. The resulting trisaccharide 1.195 was isolated in 62% yield.

Scheme 1.38 Thioimidate-only orthogonal strategy.

1.6.4

n-Pentenyl and propargyl activation

Recently, Hotha et al. reported a new promising pair of leaving groups for
orthogonal activation involving of propargyl and n-pentenyl glycosides (Scheme
1.39a).111 According to this study, NIS/TMSOTf served as an efficient activator for
selective activation of n-pentenyl glycoside 1.84 (Scheme 1.39a). In this case, either
alkylated or acylated O-propagyl glycosyl acceptors 1.56 or 1.85, respectively, worked
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equally well. As the result of this selective activation, disaccharides 1.197 and 1.86 were
isolated in 66 and 68% yield. On the other hand, propargyl glycosyl donor 1.90 can be
selectively activated over propargyl glycosyl acceptor 1.91 in the presence of AuBr3 to
afford disaccharide in 65%. This activation works particularly well for benzoylated
glycosyl acceptor 1.91 and as glycosylation of its benzylated counterpart 1.142 led to
modest yield of the respective disaccharide 1.198. This implies a more semi-orthogonal
like activation (vide supra) rather than purely orthogonal.

Scheme 1.39 Orthogonality of n-pentenyl vs. O-propargyl leaving groups.
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1.7

Selective and orthogonal activations in modern high throughput technologies

1.7.1

Intramolecular glycosylations

An intramolecular aglycone delivery (IAD) approach first introduced by Barresi
and Hindsgaul166,167 and later by Stork and Kim168,169 is the one of the most reliable
methods to obtain β-mannosides. Ogawa et al. then reported the use of a pmethoxybenzyl (PMB) group at the C-2 position as the stereocontrolling tether for βmannosylation.170 The p-methoxybenzyl assisted IAD process was used as the key
reaction for the construction of β-mannoside containing fragment that also involved
selective activation concept (Scheme 40).60,61 According to this approach, thioglycoside
donor 1.199 was linked to fluoride acceptor 1.138 via DDQ-mediated tethering. The
resulting construct 1.200 was subjected to treatment with MeOTf and DTBMP that
allowed for selective activation of the S-methyl group over the fluoro group to afford βmannoside 1.201. The free hydroxyl group in 1.201 was then acetylated, and the resulting
fluoride donor 1.202 was glycosylated with glycosyl acceptor 1.203. The resulting
trisaccharide 1.204 was obtained in 85% yield. In principle, the last step can also be
considered selective activation, as O-allyl glycosides can be activated via a two-step onepot isomerization-glycosidation sequence. A similar approach was also investigated using
polymer support.171
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Scheme 1.40 p-Methoxybenzyl mediated intramolecular aglycone delivery and selective
activation concepts.

1.7.2

One-pot synthesis

Conceptually, one-pot strategies offer the shortest pathway to oligosaccharides, as
the sequential glycosylation reactions are performed in a single flask (pot) and do not
require purification of the intermediates. It is very important for a successful one-pot
glycosylation that there is complete consumption of all building blocks and the high yield
in each glycosylation step. In addition, the requirement for very high or preferably
complete stereoselectivity in every glycosylation step becomes particularly important.
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These will ensure that only the target oligosaccharide is being produced as the major
product, thus providing high efficiency of this technique. Many variations of the one-pot
strategy have been developed,172,173 herein we focus our discussion on the approaches
based on selective activation of one type of a leaving group over another. The use of
selective activation strategy for the one-pot oligosaccharide sequencing is easy to
envisage. As illustrated in Scheme 1.41, it requires a set of suitable leaving groups (LGa,
LGb, LGc) activators that would activate one leaving group over another: A (selectively
activates LGa), B (selectively activates LGb), etc.

Scheme 1.41 A generic selective activation-based oligosaccharide synthesis in one pot.

The first one-pot synthesis based on the leaving group based activation concept
was reported by Takahashi and co-workers.57 As depicted in Scheme 1.42, this synthesis
involved the use of trichloroacetimidate donor 1.205, which was selectively activated
over thioglycoside 1.206 with TMSOTf. The SPh moiety of the formed, but not isolated,
tetrasaccharide was then glycosidated by adding glycosyl acceptor 1.207 in the presence
of NIS/TfOH to provide hexasaccharide 1.208 in 50% yield over two steps. This
approach incorporates advantages of the convergent block strategy according to which
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pre-synthesized oligosaccharide building blocks i.e. 1.205 and 1.207 are converged
together during the final assembly.

Scheme 1.42 Convergent one-pot synthesis by selective activation.

A number of related two-step one-pot syntheses have emerged, and the most
representative examples are surveyed below. As depicted in Scheme 1.43a, reaction of
bromide 1.209 and S-phenyl acceptor 1.210 was affected in the presence of silver triflate.
The S-phenyl leaving group of the intermediate disaccharide was then glycosidated by
adding glycosyl acceptor 1.211 and NIS. The resulting trisaccharide 1.212 was isolated
in 84% yield over two steps.174 In a similar fashion, a tetrasaccharide glycosyl glycerol
which represents the core structure of a glycoglycerolipid of M. taiwanesis, based on a
three-component one-pot strategy was synthesized as depicted in Scheme 1.43b.175 A
trisaccharide intermediate was formed from the glycosyl phosphite 1.213, which was
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selectively activated over selenoglycoside acceptor 1.214 in the presence of TMSOTf.
Subsequent addition of acceptor 1.215 and NIS produced the target tetrasaccharide 1.216
in 46% yield over-all. Seeberger and co-workers presented an efficient one-pot synthesis
of a pentasaccharide 1.220 shown in Scheme 1.43c.176 Accordingly, disaccharide
trichloroacetimidate 1.217 was activated with TMSOTf to react regioselectively at the C4 hydroxyl group of the thioglycoside 1.218. Subsequent addition of disaccharide
acceptor 1.219, followed by the addition of NIS/TfOH to promote the thioethyl group of
the in situ formed trisaccharide completed the sequence. The requisite pentasaccharide
1.220 was isolated in 63% yield.
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Scheme 1.43 Typical examples of two-step one-pot oligosaccharide syntheses.
A representative example involving three sequential glycosylation steps is shown
in Scheme 1.44.161 This three step activation was achieved by the stepwise activation of
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S-benzoxazolyl (SBox) glycosyl donor 1.114 over S-ethyl glycosyl acceptor 1.82 by
addition of AgOTf. Thioethyl moiety of the resulting disaccharide intermediate was then
activated over the added S-thiazolinyl (STaz) acceptor 1.115 by the addition of NIS and
catalytic TfOH. Finally, the STaz moiety of the trisaccharide intermediate was reacted
with freshly added glycosyl acceptor 1.165 in the presence of additional quantity of
AgOTf. As a result, the linear tetrasaccharide 1.221 was obtained in 73% yield over three
steps.

Scheme 1.44 One-pot synthesis of tetrasaccharide 1.221 by the three-step sequential
selective activation.

Utilizing longer sequences of selective activations are not yet routinely available.
Although a number of one-pot syntheses or large oligosaccharides has emerged, all are based
on mixed convention, typically a combination of selective and chemo or regioselective
sequential activations. For example, Ley’s group reported the synthesis of a GPI anchor
involving building blocks with well defined levels of reactivity (Scheme 1.45).177 Thus,
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armed and disarmed glycosyl fluorides (1.222, 1.223), armed and disarmed selenoglycosides
(1.224, 1.225) and thioglycoside 1.226 were all sequentially activated to provide the target
linear pentamannoside 1.227 in 8% overall yield in four steps. Evidently the first and the third
steps involved chemoselective activations, whereas the second and fourth steps involved
selective activations of fluoride over SePh and SePh over SPh, respectively.

Scheme 1.45 Ley’s synthesis via alternating chemoselective and selective couplings.

Mukaiyama reported an elaborate one-pot sequence that resulted in the formation of a
phytoalexin elicitor heptasaccharide 1.232 in 48% yield.178 As depicted in Scheme 1.46, the
synthesis of heptasaccharide 1.232 involved a combination of sequential selective (fluoride
1.228 over thioglycoside 1.229) and chemoselective activations (armed SEt disaccharide
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intermediate over disarmed acceptor 1.230), as well as convergent approach (4 + 3, building
block 1.231), all in one pot.

Scheme 1.46 Mukaiyama’s one-pot synthesis involving the elements of orthogonal
activation.

A similar target was obtained by Takahashi in a six-step one-pot synthesis of
heptasaccharide using a Quest 210 manual synthesizer.179 As depicted in Scheme 1.47, this
one-pot synthesis required the sequential addition of seven reaction components 1.233-1.239
using four different leaving groups. Sequential activations employed herein included:
activation of glycosyl bromide 1.233 (activated with AgOTf over S-ethyl acceptor), ethyl
thioglycosides 1.234 and 1.235 (with MeOTf over fluoride acceptor 1.236), tetrasaccharide
fluoride (with Cp2HfCl2/AgOTf over S-phenyl acceptor 1.237) and phenyl thioglycosides
1.238 and hexasaccharide (with DMTST in the armed-disarmed fashion). The resulting
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protected phytoalexin elicitor heptasaccharide 1.240 was isolated in 24% yield over six steps.
To the best of our knowledge, this is the only selective activation-based synthesis that
incorporates the elements of the orthogonal-like activations in one-pot (steps three and four).

Scheme 1.47 Takahashi’s synthesis using the elements of orthogonal activations.
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1.7.3

Polymer-supported synthesis

Solid-phase synthesis has been developed and widely utilized in a routine
preparation of oligopeptides and oligonucleotides, and is attracting renewed attention in
connection with combinatorial chemistry. The use of polymer supports in oligosaccharide
synthesis has also been attractive and several intriguing approaches have been reported.
Most of the concepts involve glycosyl acceptor bound approach, with examples involving
glycosyl acceptor bound strategies that allow for selective activations also known. For
instance, Kahne et al. reported selective activation of sulfoxide donor 1.241 over the
Merrifield resin –bound thioglycoside acceptor 1.242 in the presence of Tf2O and
DTBMP (Scheme 1.48).180 Upon completion of the sequencing that resulted in the
formation of trisaccharide 1.245, the thioglycoside linker is cleaved under mild
conditions employing mercuric trifluoroacetate.

Scheme 1.48 Utilizing glycosyl sulfoxides in selective activations over thioglycoside
bound to the polymer support.

61

An example of a donor-bound approach utilizing selective activations on solid
phase synthesis is the synthesis of the Leb blood group antigen reported by Seeberger and
co-workers (Scheme 1.49).181,182 Glycal connected to Merrifield’s resin 1.246 was
subjected to epoxidation with DMDO, followed by coupling with glycal acceptor 1.247
in the presence of ZnCl2. Fucosyl fluoride donor 1.248 was then activated over polymerbound glycal disaccharide 1.249 in the presence of Sn(OTf)2 and DTBP. This steps
incorporates the elements of a two-directional concept developed by Boons.183,184 The
resulting tetrasaccharide glycal 1.250 was then converted into the corresponding 2-amino
thioglycoside 1.251. This transformation allowed the continuation of the sequence that
resulted in glycosidation of 1.251 with glycal acceptor 1.252. The resulting
pentasaccharide was then cleaved off of the polymer support to afford pentasaccharide
1.253 in 20% over-all. Selective activation of the SBox bound glycosyl donor over
solution phase thioglycoside acceptor in the presence of TMSOTf was also reported.185
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Scheme 1.49 Solid phase synthesis of Leb blood-group antigen analog.

The application of an orthogonal strategy utilizing polymer support was also
developed by Ogawa in 1996.39 Ogawa reported a combination of chemistry on polymer
supports and orthogonal glycosylation (thioglycosides and glycosyl fluorides) which
resulted in the construction of oligosaccharide by minimize the number of operation. To
illustrate this concept, a representative example reported by Kanie et al. (Scheme 1.50) is
included.186 According to this approach, polymer-bound glycosyl donor 1.254 was
activated selectively over fluoride acceptor 1.15 in the presence of DMTST. The resulting
disaccharide 1.255 was activated over S-phenyl acceptor 1.256 in the presence of
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Cp2Hf(OTf)2. Finally, S-phenyl trisaccharide 1.257 was glycosidated with octanol in the
presence of DMTST.

Scheme 1.50 Orthogonal glycosylation reactions on solid phase for synthesis of fucosyl
galactose oligosaccharides.

1.8

Conclusions and future directions
It is critical to make complex carbohydrates more accessible to the general

chemical, biochemical, and industrial audience to keep pace with the exploding area of
glycobiology. This can be only achieved by the development of methods and strategies
for efficient oligosaccharide synthesis that would be applicable for both laboratory and
industrial preparation. A number of excellent strategies that offer a reasonably efficient
route to oligosaccharide assembly have already emerged. Important discoveries surveyed
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in this article have already allowed scientists to synthesize complex oligosaccharides and
glycoconjugates for structural, biological, and medical studies.

Nevertheless,

carbohydrates of even moderate complexity still present a considerable challenge, even to
experts. No expeditious strategy developed to date can offer an easy and reliable access
to all full range of compounds of interest. Some strategies offer a very efficient approach
to certain sequences, but in general each target still requires careful selection of methods,
conditions, and strategies.
The development of efficient and general methods for the expeditious synthesis of
complex carbohydrates will undoubtedly remain an important and active arena for
scientific endeavours during the 21st century. In the coming years, glycoscientists are
expected to have developed simple, efficient, and flexible approaches to oligosaccharide
assembly that will complement existing methodologies and bring our ability to obtain
complex oligosaccharides up to a significantly higher level. The recent innovations
surveyed herein make contemporary glycoscientists well positioned to undertake further
studies. Future developments may be expected to incorporate existing methodologies, and
combinations thereof, while blending in new concepts and technologies.
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2.1

Introduction
With increasing demand for the synthesis of biologically important and

therapeutically active oligosaccharides and glycoconjugates, efforts to expand the arsenal
of glycosylation methods and techniques have emerged. In spite of significant recent
advances in the areas of stereoselective glycosylation1,2 and expeditious oligosaccharide
synthesis,3,4 the construction of complex oligosaccharides with high efficiency and
complete stereoselectivity remains a difficult task. As a part of a program to develop new
methods and strategies for glycochemistry, we became interested in glycosyl
thioimidates, a class of glycosyl donors with the generic leaving group SCR1=NR2.5,6 We
have already reported the synthesis of S-benzoxazolyl (SBox)7,8 and S-thiazolinyl
(STaz)9,10 glycosides and evaluated their properties in stereoselective glycosylations and
expeditious oligosaccharide syntheses. Metal salt-based promoters were shown to provide
efficient activation of the thioimidoyl moiety for glycosylation.8,11 Among a variety of
metal salts investigated, arguably, silver trifluoromethanesulfonate (AgOTf) was one of
the best choices for the activation of the SBox and STaz moieties for a variety of
synthetic applications. Beyond the scope of our own research program, AgOTf has been
commonly employed as an activator for many other classes of glycosyl donors including
glycosyl bromides,12-14 chlorides,15 trichloroacetimidates,16 and seleno glycosides.17 In
spite of wide applicability and high versatility of AgOTf, there are some significant
drawbacks that limit the usage of this promoter in synthesis. In a majority of applications,
AgOTf requires fresh activation by repetitive co-evaporation with toluene followed by
extended drying under vacuum directly prior to use. In addition, we noticed that the
quality of commercial reagent may significantly vary depending on the supplier and the
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batch. It should be noted that the use of AgOTf as an acidic additive in NIS-promoted
glycosidation of thioglycosides does not require preactivation of AgOTf. Bearing in mind
these drawbacks, we questioned if any other silver salts could be used to achieve an
efficient glycosidation of a variety of glycosyl donors and would produce reproducible
results without the requirement of the preactivation or azeotropic dehydration. Herein we
present a report that demonstrates the use of silver tetrafluoroborate (AgBF4) as a potent
promoter for the activation of various types of glycosyl donors. It should be noted that
AgBF4 has already been used in glycosylations, yet these applications, including
alcoholysis of glycosyl bromides,18,19 synthesis of C-glycosides from chlorides,20
glycosidation of 2-deoxy thioglycosides,21 and α-stereoselective glycosidation of 1,2
anhydro sugars,22 were scarce and scattered. In this context, Cp2ZrCl2–AgBF4 in benzene
has proven to be a powerful promoter combination for the activation of tetra-O-benzyl-Dmannosyl fluoride.23

2.2

Results and discussion
To generate a broad array of glycosyl donors we investigated whether thiazolinyl

2,3,4,6-tetra-O-benzyl-1-thio-β-D glucopyranoside 2.5a10 could serve as a common
precursor. These studies were successful and we discovered that the STaz glycoside 2.5a
can be directly converted into the following glycosyl donors: acetate 2.1, bromide 2.2a,
chloride 2.8, fluoride 2.9, and hemiacetal 2.10 in excellent yields (84–95%, Scheme 2.1).
Moreover, glycosyl bromide 2.2a was then used as a precursor for the next synthetic
steps to obtain benzoxazolyl, benzothiozolyl, and ethyl thioglycosides (2.3a, 2.4a, and
2.6), as well as n-pentenyl glycoside 2.7—all with exclusive β stereoselectivity. The
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hemiacetal

derivative

2.10

was

converted

into

the

corresponding

glycosyl

trichloroacetimidate 2.11 as shown in Scheme 2.1.

Scheme 2.1 Conversion of the a common STaz glycoside 2.5a into a range of glycosyl
donors

Synthesis of a range of differently protected glycosyl thioimidates has been
similarly accessed and is depicted in Scheme 2.2. Yields given are over-all yields for two
synthetic steps.
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Scheme 2.2 Conversion of the STaz glycosides 2.5b,c into thioimidates 2.3b,c and
2.4b

Having synthesized a library of glycosyl donors, we performed a number of test
glycosylation reactions using AgBF4 as a promoter (Table 2.1). Since we wanted to
determine whether the glycosylations could be performed without pre-activation of
AgBF4, all reactions were performed with commercial reagent as received, without
further conditioning.
Glycosidation of glycosyl acetate 2.1 with glycosyl acceptor 2.13 in the presence
of AgBF4 did not proceed (entry 3). A similar coupling in the presence of BF3–Et2O, a
conventional promoter for the activation of glycosyl acetates,24 gave disaccharide 2.17a
(Fig. 2.1) in 91% yield, although it required 16 h for the reaction to complete. We
determined that the reaction time of this reaction could be significantly reduced (16 h vs
5 h, entries 4 and 5) by adding 20–50 mol % of AgBF4. In these couplings, even higher
yield of 2.17a (95%) and an improved stereoselectivity were detected.
Glycosidation of glycosyl bromides 2.2 and 2.2 could be efficiently accomplished
with AgBF4, although the coupling of per-benzoylated bromide 2.2, prepared as shown in
Scheme 2.2, with the sterically hindered acceptor 2.14 required prolonged reaction time
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(entries 15–16). These results were comparable with the glycosylations using traditional
bromide activators-silver carbonate,25,26 or mercury salts.27,28

Table 2.1 AgBF4 promoted glycosylations of glycosyl acceptor 2.12-2.15

Entry

Donor

Acceptor

Time

Product

Yield (%)

α/β Ratio

1

2.1

2.13

24 h

2.17a

-a

-

2b

2.1

2.13

16 h

2.17a

91

1.4/1

3c

2.1

2.13

5h

2.17a

95

2.0/1

4

2.2a

2.13

5 min

2.17a

92

2.4/1

5

2.2b

2.13

5 min

2.17b

96

β only

6

2.2b

2.14

24 h

2.18b

82

β only

7

2.3a

2.13

10 min

2.17a

89

1.2/1

8

2.3b

2.13

10 min

2.17b

91

β only

9

2.3b

2.14

15 min

2.18b

84

β only

10

2.3c

2.13

15 min

2.17c

91

1.6/1

11

2.4a

2.15

5 min

2.19a

87

7.4/1

12

2.4b

2.13

20 min

2.17b

90

β only

84

13

2.5a

2.13

5 min

2.17a

95

1.3/1

14

2.5a

2.14

5 min

2.18a

92

1.4/1

15

2.5b

2.13

10 min

2.17b

90

β only

16

2.5c

2.13

20 min

2.17c

75

1.2/1

17

2.6

2.13

24 h

2.17a

-a

-

18d

2.6

2.13

24 h

2.17a

91

1.2/1

19e

2.6

2.13

10 min

2.17a

92

1.2/1

20

2.7

2.13

24 h

2.17a

-a

-

21d

2.7

2.13

24 h

2.17a

89

1.0/1

22e

2.7

2.13

20 min

2.17a

76

1.2/1

23

2.8

2.13

5 min

2.17a

97

1.6/1

24

2.8

2.12

10 min

2.16a

91

1/3.4

25

2.9

2.13

20 h

2.17a

81

2.0/1

26

2.9

2.15

1.5 h

2.19a

81

2.3/1

27

2.10

2.13

24 h

2.17a

-a

-

28

2.11

2.13

5 min

2.17a

80

1/1.5

29

2.11

2.12

2 days

2.16a

65

1/5.4

a

No product formation was detected; all glycosylations were promoted with AgBF4
except the following.
b
-3.0 equiv of BF3–Et2O were used.
c
-3.0 equiv of BF3–Et2O and 0.5 equiv of AgBF4 were used.
d
-2.0 equiv of NIS was used.
e
-2.0 equiv of NIS and 0.5 equiv of AgBF4 were used.
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Figure 2.1 Structure of disaccharide 2.16-2.19

Glycosidation of glycosyl thioimidates 2.3-2.5 was smoothly driven to completion
in a matter of minutes (entries 7–16). All glycosylations proceeded with very high
conversion yields, comparable or even exceeding those achieved in glycosylations
promoted with preactivated AgOTf. For example, AgBF4-promoted couplings depicted in
entries 14 and 16 (Table 2.1) proceeded in 92% (90% with AgOTf) and 75% (70% with
AgOTf) yield, respectively.9 While the anchimerically assisted couplings with
benzoylated glycosyl donors were β stereoselective, only fair α-stereoselectivity was
achieved with 2-O-benzylated glycosyl donors. All couplings were performed in the
neutral solvent since the stereoselectivity optimization was not a primary intention of
these studies.
Promoters for thioglycoside and n-pentenyl glycoside activation include thiophilic
reagents, among which NIS/TfOH or NIS/TMSOTf are arguably the most common.29,30
Therefore, not surprisingly, the activation of stable glycosyl donors, thioglycoside 2.6 or
n-pentenyl glycoside 2.7, did not take place in the presence of AgBF4. It should be noted
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that NIS alone can also activate both S-ethyl and n-pentenyl glycosides, however, these
transformations require prolonged reaction time (entries 18 and 21). Having decided to
investigate whether these glycosyl donors can be activated by NIS/AgBF4 system, we
discovered that these coupling reactions proceeded very rapidly and provided the
corresponding disaccharide in minutes (entries 19 and 22). We then demonstrated that
AgBF4 could be employed as a suitable promoter for glycosidation of chloride 2.8,
fluoride 2.9, or trichloroacetimidate 2.11, whereas the hemiacetal derivative 2.10
remained inert under these reaction conditions (entry 23-29).
Based on the results summarized in Table 2.1, we anticipated that it might be
possible to activate glycosyl halides, S-benzothiazolyl, SBox, or STaz glycosides over the
SEt or n-pentenyl moieties in the presence of AgBF4. We have already reported that
selective activation of SBox and STaz glycosides over SEt glycosyl acceptor can be
achieved in the presence of AgOTf.7,31 Also in this case, AgBF4 was found to be capable
of providing smooth couplings with consistently high yields (Table 2.2). We observed
that glycosidation of glycosyl fluoride 2.9 was sluggish and the moderate to good yields
presented in Table 2.2 are based on unreacted acceptor recovery (entries 1 and 5).
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Table 2.2 Selective activation of various glycosyl donors over n-pentenyl acceptor 2.20
and SEt acceptor 2.22

a

Entry

Donor

Acceptor

Time

Product

Yield (%)

α/β Ratio

1

2.3a

2.20

10 min

2.21

86

1.1/1

2

2.4a

2.20

20 min

2.21

85

3.3/1

3

2.5a

2.20

10 min

2.21

83

1/1.2

4

2.9

2.20

16 h

2.21

65a

1.6/1

5

2.2a

2.22

15 min

2.23

84

1.6/1

6

2.3a

2.22

20 min

2.23

87

2.01

7

2.5a

2.22

15 min

2.23

89

2.41

8

2.8

2.22

15 min

2.23

84

2.2/1

9

2.9

2.22

24 h

2.23

83a

2.41

This yield is based on the recovery acceptor.

Based on the results of the selective activations, we assumed that it could be
possible to perform the activation sequence in a highly efficient one-pot fashion.
Presumably, any building block that can be activated with AgBF4 can be used as the
glycosyl donor for the first activation step. We chose to investigate SBox and STaz
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glycosides as well as glycosyl bromides as glycosyl donors. Glycosyl acceptors should
withstand AgBF4 activation, but in turn could be readily activated by addition of NIS.
Either S-ethyl or n-pentenyl leaving groups could be used for this purpose. An example
shown in Scheme 2.3 makes use of the STaz leaving group in 2.5a for the first coupling
step. At this stage the S-ethyl moiety of the glycosyl acceptor 2.24 remains inert. Upon
the formation of the intermediate disaccharide, its SEt moiety can then be activated for
the reaction with the newly added acceptor 2.13 by adding 2.0 equiv of NIS. As
demonstrated above, NIS along with AgBF4 (used in excess and is remaining from the
previous step) serves as an efficient promoter for this type of glycosylation. As a result of
this two-step activation, trisaccharide 2.25 was isolated in 72% yield. Other leaving
group combinations mentioned above were also found to be capable of the one-pot
activations and provided the corresponding trisaccharides in 55–70% overall yields.

Scheme 2.3 One-pot glycosylation: synthesis of trisacharide 2.25
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2.3

Conclusion
In summary, we have identified silver tetrafluoroborate as an excellent promoter

for the activation of various glycosyl donors, prepared from the common precursor
bearing the STaz anomeric moiety. Easy handling and no requirement for azeotropic
dehydration prior to the application makes AgBF4 especially beneficial in comparison to
the commonly used AgOTf. We also demonstrated that selective activation of glycosyl
halides or thioimidates over thioglycosides or n-pentenyl glycosides could lead to simple
one-pot syntheses via sequential selective activation of one leaving group over another.
Therefore, we believe that AgBF4 should be considered as a powerful and convenient
alternative for silver(I) activated glycosylations.

2.4

Experiment part

2.4.1

General
Column chromatography was performed on silica gel 60 (70-230 mesh), reactions

were monitored by TLC on Kieselgel 60 F254. The compounds were detected by
examination under UV light and by charring with 10% sulfuric acid in methanol.
Solvents were removed under reduced pressure at <40 °C. Dichloromethane and 1,2dichloroethane were distilled from CaH2 directly prior to application. Methanol was dried
by refluxing with magnesium methoxide, distilled and stored under argon. Pyridine was
dried by refluxing with CaH2 and then distilled and stored over molecular sieves (3Å).
Molecular sieves (3Å), used for reactions, were crushed and activated in vacuo at 390 °C
during 8 h in the first instance and then for 2-3 h at 390 °C directly prior to application.
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AgBF4 (Acros) was used as received. Optical rotations were measured at ‘Jasco P-1020’
polarimeter. 1H-NMR spectra were recorded at 300 or 500 MHz, 13C-NMR spectra were
recorded at 75 or 125 MHz. HRMS determinations were made with the use of JEOL
MStation (JMS-700) Mass Spectrometer.

2.4.2

Transformation of the STaz moiety into other leaving groups: synthesis of

glycosyl donors

1-O-Acetyl-2,3,4,6-tetra-O-benzyl-D-glucopyranose (2.1)
Pd(OAc)2 (35 mg, 0.156 mmol) was added to a mixture of 2-thiazolinyl 2,3,4,6-tetra-Obenzyl-1-thio-β-D-glucopyranoside (2.5a, 50 mg, 0.078 mmol) and activated molecular
sieves 3Å (150 mg) in dry (ClCH2)2 (0.5 mL). The reaction mixture was stirred under
argon for 24 h at 55 °C. Upon completion, the solid was filtered-off and the filtrate was
concentrated under reduced pressure. The residue was purified by column
chromatography on silica gel (ethyl acetate/ hexane gradient elution) to afford 1-Oacetate 2.1 as a colorless syrup in 72% yield (α/β = 1.6/1). Analytical data for 2.1 were
essentially the same as reported previously.32

2-Benzoxazolyl 2,3,4,6-tetra-O-benzyl-1-thio-β-D-glucopyranoside (2.3a)
A mixture of 2.4a (50 mg, 0.078 mmol) and activated molecular sieves 3Å (40 mg) in dry
CH2Cl2 (1.2 mL) was stirred under argon for 1 h. Freshly prepared solution of Br2 in dry
CH2Cl2 (0.75 mL, 1/165, v/v) was then added dropwise over the period of 5 min at rt.
Quantitative TLC estimates were made based on the accumulation of 2,3,4,6-tetra-O-
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benzyl-α-D-glucopyranosyl bromide 2.2a. After that, the solvent was evaporated under
reduced pressure at rt. The residue containing crude 2.2a was then treated dissolved in
dry acetone (0.5 mL) and the potassium salt, KSBox, (22 mg, 0.117 mmol) and 18crown-6 (4 mg, 0.012 mmol) were added. The reaction mixture was stirred under argon
for 1 h at rt. After that, the mixture was diluted with CH2Cl2 (20 mL) and washed with
water (10 mL), 1% aq. NaOH (10 mL) and water (3 x 10 mL), the organic phase was
separated, dried, and concentrated in vacuo. The residue was purified by silica gel
column chromatography (ethyl acetate/hexane gradient elution) to afford the title
compound 2.3a as a white foam in 82% yield. Analytical data for 2.3a were essentially
the same as reported previously.8

2-Benzothiazolyl 2,3,4,6-tetra-O-benzyl-1-thio-β-D-glucopyranoside (2.4a).
Crude glycosyl bromide 2.2a (~48 mg, 0.078 mmol), obtained as described for the
synthesis of 2.3a, was dissolved in dry acetone (0.5 mL) and potassium salt of 2mercaptobenzotriazole (24 mg, 0.117 mmol) and 18-crown-6 (4 mg, 0.012 mmol) were
added. The reaction mixture was stirred under argon for 1 h at rt, then diluted with
CH2Cl2 (20 mL) and washed with water (10 mL), 1% aq. NaOH (10 mL), and water (3 x
10 mL). The organic phase was separated, dried, and concentrated in vacuo. The residue
was purified by silica gel column chromatography (ethyl acetate/hexane gradient elution)
to afford the title compound 2.4a as a white foam in 75% yield. Analytical data for 2.4a
were essentially the same as reported previously.33
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Ethyl 2,3,4,6-tetra-O-benzyl-1-thio-β-D-glucopyranoside (2.6)
A mixture of ethanethiol (17 μL, 0.225 mmol) and sodium hydride (1.0 mg, 0.025 mmol)
was added to a solution of 2.2a (~95 mg, 0.15 mmol), prepared as described for the
synthesis of 2.3a, in dry CH2Cl2 (1.0 mL) at 0 °C and the resulting mixture was stirred
under argon for 1 h at rt. The reaction mixture was then diluted with CH2Cl2 (20 mL) and
washed with water (10 mL), 20% aq. NaHCO3 (10 mL), and water (3 x 10 mL), the
organic phase was separated, dried, and concentrated in vacuo. The residue was purified
by silica gel column chromatography (ethyl-acetate/hexane gradient elution) to afford the
title thioglycoside 2.6 as a white foam in 92% yield. Analytical data for 2.6 were
essentially the same as reported previously.34

2,3,4,6-Tetra-O-benzyl-α-D-glucopyranosyl chloride (2.8)
To a stirred solution of 2.5a (100 mg, 0.15 mmol) and dimethylformamide (6 μL, 0.075
mmol) in dry CH2Cl2 (1.2 mL) under argon, thionyl chloride (34 μL, 0.45 mmol) was
added dropwise. The reaction mixture was kept for 1 h and then concentrated under the
reduced pressure. The residue was purified by short-path silica gel column
chromatography (ethyl acetate/hexane gradient elution) to afford the title compound 2.8
as a colorless syrup in 84% yield. Analytical data for 2.8 were essentially the same as
reported previously.35

2,3,4,6-Tetra-O-benzyl-D-glucopyranosyl fluoride (2.9)
To a stirred solution of 2.5a (100 mg, 0.15 mmol) in THF (1.2 mL) diethylaminosulfur
trifluoride (DAST, 72 μL, 0.55 mmol) was added at -30 °C under argon. The external
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cooling was then removed and the reaction mixture was stirred for 24 h at rt. After that,
the solution was cooled to -30 °C and methanol (0.1 mL) was added, the resulting
mixture was warmed to rt and the volatiles were evaporated off in vacuo. The residue was
dissolved in CH2Cl2 (20 mL) and washed successively with water (10 mL), 20% aq.
NaHCO3 (10 mL), and water (3 x 10 mL). The organic phase was separated, dried, and
concentrated in vacuo. The residue was purified by short-path silica gel column
chromatography (ethyl acetate/hexane gradient elution) to afford the title fluoride 2.9 as a
white foam in 88% yield (α/β = 1/2.8). Analytical data for 2.9 were essentially the same
as reported previously.36,37

2,3,4,6-Tetra-O-benzyl-D-glucopyranose (2.10)
A solution of 2.5a (65 mg, 0.10 mmol) and N-bromosuccinimide (NBS) (45 mg, 0.20
mmol) in acetone/water (1.5 mL, 9/1, v/v) was stirred for 16 h at rt. The reaction mixture
was then diluted with CH2Cl2 (20 mL) and washed with water (10 mL), 20% aq.
NaHCO3 (10 mL), and water (3 x 10 mL). The organic phase was separated, dried, and
concentrated in vacuo. The residue was purified by silica gel column chromatography
(ethyl acetate/hexane gradient elution) to afford the title hemiacetal 2.10 as a colorless
syrup in 90% yield (α/β = 1/1). Analytical data for 2.10 were essentially the same as for
the commercial sample.

2,3,4,6-Tetra-O-benzyl-α-D-glucopyranosyl trichloroacetimidate (2.11)
NaH (8 mg, 0.37 mmol) was added portionwise to a stirred solution of compound 2.10
(100 mg, 0.185 mmol) and trichloroacetonitrile (85 μL, 0.84 mmol) in dry CH2Cl2 (2
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mL). After stirring for 3 h at rt, the reaction mixture was concentrated under the reduced
pressure. The residue was purified by column chromatography on silica gel (ethyl
acetate/ hexane gradient elution) to afford the title compound 2.11 as a colorless syrup in
82% yield. Analytical data for 2.11 were essentially the same as reported previously.38

2.4.3

General

Glycosylation

Procedures:

Synthesis

of

O-Glycosides

and

Oligosaccharides.

Method A – Activation with AgBF4.
A mixture containing the glycosyl donor (0.11 mmol), glycosyl acceptor (0.10 mmol),
and freshly activated molecular sieves (3Å, 200 mg) in (Cl2CH2)2 (2mL) was stirred
under argon for 1.5 h. BF3.Et2O (40 μL, 0.3 mmol) was added and the reaction mixture
was stirred for 16 h at rt. It was then diluted with CH2Cl2, the solid was filtered-off and
the residue was washed with CH2Cl2. The combined filtrate (30 mL) was washed with
20% aq. NaHCO3 (10 mL) and water (3 x 10 mL). The organic phase was separated,
dried with MgSO4, and concentrated in vacuo. The residue was purified by column
chromatography on silica gel (ethyl acetate/hexane gradient elution) to afford the
disaccharide derivative.

Method B – Activation of glycosyl donor 2.1 with BF3.Et2O
A mixture containing the glycosyl donor (0.11 mmol), glycosyl acceptor (0.10 mmol),
and freshly activated molecular sieves (3Å, 200 mg) in (Cl2CH2)2 (2mL) was stirred
under argon for 1.5 h. BF3.Et2O (40 μL, 0.3 mmol) was added and the reaction mixture
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was stirred for 16 h at rt. It was then diluted with CH2Cl2, the solid was filtered-off and
the residue was washed with CH2Cl2. The combined filtrate (30 mL) was washed with
20% aq. NaHCO3 (10 mL) and water (3 x 10 mL). The organic phase was separated,
dried with MgSO4, and concentrated in vacuo. The residue was purified by column
chromatography on silica gel (ethyl acetate/hexane gradient elution) to afford the
disaccharide derivative.

Method C- Activation of 2.1 with BF3.Et2O/AgBF4. A mixture of the glycosyl donor (0.11
mmol), glycosyl acceptor (0.10 mmol), and freshly activated molecular sieves (3 Å, 200
mg) in (Cl2CH2)2 (2 mL) was stirred under argon for 1.5 h. BF3.Et2O (40 μL, 0.33 mmol)
and AgBF4 (10 mg, 0.05 mmol) were added and the reaction mixture was stirred for 5 h
at rt. Upon completion, it was diluted with CH2Cl2, the solid was filtered-off and the
residue was washed with CH2Cl2. The combined filtrate (30 mL) was washed with 20%
aq. NaHCO3 (10 mL) and water (3 x 10 mL). The organic phase was separated, dried
with MgSO4, and concentrated in vacuo. The residue was purified by column
chromatography on silica gel (ethyl acetate/hexane gradient elution) to afford the
disaccharide derivative.

Method D - Activation of 2.6 and 2.7 with NIS. A mixture of the glycosyl donor (0.11
mmol), glycosyl acceptor (0.10 mmol), and freshly activated molecular sieves (3 Å, 200
mg) in (Cl2CH2)2 (2 mL) was stirred for 1.5 h under argon. NIS (50 mg, 0.22 mmol) was
then added and the reaction mixture was stirred for 24 h at rt. Upon completion, the solid
was filtered-off and the residue was washed with CH2Cl2. The combined filtrate (30 mL)
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was washed with 20% aq. Na2S2O3 (10 mL) and water (3 x 10 mL). The organic phase
was separated, dried over MgSO4, and concentrated in vacuo. The residue was purified
by column chromatography on silica gel (ethyl acetate/ hexane gradient elution) to afford
the disaccharide derivative.

Method E - Activation of 2.7 and 2.8 with NIS/AgBF4. A mixture of the glycosyl donor
(0.11 mmol), glycosyl acceptor (0.10 mmol), and freshly activated molecular sieves (3 Å,
200 mg) in (Cl2CH2)2 (2 mL) was stirred for 1.5 h under argon. NIS (50 mg, 0.22 mmol)
and AgBF4 (10 mg, 0.05 mmol) were added and the reaction mixture was stirred for 1020 min at rt. Upon completion, the solid was filtered-off and the residue was washed with
CH2Cl2. The combined filtrate (30 mL) was washed with 20% aq. Na2S2O3 (10 mL) and
water (3 x 10 mL). The organic phase was separated, dried over MgSO4, and
concentrated in vacuo. The residue was purified by column chromatography on silica gel
(ethyl acetate/ hexane gradient elution) to afford the disaccharide derivative.

Pent-4-en-1-yl 2,3,4,6-tetra-O-benzyl-1-thio-β-D-glucopyranoside (2.7)
The title compound was synthesized from glycosyl bromide 2.2a, obtained as described
for the synthesis of 2.3a, and 4-penten-1-ol by Method A in 89% yield as a white foam.
Analytical data for 2.7 were essentially the same as reported previously.39

Methyl

4-O-(2,3,4,6-tetra-O-benzyl-D-glucopyranosyl)-2,3,6-tri-O-benzyl-α-D-

glucopyranoside (2.16a)
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The title compound was obtained by Method A from 2.1 and 2.1240 in 65% yield (α/β =
1/5.4) or 2.6 and 2.12 in 91% yield (α/β = 1/3.4). Analytical data for 2.16a were
essentially the same as reported previously.41

Methyl

6-O-(2,3,4,6-tetra-O-benzyl-D-glucopyranosyl)-2,3,4-tri-O-benzyl-α-D-

glucopyranoside (17a).
The title compound was obtained by Method A from glycosyl donors 2.2a, 2.3a, 2.5a,
2.8, 2.9 or 2.11 and glycosyl acceptor 2.1342 in 92% (α/β 2.4:1), 89% (α/β 1.2:1), 95%
(α/β 1.3:1), 97% (α/β 1.6:1), 81% (α/β 2:1) and 80% (α/β 1.5:1) yield, respectively. (see
Table 2.1). In addition, the title compound was obtained by Method B from 2.2 and 2.13
in 91% yield (α/β = 1.4/1), by Method C - from 2.1 and 2.13 in 95% yield (α/β = 2/1), by
Method D obtained from 2.6 or 2.7 and 2.13 in 91% (α/β 1.2:1) and 89% (α/β 1:1) and
by Method E obtained from 2.6 or 2.7 and 2.13 in 92% (α/β 1.2:1) and 76% (α/β 1.2:1).
Analytical data for 2.17a were essentially the same as reported previously.43

Methyl

6-O-(2,3,4,6-tetra-O-benzoyl-β-D-glucopyranosyl)-3,4,6-tri-O-benzyl-α-D-

glucopyranoside (2.17b): This compound was obtained by Method A from glycosyl
donors 2.2b, 2.3b, 2.4b or 2.5b and glycosyl acceptor 2.13 in 96%, 91%, 90% and 90%
yield, respectively. Analytical data for 17b were essentially the same as reported
previously.44

Methyl 6-O-(3,4,6-tri-O-acetyl-2-O-benzyl-D-glucopyranosyl)-2,3,4-tri-O-benzyl-α D-glucopyranoside (17c)
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This compound was obtained by Method A from glycosyl donors 2.3c or 2.5c and
glycosyl acceptor 2.13 in n 91% (α/β 1.6:1) and 75% (α/β 1.2:1), respectively. Analytical
data for 2.17c were essentially the same as reported previously.10

Methyl

2-O-(2,3,4,6-tetra-O-benzyl-D-glucopyranosyl)-3,4,6-tri-O-benzyl-α

-D-

glucopyranoside (2.18a)
The title compound was obtained by Method A from glycosyl donor 2.5a and glycosyl
acceptor 2.14 in 92% yield (α/β = 1.4/1). Analytical data for 2.18a were essentially the
same as reported previously.10

Methyl 2-O-(2,3,4,6-tetra-O-benzoyl-β-D-glucopyranosyl)-3,4,6-tri-O-benzyl-α -Dglucopyranoside (2.18b)
This compound was obtained by Method A from glycosyl donor 2.2b and glycosyl
acceptor 2.14 in 82% yield. Analytical data for 2.18b were essentially the same as
reported previously.10

Methyl

2-O-benzyl-3-O-(2,3,4,6-tetra-O-benzyl-D-glucopyranosyl)-4,6-O

-

benzylidene-α-D-glucopyranoside (2.19a). This compound was obtained by Method A
from glycosyl donors 2.4a or 2.9 and glycosyl acceptor 2.1545 in 87 % (α/β 7.4:1) and
81% (α/β 2.3:1), respectively. Analytical data for 2.19a were essentially the same as
reported previously.46
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Pent-4-en-1-yl

3-O-(2,3,4,6-tetra-O-benzyl-D-glucopyranosyl)-4,6-O-benzylidene-2-

deoxy-2-(2,2,2-trichloroethoxycarbamoyl)−β−D-galactopyranoside (2.21)
This compound was obtained by Method A from glycosyl donors 2.2a, 2.4, 2.5 or 2.9 and
glycosyl acceptor 2047 in 86% (α/β 1.1:1), 85% (α/β 1.3:1), 83% (α/β 1.2:1) and 65%
(α/β 1.6:1) yield, respectively. Analytical data for 2.21 were essentially the same as
reported previously.10

Ethyl 6-O-(2,3,4,6-tetra-O-benzyl-D-glycopyranosyl)-2,3,4-tri-O-benzyl-1-thio−β-Dglucopyranoside (23)
This compound was obtained by Method A from glycosyl donors 2.2a, 2.4a, 2.5a, 2.8 or
2.9 and glycosyl acceptor 2.2248 in 84% (α/β 1.6:1), 87% (α/β 2:1), 89% (α/β 2.4:1),
84% (α/β 2.2:1) and 83 (α/β 2.4:1) yield, respectively. (see Table 2.2). Analytical data
for 2.23 were essentially the same as reported previously.17

Methyl 2,3,4,6-tetra-O-benzoyl-β-D-glucopyranosyl-(1→6)-2,3,4-tri-O-benzoyl-β-Dgalactopyranosyl-(1→6)-2,3,4-tri-Ο-benzyl-α-D-glucopyranoside (2.25)
This compound was obtained by one-pot glycosylation procedure in 55-70% overall yield
(22.b 62%, 2.3b 70%, 2.4b 55%, and 2.5b 72%). [α]D24.8 = + 56.74 (c = 1, CHCl3); Rf =
0.47 (ethyl acetate/hexane, 4.5/5.5, v/v); 1H NMR: δ = 3.24 (s, 3H; OCH3), 3.33 (m, 2H,
H-2, 4), 3.51 (m, 2H, H-6a,5), 3.85 (dd, 1H, J3,4 = 9.0 Hz, H-3), 3.87 (m, 1H, H-6a”),
3.93 (dd, 1H, H-6a), 4.01-4.10 (m, 3H, H-5’,5”,6b”), 4.32 (s, 1H; CH2Ph), 4.33 (dd, 1H,
H-6a’), 4.47 (d, 1H; CH2Ph), 4.50 (d, 1H, J1’,2’ = 8.0 Hz, H-1’), 4.51 (d, 1H, J1,2 = 3.4
Hz, H-1), 4.55 (d, 1H; CH2Ph), 4.55 (dd, 1H, H-6b’), 4.69 (dd, 2H; CH2Ph), 4.88 (d, 1H,
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CH2Ph), 4.91 (d, 1H, J1”,2” = 7.8 Hz, H-1”), 5.52 (dd, 1H, J2”,3” = 3.5 Hz, H-2”), 5.54 (dd,
1H, J3’,4’ = 7.8 Hz, H-3’), 5.65 (dd, 1H, J4”,5” = 9.8 Hz, H-4”), 5.75 (dd, 1H, J2’,3’ = 8.0
Hz, H-2’), 5.84 (d, 1H, J4’,5’ = 2.5 Hz, H-4’), 5.86 (dd, 1H, J3”,4” = 10.4 Hz, H-3”), 7.098.05 (m, 50H, aromatic);

13

C NMR: δ = 55.4, 63.0, 68.0, 68.4, 68.9, 69.6, 69.7, 70.0,

71.8, 72.1, 72.5, 73.0, 73.6, 74.7, 75.6, 77.4, 80.0, 80.1, 98.2, 101.3, 101.8, 127.7 (×2),
127.8, 128.0 (×2), 128.1, 128.2, 128.3, 128.3, 128.4 (×3), 128.5 (×2), 128.6 (×5), 128.6
(×6), 128.7 (×2), 128.7 (×2), 128.9, 129.0, 129.0, 129.3, 129.4, 129.5, 129.7, 129.9 (×2),
129.9 (×6), 130.0 (×3), 130.1 (×2), 133.3 (×2), 133.4, 133.5 (×2), 133.6, 133.6 (×2),
138.4,.138.6, 139.1, 165.1, 165.3, 165.6, 165.7, 166.0, 166.2. HR-FAB MS: calcd for
C90H80O23 [M+H]+: 1559.4547 ; found: 1559.4550. (See Appendix; Figure A-1, A-2, and
A-3)
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CHAPTER III

Unexpected orthogonalilty of S-benzoxazolyl and S-thiazolinyl glycosides:
Application to expeditious oligosaccharide assembly

_____________________________________________________________________
Kaeothip, S.; Pornsuriyasak, P.; Demchenko, A. V. “Unexpected orthogonalilty of SBenzoxazolyl and S-Thiazolinyl glycosides: Application to expeditious oligosaccharide
assembly”, Org. Lett. 2009, 11, 799-802.
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3.1

Introduction
Traditional linear approaches to oligosaccharide assembly are often cumbersome

and consequently the availability of complex glycostructures remains insufficient to
address the challenges of modern glycosciences.P1-3 Recent improvements in strategies
for oligosaccharide assembly, have significantly shortened the number of synthetic steps
required by minimizing protecting group manipulations between glycosylation steps.4-9
One of the most flexible assembly strategies is the orthogonal concept.10,11 Unlike the
armed-disarmed approach,12 the orthogonal activation is not reliant on the nature of the
protecting groups, which can interfere with stereoselectivity. The only requirement for
the orthogonal approach is a set of two orthogonal leaving groups and a pair of suitable
activators. Unfortunately, this simple concept is still limited to the following two
examples: Ogawa’s S-ethyl and fluoride,10,11 and the thioimidate S-thiazolinyl (STaz) and
S-alkyl/aryl.13,14 In addition, a related, albeit less flexible, semi-orthogonal approach with
the use of S-ethyl and O-pentenyl glycosides was reported,15 and was recently extended
to fluoride/pentenyl leaving groups. Overall, the orthogonal strategy is an excellent
concept for flexible sequencing of oligosaccharides that remains under explored, with too
few examples to become universal. The excellent glycosyl donor properties of glycosyl
thioimidates and their unique activation conditions have led to a number of useful
developments for oligosaccharide synthesis, including the orthogonal approach.13,14 From
our previous studies we had determined the S-benzoxazolyl (SBox) glycosyl donors16,17
to be significantly more reactive than their STaz counterparts,13,14 and, although direct
selective activations of the SBox donors over STaz acceptors were reported in the
presence of Cu(OTf)2,13,14 no comprehensive side-by-side comparisons had been
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performed.

3.2

Results and Discussion
With the main purpose of determining relative reactivity patterns of thioimidates,

we set-up a series of glycosidations including STaz,13,14 SBox,16,17 and structurally related
Mukaiyama’s S-benzothiazolyl (SBaz) derivatives.18 All reactions of benzylated glycosyl
donors 3.1-3.3 with glycosyl acceptor 3.4 promoted with MeOTf were very effective, and
disaccharide 3.5 was obtained in high yields (Table 3.1). Although the disparity amongst
the reaction times was unremarkable, it was evident that glycosidation of the STaz
glycoside 3.1 (entry 1) was about two times slower than that of its SBox counterpart 3.2
(entry 2), with the reactivity of the SBaz glycoside 3 (entry 3) somewhere in the middle.
To gain better control of the glycosylations and to achieve a more precise
differentiation of reactivity between the different thioimidates, we turned to investigating
other activators. Amongst these, results obtained with common alkylating (and acylating)
reagents were particularly attractive. For example, MeI was only effective for
glycosidation of per-benzylated STaz glycoside 3.1 (entry 4). Surprisingly, when these
reaction conditions were applied to the glycosidation of expectedly more reactive SBox
and SBaz glycosides, no glycosylation took place (entry 5). Also BnBr was only effective
for glycosidation STaz derivative 3.1, whereas glycosyl donors 3.2 or 3.3 gave only trace
amounts of products (entries 6-8).
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Table 3.1 Alkylation-initiated glycosidation of benzylated thioimidates 3.1-3.3

Entry

Donor

Promoter
(equiv, temp)

Time

Product 3.5
Yield (%), α/β ratio

1

3.1

MeOTf (3, rt)

0.75 h

87%, 1.4/1

2

3.2

MeOTf (3, rt)

0.33 h

88%,1.6/1

3

3.3

MeOTf (3, rt)

0.58 h

89%, 1.6/1

4

3.1

MeI (9, rt)

120 h

89%, 8.0/1

5

3.2 or 3.3

MeI (9-15, rt)

120 h

no reaction

6

3.1

BnBr (3, 55 oC)

24 h

90%, 3.5/1

7

3.2

BnBr (3-9, 55oC)

120 h

traces

8

3.3

BnBr (3-9, 55oC)

120 h

no reaction
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Subsequently, similar observations have been made with less reactive perbenzoylated glycosyl donors. Thus, all reactions of benzoylated glycosyl donors 3.6-3.8
with glycosyl acceptor 3.4 promoted with MeOTf were very effective, and disaccharide
3.9 was obtained in high yields (Table 3.2, entries 1-3). With MeI though, no
glycosidation of benzoylated glycosyl donors 3.6-3.8 took place (entry 4). BnBr was only
effective for the STaz derivative 3.6, (entry 5), whereas glycosidation of glycosyl donors
3.7 or 3.8 gave no products (entry 6). It should be noted that all reactions with benzylated
glycosyl donors (Table 3.1) were significantly faster than those with their benzoylated
counterparts (Table 3.2).

Table 3.2 Alkylation-initiated glycosidation of benzoylated thioimidates 3.6-3.8
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Entry

Donor

Promoter
(equiv, temp)

Time

Product 3.9
Yield (%), α/β ratio

1

3.6

MeOTf (3, rt)

2h

97%, β only

2

3.7

MeOTf (3, rt)

1h

95%, β only

3

3.8

MeOTf (3, rt)

2h

84%, β only

4

3.6-3.8

MeI (9-15, rt)

120 h

No reaction

5

3.6

BnBr (3, 55 oC)

72 h

79%, β only

6

3.7 or 3.8

BnBr (3-9, 55oC)

120 h

no reaction

This discovery signified the gap in our understanding of the thioimidate activation
and created a basis for the development of the STaz-SBox orthogonal strategy. The
uniqueness of this approach would be that both leaving groups employed are of
essentially the same class. Although certain pathways for the activation of thioimidates
were postulated (Scheme 3.1),19-21 little proof had been available until our recent
mechanistic study,16,17 wherein we showed that MeOTf-promoted activation of the SBox
glycosyl donor 3.10 proceeds via the anomeric sulfur atom (direct activation). This was
confirmed by isolating the departed S-methylated aglycone MeSBox (3.11, Scheme 3.1).
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Scheme 3.1 Activation of thioimidates: a study with SBox glycoside 3.10.

Since the exact nature of the STaz activation was not known, our working
hypothesis for this study was based on our previous findings with the SBox moiety,
taking into consideration the structural differences between the two moieties. We
anticipated that the activation of the STaz moiety proceeds via the nitrogen (remote
activation), as opposed to the direct activation of the SBox moiety. This remote activation
of STaz would lead to a marginally slower reaction with a powerful promoter, such as
MeOTf (refer to Tables 3.1 and 3.2). When weak alkylating reagents are used (MeI,
BnBr), a powerful nucleophile is needed to replace the iodine or bromine, respectively.
Evidently, this can be predominantly achieved with STaz glycosides that bear the reactive
nitrogen atom, but not with the SBox glycosides, which can only be activated via the
exocyclic sulfur16,17 (Figure 3.1). For comparison, previous reports suggest that SPh
glycosides do not react with MeI (direct activation), while S-pyridyl derivatives do
(remote activation is postulated).21
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Figure 3.1 Working hypothesis for thioimidate activation.

The credibility of this working hypothesis was verified by a series of experiments
in which glycosyl donor 3.1 was reacted with the standard acceptor 3.4 in the presence of
BnBr (Scheme 3.2). Upon disappearance of 3.1, the reaction mixture was concentrated in
vacuo and the fastest moving UV-active spot, corresponding to the benzylated aglycone,
was separated from the disaccharide product 3.5 by column chromatography on silica gel.
The structure of the isolated alkylated aglycone was assigned as thioamide 3.13
(BnNTaz) by X-ray (Figure 3.2) and UV (λmax = 277 nm, C=S).

Scheme 3.2 Mechanism of thioimidate activation with BnBr.

112

A similar reaction between 3.2 and 3.4 was significantly slower, nevertheless, we
succeeded in isolating the departed aglycone, which was assigned as thioimide 3.14
(BnSBox) by X-Ray (Figure 3.2) and UV (λmax = 280, 287 nm, C=N), as anticipated. To
exclude the impact of tautomerization of the products both reactions were monitored by
HPLC (Figure 3.3).

Figure 3.2 X-ray structure of compound 3.14 and 3.15

113

Br
A
OBn
O

BnO
BnO

BnO

O
O

BnO
BnO

BnO
OMe

B
S

S
N

C
OBn
O

BnO
BnO

S
BnO
D

BnO
BnO

OH
O
BnO
OMe

E

Figure 3.3 HPLC chromatograms of reaction mixture at 1h, 2h, 3h, 5h, 9h and 16h

114

N
S

With a better understanding of the mechanistic pathway, we were well positioned
to undertake further studies of expeditious oligosaccharide assembly. First, the activation
of STaz donors 3.1 and 3.6 over SBaz/SBox acceptors 3.15a-c was investigated in the
presence of BnBr or MeI. As a result, disaccharides 3.16a-c were obtained in good yields
(70-82%, Table 3.3). Conversely, SBox donor 3.7 was also activated over the STaz
acceptor 3.15d. This activation could be accomplished in the presence of a variety of
activators, amongst which Bi(OTf)3 was the most promising; disaccharide 3.16d was
obtained in 69% yield. The terminal SBox moieties of 3.16b or 3.16c could be
glycosidated either with model acceptor 3.4 or with STaz acceptor (3.15d). Conversely,
the STaz moiety of 3.16d could be glycosidated with 3.4 or activated over the SBox
acceptor (3.15c). The resulting trisaccharides 3.17a-d were isolated in 62-92% yields
(Table 3.3), with 1,6-anydro and hemiacetal being the major by-products identified.
Among trisaccharides generated, 3.17c and 3.17d can be used in subsequent sequencing.

Table 3.3 Orthogonal activations for oligosaccharide synthesis

115

Entry

Donor

Acceptor A

Promoter A

1

a

Disaccharide

Acceptor B

(yield, α/β)

B

3.4

BnBr

Promoter
a

(75%, β only)

3.4

MeI

(yield, α/β)

AgBF4

(70%, β only)

2

Trisaccharide

AgOTf

(82%, 6/1)
(92%, 1.6/1)
3

3.6

BnBr

3.4

AgOTf

3.15d

Bi(OTf)3

3.17a
(72%, β only)

(76%, β only)

4

3.16c

(62%, β only)
Bi(OTf)3

5

3.4

AgBF4

3.15c

BnBr

3.17a
(81%, β only)

(69%, β only)

3.16d

6

(67%, β only)

a

– Conditions: All glycosylations were performed in 1,2-dichloromethane in the
presence of molecular sieves (3 Å). Promoters: BnBr (3 equiv, 55 oC); AgBF4 (3 equiv,
rt); MeI (9 equiv, 55 oC); AgOTf (2 equiv, rt); Bi(OTf)3 (3 equiv, 0 oC Æ rt). Reaction
time: 3.16a - 24 h, 3.16b – 16 h, 3.16c – 24 h, 3.16d – 1h, 3.17a – 30, 30, and 40 min
(entries 1, 3, and 5, respectively), 3.17b – 15 min, 3.17c – 2 h, 3.17d – 36 h.
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The further study of this methodology was applied to the synthesis of a β-(1→6)linked hexasaccharide via the five-step selective activation sequence which was
employing six different leaving groups as depicted in Scheme 3.33. The synthesis began
with the selective activation of thiocyanate donor 3.18 over STaz glycosyl acceptor 3.15d
using Cu(OTf)2 as a promoter. The STaz leaving group of disaccharide 3.16d was then
directly activated over SBox acceptor 3.15c with benzyl bromide to give trisaccharide
3.17d. The SBox moiety of 3.17d was then selectively activated over fluoride acceptor
3.19 in the in presence of MeOTf. The resulting tetrasaccharide 3.20 was glycosidated
with thioglycoside acceptor 3.21 in presence of AgClO4/Cp2ZrCl2 to provide
pentasaccharides 3.22. Finally, the S-ethyl leaving group of 3.22 was selectively activated
over n-pentenyl acceptor 3.23 in the presence of MeOTf as a promoter to furnish the
hexasaccharide 3.24 in 72% yield.22

3.3

Conclusions
In conclusion, a mechanistic study of the alkylation pathway for the activation of

glycosyl thioimidates has led to the development of the “thioimidate-only orthogonal
strategy”. The synthesis of trisaccharides 3.17a-d clearly illustrates the entirely
orthogonal character of the SBox and STaz derivatives.
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and STaz glycosides in the synthesis of 1,2-trans hexasaccharide.

3.4

Experimental part

3.4.1

General
Column chromatography was performed on silica gel 60 (70-230 mesh), reactions

were monitored by TLC on Kieselgel 60 F254. The compounds were detected by
examination under UV light and by charring with 10% sulfuric acid in methanol.
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Solvents were removed under reduced pressure at <40 oC. CH2Cl2, ClCH2CH2Cl, and
MeCN were distilled from CaH2 directly prior to application. Methanol was dried by
refluxing with magnesium methoxide, distilled and stored under argon. Pyridine was
dried by refluxing with CaH2 and then distilled and stored over molecular sieves (3Å).
Molecular sieves (3Å or 4Å), used for reactions, were crushed and activated in vacuo at
390 °C during 8 h in the first instance and then for 2-3 h at 390 °C directly prior to
application. AgOTf (Acros) was co-evaporated with toluene (3 x 10 mL) and dried in
vacuo for 2-3 h directly prior to application. Optical rotations were measured at ‘Jasco P1020’ polarimeter. 1H-NMR spectra were recorded at 300 or 500 MHz, 13C-NMR spectra
were recorded at 75 or 125 MHz. HRMS determinations were made with the use of JEOL
MStation (JMS-700) Mass Spectrometer.

3.4.2 Synthesis of glycosyl acceptor

Benzothiazol-2-yl 2,3,4-tri-O-benzoyl-1-thio-β-D-glucopyranoside (3.15a)
Benzothiazol-2-yl 2,3,4,6-tetra-O-acetyl-1-thio-β-D-glucopyranoside23 (550 mg, 1.1
mmol) was dissolved in methanol (5 mL) and the pH 8-9 was adjusted by careful addition
of 1M solution of NaOCH3 in MeOH (~0.1 mL). The reaction mixture was kept for 1 h at
rt, then Dowex (H+) was added until a neutral pH was reached. The resin was filtered off
and washed with methanol (3 x 5 mL). The combined filtrate was concentrated in vacuo
and dried. The residue was dissolved in dry pyridine (5.0 mL) and triphenylmethyl
chloride (439 mg, 1.57 mmol) was added. The reaction mixture was left stirring for 16 h
at rt. After that, the reaction mixture was cooled to 0 °C and benzoyl chloride (0.49 mL,
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4.21 mmol) was added dropwise. The reaction mixture was allowed to gradually warm
up. Upon stirring for 3 h at rt, the reaction was quenched with methanol (5 mL), coevaporated with toluene (3 x 10 mL), then diluted with dichloromethane (20 mL) and
washed with 1N HCl (10 mL), water (10 mL), sat. NaHCO3 (10 mL), and water (3 x 10
mL). The organic layer was separated, dried with MgSO4, and concentrated in vacuo. The
residue was purified by silica gel column chromatography (ethyl acetate-toluene gradient
elution). After that, the product was dissolved in dichloromethane (10 mL) containing
one drop of water and trifluoroacetic acid (0.2 mL) was added dropwise. Upon
completion, the reaction was then diluted with dichloromethane (10 mL), washed with
saturated NaHCO3 (10 mL) and water (3 x 15 mL). The organic layer was separated,
dried with MgSO4 and concentrated in vacuo. The residue was purified by silica gel
column chromatography (ethyl acetate-toluene gradient elution) to obtain 3.15a as yellow
amorphous solid in 64% yield. Rf = 0.35 (ethyl acetate/toluene, 1.5/8.5, v/v); [α]D23 = 0.48
(c = 1.0, CHCl3); 1H NMR: δ, 2.75 (broad s, 1H, OH), 3.86 (m, 2H, H-6a, 6b), 4.06 (m,
1H, H-5), 5.62 (dd, 1H, J4,5 = 4.7 Hz, H-4), 5.74 (dd, 1H, J2,3 = 4.5 Hz, H-2), 5.97 (d, 1H,
J1.2 = 10.2 Hz, H-1), 6.11 (dd, 1H, J3,4 = 9.6 Hz, H-3), 7.2- 8.10 (m, 19H, aromatic) ppm;
13

C NMR: δ, 60.6, 61,7, 69.4, 70.8, 74.0, 79.7, 84.4, 121.3, 122.5, 125.2, 126.6, 128.6

(×4), 128.7, 128.7 (×2), 128.8, 128.9, 129.9 (×2), 130.1 (×3), 133.6, 133.7, 134.0, 135.8,
152.9, 162.4, 165.4, 165.9, 166.1 ppm; HR FAB MS [M+Na]+ calcd for C34H27NO8S2Na
664.1076, found 664.1085.

3.4.3

General glycosylation procedures
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Method A. A typical MeOTf - promoted glycosylation procedure: A mixture of the
glycosyl donor (0.11 mmol), glycosyl acceptor (0.10 mmol), and freshly activated
molecular sieves (3Å, 200 mg) in (ClCH2)2 (2 mL) was stirred under argon for 1 h.
MeOTf (0.33 mmol) was added and the reaction mixture was stirred for 20 min – 2 h.
Upon completion, the reaction mixture was diluted with CH2Cl2 (30 mL) and washed
with water (10 mL), saturated NaHCO3 (10 mL) and water (3 x 10 mL). The organic
phase was separated, dried and concentrated in vacuo. The residue was purified by
column chromatography on silica gel (acetone/toluene gradient elution) to allow the
corresponding disaccharide. Anomeric ratios (if applicable) were determined by
comparison of the integral intensities of relevant signals in 1H NMR spectra.

Method B. A typical MeI - promoted glycosylation procedure. A mixture of the glycosyl
donor (0.11 mmol), glycosyl acceptor (0.10 mmol), and freshly activated molecular
sieves (3Å, 200 mg) in (ClCH2)2 (2 mL) was stirred under argon for 1 h, then MeI (1.01.5 mmol) was added. The reaction mixture was stirred for 60 h at rt. Upon completion,
the reaction mixture was diluted with CH2Cl2, the solid was filtered-off and the residue
was washed with CH2Cl2. The combined filtrate (30 mL) was washed with 20% aq.
NaHCO3 (10 mL) and water (3 x 10 mL), the organic phase was separated, dried with
MgSO4 and concentrated in vacuo. The residue was purified by column chromatography
on silica gel (ethyl acetate/hexane gradient elution) to allow the corresponding di- or
oligosaccharide. Anomeric ratios (if applicable) were determined by comparison of the
integral intensities of relevant signals in 1H NMR spectra.
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Method C – A typical BnBr- promoted glycosylation procedure:

A mixture of the

glycosyl donor (0.11 mmol), glycosyl acceptor (0.10 mmol), and freshly activated
molecular sieves (3Å, 200 mg) in (ClCH2)2 (2 mL) was stirred under argon for 1 h, then
BnBr (0.33-0.99 mmol) was added. The reaction mixture was stirred for 24-36 h at 55 °C.
Upon completion, the reaction mixture was diluted with CH2Cl2, the solid was filteredoff and the residue was washed with CH2Cl2. The combined filtrate (30 mL) was washed
with 20% aq. NaHCO3 (10 mL) and water (3 x 10 mL), the organic phase was separated,
dried with MgSO4 and concentrated in vacuo. The residue was purified by column
chromatography on silica gel (ethyl acetate/hexane gradient elution) to afford the
corresponding di- or oligosaccharide. Anomeric ratios (if applicable) were determined by
comparison of the integral intensities of relevant signals in 1H NMR spectra.

Method D – A typical Bi(OTf)3- promoted glycosylation procedure: A mixture the
glycosyl donor (0.11 mmol), glycosyl acceptor (0.10 mmol), and freshly activated
molecular sieves (3 Å, 200 mg) in (ClCH2)2 (2mL) was stirred under argon for 1 h. The
reaction mixture was cooled down at 0°C and then Bi(OTf)3 (0.22 mmol) was added into
the solution. After that the reaction mixture was stirred for 1-2 h at rt. Upon completion,
the reaction mixture was diluted with CH2Cl2, the solid was filtered-off, and the residue
was washed with CH2Cl2. The combined filtrate (30 mL) was washed with 20% aq.
NaHCO3 (15 mL) and water (3 × 10 mL), and the organic phase was separated, dried
over MgSO4, and concentrated in vacuo. The residue was purified by column
chromatography on silica gel (ethyl acetate/hexane gradient elution) to afford a di- or
oligosaccharide derivative.
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Method E – A typical AgOTf- promoted glycosylation procedure: A mixture the glycosyl
donor (0.11 mmol), glycosyl acceptor (0.10 mmol), and freshly activated molecular
sieves (3 Å, 200 mg) in (ClCH2)2 (2mL) was stirred under argon for 1 h. Freshly
conditioned AgOTf (0.22 mmol) was added and the reaction mixture was stirred for 1–2
h at rt and then diluted with CH2Cl2, the solid was filtered-off, and the residue was
washed with CH2Cl2. The combined filtrate (30 mL) was washed with 20% aq. NaHCO3
(15 mL) and water (3 × 10 mL), and the organic phase was separated, dried over MgSO4,
and concentrated in vacuo. The residue was purified by column chromatography on silica
gel (ethyl acetate/hexane gradient elution) to afford an oligosaccharide derivative.

Method F – A typical AgBF4- promoted glycosylation procedure: A mixture the glycosyl
donor (0.11 mmol), glycosyl acceptor (0.10 mmol), and freshly activated molecular
sieves (3 Å, 200 mg) in (ClCH2)2 (2mL) was stirred under argon for 1 h. AgBF4 (0.22
mmol) was added and the reaction mixture was stirred for 2 h at rt and then diluted with
CH2Cl2, the solid was filtered-off, and the residue was washed with CH2Cl2. The
combined filtrate (30 mL) was washed with 20% aq. NaHCO3 (15 mL) and water (3 × 10
mL), and the organic phase was separated, dried over MgSO4, and concentrated in vacuo.
The residue was purified by column chromatography on silica gel (ethyl acetate/hexane
gradient elution) to afford an oligosaccharide derivative.

Method G-MeOTf promoted glycosylation procedure: A mixture the glycosyl donor (0.11
mmol), glycosyl acceptor (0.10 mmol), and freshly activated molecular sieves (3 Å, 200
mg) in (ClCH2)2 (2mL) was stirred under argon for 1 h. MeOTf (0.33 mmol) was then
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added into the solution. After that the reaction mixture was stirred for 3-5 h at rt. Upon
completion, the reaction mixture was diluted with CH2Cl2, the solid was filtered-off, and
the residue was washed with CH2Cl2. The combined filtrate (30 mL) was washed with
20% aq. NaHCO3 (15 mL) and water (3 × 10 mL), and the organic phase was separated,
dried over MgSO4, and concentrated in vacuo. The residue was purified by column
chromatography on silica gel (ethyl acetate/hexane gradient elution) to afford a di- or
oligosaccharide derivative. Anomeric ratios (if applicable) were determined by
comparison of the integral intensities of relevant signals in 1H-NMR spectra.

Method H-AgClO4/Cp2ZrCl promoted glycosylation procedure: A mixture the glycosyl
donor (0.11 mmol), glycosyl acceptor (0.10 mmol), and freshly activated molecular
sieves (4 Å, 200 mg) in (ClCH2)2 (2mL) was stirred under argon for 1 h. AgBF4 (0.22
mmol) and Cp2ZrCl (0.22 mmol) were then added into the solution. After that the
reaction mixture was stirred for 3-5 h at rt. Upon completion, the reaction mixture was
diluted with CH2Cl2, the solid was filtered-off, and the residue was washed with CH2Cl2.
The combined filtrate (30 mL) was washed with 20% aq. NaHCO3 (15 mL) and water (3
× 10 mL), and the organic phase was separated, dried over MgSO4, and concentrated in
vacuo. The residue was purified by column chromatography on silica gel (ethyl
acetate/hexane gradient elution) to afford a di- or oligosaccharide derivative. Anomeric
ratios (if applicable) were determined by comparison of the integral intensities of relevant
signals in 1H-NMR spectra.
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Methyl

2,3,4-tri-O-benzyl-6-O-(2,3,4,6-tetra-O-benzyl-D-glucopyranosyl)-α-D-

glucopyranoside (3.5). The title compound was obtained as a colorless syrup by a range
of methods in 87-90% yield (see Table 3.1 of the manuscript). Analytical data for 3.8 was
in good agreement with those reported previously.24

Methyl

2,3,4-tri-O-benzoyl-6-O-(2,3,4,6-tetra-O-benzoyl-D-glucopyranosyl)-α-D-

glucopyranoside (3.9). The title compound was obtained as a white foam by a variety of
methods shown in Table 3.2 in the manuscript in 79-97% yield. Analytical data for 3.9
was in good agreement with those reported previously.25

Benzothiazol-2-yl

2,3,4-tri-O-benzoyl-6-O-(2,3,4,6-tetra-O-benzoyl-β-D-

glucopyranosyl)-1-thio-β-D-glucopyranoside (3.16a). The title compound was obtained
by Method C from 2-thiazolinyl 2,3,4,6-tetra-O-benzoyl-1-thio-β-D-glucopyranoside
(3.6)14 and 3.15a in 70% yield as a white foam. Analytical data for 3.16a: Rf = 0.6 (ethyl
acetate/toluene, 1/4, v/v ); [α]D24 +49.9 (c = 1, CHCl3); 1H NMR; δ, 3.58 (m, 2H, H6a,6b), 4.12 (m, 2H, H-5,5’), 4.36 (dd, 1H, J5’,6b’ = 7.4 Hz, H-6b’), 4.48 (dd, 1H, J5’,6a’ =
2.8 Hz, J6a’,6b’ = 12.1 Hz, H-6a’), 4.60 (m, 1H, H-4), 5.44 (d, 1H, J4’,5’ = 8.7 Hz, H-4’),
5.72 (m, 2H, H-3,3’), 5.85 (d, 1H, J1,2 = 10.1 Hz, H-1), 5.93 (dd, 1H, J2’,3’ = 9.4 Hz, H2’), 5.95 (dd, 1H, J2,3 = 5.0 Hz, H-2), 7.1-8.10 (m, 39H, aromatic); 13C NMR: δ, 63.1,
64.2, 67.7, 68.6, 69.3, 69.3, 70.8, 72.1, 74.3, 77.4, 84.6, 98.0, 121.2 (×2), 122. 5, 125.1,
125.5, 126.5, 126.7 (×2), 128.4 (×2), 128.4 (×2), 128.5 (×3), 128.6 (×2), 128.6 (×3),
128.7 (×2), 128.7 (×2), 128.9, 128.9, 129.0, 129.2 (×2), 129.4, 129.9 (×2), 129.9 (×5),
130.1 (×2), 130.1 (×3), 130.3 (×2), 133.1, 133.7 (×2), 133.7, 134.5, 135.9, 152. 9, 162.5,

125

164.5, 165.3 (×2), 165.9, 166.2 ppm; HR FAB MS [M+Na]+ calcd for C68H53NO17S2Na
1242.2653, found 1242.2683.

Benzoxazol-2-yl

2,3,4-tri-O-benzyl-6-O-(2,3,4,6-tetra-O-benzyl-α/β-D-

glucopyranosyl)-1-thio-β-D-glucopyranoside (3.16b). The title compound was obtained
from

2-thiazolinyl

2,3,4,6-tetra-O-benzyl-1-thio-β-D-glucopyranoside

(3.1)14

and

benzoxazolyl 2,3,4-tetra-O-benzyl-1-thio-β-D-glucopyranoside (3.15b)26 by Method B in
82% yield and Method C in 85% yield, as a colorless syrup. Analytical data for 3.16b: Rf
= 0.52 (ethyl acetate/hexane, 3/7, v/v); 1H NMR; δ, 3.28 (dd, 1H, J2,3 = 9.8 Hz, H-2), 3.82
(dd, J3’,4’ = 9.2 Hz, H-3’), 3.42-3.82 (m, 10H, H-3, 4, 5, 6a, 6b, 2’, 4’, 5’, 6a’, 6b’), 4.434.95 (m, 14H, CH2Ph), 4.98 (d, 1H, J1,2 = 3.4 Hz, H-1), 5.09 (d, 1H, J1’,2’ = 3.5 Hz, H-1’),
5.38 (d, 1H, J1,2 = 10.1 Hz, H-1), 7.10-7.65 (m, 39H, aromatic); 13C NMR: δ, 65.5, 68.7,
70.4, 72.3, 73.5, 75.0, 75.3, 75.7, 75.8, 77.4, 79.8, 80.3, 80.8, 81.8, 85.0, 86.7, 97.3,
119.2, 124.4, 124.6, 127.6 (×2), 127.6 (×2), 127.7 (×2), 127.8 (×2), 127.8 (×3), 128.0
(×3), 128.0 (×3), 128.1 (×3), 128.3 (×3), 128.5 (×3), 128.5 (×3), 128.6 (×3), 128.6 (×3),
128.7 (×2), 137.7, 138.2, 138.4, 138.5, 138.7, 138.7, 138.8, 139.0, 142.0, 152.0, 161.7
ppm; HR FAB MS [M+Na]+ calcd for C68H67NO11SNa 1128.4333, found 1128.4368.

Benzoxazol-2-yl

2,3,4-tri-O-benzoyl-6-O-(2,3,4,6-tetra-O-benzoyl-β-D-

glucopyranosyl)-1-thio-β-D-glucopyranoside (3.16c). The title compound was obtained
by Method C from 2-thiazolinyl 2,3,4,6-tetra-O-benzoyl-1-thio-β-D-glucopyranoside
(3.6)14 and benzoxazolyl 2,3,4-tetra-O-benzoyl-1-thio-β-D-glucopyranoside (3.15c)27 in
76% yield as a colorless syrup. Analytical data for 3.16c: Rf = 0.45 (ethyl acetate/hexane,
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7/3, v/v); [α]D24= 48.5 (c = 1, CHCl3]; 1H NMR; δ, 3.53 (dd, 1H, J5,6b = 8.3 Hz, H-6b),
3.86 (dd, 1H, J6a,6b = 4.8 Hz, H-6a), 4.12 (m, 1H, H-5’), 4.15 (m, 1H, H-5), 4.34 (dd, 1H,
J5,6b’ = 7.9 Hz, H-6b), 4.47 (dd, 1H, J6a’,6b’ = 2.6 Hz), 4.74 (m, 1H, H-2), 5.43 (d, 1H, J4’,5’
= 8.4 Hz, H-4’), 5.68 (dd, 1H, J4,5 = 9.8 Hz, H-4), 5.72 (dd, 1H, J3’,4’ = 9.6 Hz, H-3’),
5.90-5.99 (m, 3H, H-1, 1’, 2’), 7.09-8.10 (m, 39H, aromatic);
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C NMR: δ, 63.3, 64.4,

67.8, 68.8, 79.4, 71.0, 72.3, 74.5, 77.6, 84.3, 110.5, 119.2, 121.4, 124.9, 124.9, 126.9
(×2), 128.7 (×5), 128.8 (×5), 128.9 (×2), 129.0, 129.1, 129.2, 129.5, 129.5, 130.5 (×3),
130.1 (×5), 130.3 (×5), 130.5 (×2), 133.3, 133.7, 133.8 (×3), 133.9, 134.7, 141.9, 152.2,
164.7, 165.5, 165.5, 165.6, 166.1, 166.4 ppm; HR FAB MS [M+Na]+ calcd for
C68H53NO18SNa 1226.2281, found 1226.2283.

2-Thiazolinyl 2,3,4-tri-O-benzoyl-6-O-(2,3,4,6-tetra-O-benzoyl-β-D-glucopyranosyl)1-thio-β-D-glucopyranoside (3.16d). The title compound was obtained by Method D
from benzoxazolyl 2,3,4,6-tetra-O-benzoyl-1-thio-β-D-glucopyranoside (3.7)17 and 2thiazolinyl 2,3,4,6-tetra-O-benzoyl-1-thio-β-D-glucopyranoside (3.15d)14 in 69% yield as
a white foam. Analytical data for 3.16d was in a good agreement with those reported
previously.28

Methyl

2,3,4-tri-O-benzyl-6-O-[2,3,4-tri-O-benzoyl-6-O-(2,3,4,6-tetra-O-benzoyl-β-

D-glucopyranosyl)-b-D-glucopyranosyl]-β-D-glucopyranoside (3.17a).

The title

compound was obtained as a colorless syrup by Method E from methyl 2,3,4-tri-Obenzyl-α-D-glucopyranoside (3.4)29 and 3.16c in 72% yield and Method F from 3.4 and
3.16a in 75% yield and from 3.4 and 3.16d in 81% yield. Analytical data for 3.17a was
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in a good agreement with those reported previously.30

Methyl

2,3,4-tri-O-benzyl-6-O-[2,3,4-tri-O-benzyl-6-O-(2,3,4,6-tetra-O-benzyl-D-

glucopyranosyl)-D-glucopyranosyl]-α-D-glucopyranoside (3.17b). The title compound
was obtained by Method E from 3.4 and 3.16b in 92% yield as a white amorphous solid.
Analytical data for α/β−3.17b; Rf = 0.48 (ethyl acetate/hexane, 3:7, v/v );
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C NMR: δ,

55.4, 70.7, 70.8, 72.4, 72.5., 72,6, 73.5, 73.6, 73.6, 75.1, 75,1, 75.2, 75.6, 75.7, 75.7, 75.7,
75.8, 75.9, 77.4, 78.0, 80.0, 80.3, 80.3, 80.4, 80.5, 81.9, 82.1, 82.3, 82.4, 84.9, 97.3, 97.4,
97.5, 98.1, 98.2, 98.2, 103.7, 127.7, 127.7, 127.8, 127.9, 127.9, 127.9, 128.0, 128.0,
128.1, 128.2, 128.3, 128.5, 128.5, 128.6, 128.6, 138.2, 138.3, 138.4, 138.5, 138.6, 138.6,
138.7, 138.8, 138.9, 139.0, HR FAB MS [M+Na]+ calcd for C89H94O16Na 1441.6440,
found 1441.6437.

2-Thiazolinyl

2,3,4-tri-O-benzoyl-6-O-(2,3,4-tri-O-benzoyl-6-O-(2,3,4,6-tetra-O-

benzoyl-β-D-glucopyranosyl)-β-D-glucopyranosyl)-1-thio-β−D-glucopyranoside
(3.17c). The title compound was obtained by Method D from 16c and 15d in 62 % yield
as a white foam. Analytical data for 17c: Rf = 0.46 (ethyl acetate/toluene, 1/4, v/v );
[α]D21 = 5.84 (c = 1, CHCl3); 1H NMR; δ, 3.29-3.39 (m, 2H, CH2S), 3.59 (m, 1H, H-6a’),
3.85 (m, 2H, H-5’,6b”), 4.00 (m, 1H, 6a”), 4.13-4.29 (m, 2H, CH2N), 4.44 (m, 2H, H-5,
6a’), 4.66 (m, 1H, H-6b), 4.67 (d, 1H, J1”,2” = 7.8 Hz, H-1”), 5.04 (dd, 1H, J4”,5” = 9.5 Hz,
H-4”), 5.11 (dd, 1H, J2”.3” = 7.8 Hz, H-2”), 5.21 (d, 1H, J1’,2’ = 7.9, H-1’), 5.27 (dd, 1H,
J2’,3’ = 4.0 Hz, H-2’), 5.59-5.62 (m, 2H, H-3”, 4’), 5.65 (dd, 1H, J4,5 = 8.3 Hz, H-4), 5.77
(dd, 1H, J2,3 = 7.1 Hz, H-2), 5.78 (d, 1H, J1,2 = 7.9 Hz, H-1), 5.91 (dd, 1H, J3,4 = 9.6 Hz,
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H-3), 6.15 (dd, 1H, J3’,4’ = 9.7 Hz, H-3’), 7.15-8.10 (m, 50H, aromatic);
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C NMR: δ,

58.8, 63.5, 64.4, 68.2, 68.4, 69.8, 69.9, 70.6, 70.8, 72.0, 72.3, 72.5, 72.9, 73.0, 74.2, 74.3,
83.5, 100.2, 101.5, 125.5 (×2), 127.2, 127.9, 128.4 (×2), 128.4 (×2), 128.5 (×2), 128.5
(×2), 128.5 (×3), 128.6 (×2), 128.6 (×4), 128.8 (×2), 128.8, 128.9 (×2), 129.0, 129.1,
129.1 (×3), 129.2 129.3, 129.4 (×2), 129.5, 129.8, 129.9 (×2), 130.0 (×3), 130.0 (×5),
130.1(×3), 130.1 (×2), 130.2 (×2), 130.3 (×2), 130.3 (×2), 133.3, 133.3, 133.4 (×2), 133.5
(×2), 133.6, 133.6, 165.2, 165.3, 165.4, 165.6 (×2), 166.0, 166.0, 166.4 ppm; HR FAB
MS [M+Na]+ calcd for C91H75NO25S2Na 1668.3967, found 1668.4023. (See Appendix;
Figure A-4, A-5, and A-6)

Benzoxazol-2-yl

2,3,4-tri-O-benzoyl-6-O-(2,3,4-tri-O-benzoyl-6-O-(2,3,4,6-tetra-O-

benzoyl-β-D-glucopyranosyl)-β-D-glucopyranosyl)-1-thio-β−D-glucopyranoside
(3.17d). The title compound was obtained by Method B from 16d and 15c in 67% yield
as a colorless syrup. Analytical data for 3.17d: Rf = 0.48 (ethyl acetate/toluene, 1.5/8.5,
v/v ); [α]D28= 47.4 (c = 1, CHCl3); 1H-n.m.r.: δ, 3.43-3.45 (m, 2H, H-6a, 6b), 3.66 (dd,
1H, J5’,6a’ = 5.5 Hz, J6a’,6b’ = 11.5 Hz, H-6a’), 3.84 (m, 1H, H-5’), 4.06-4.16 (m, 3H, H-5,
5’’, 6b’), 4.30 (dd, 1H, J5”,6a” = 5.1 Hz, J6a”,6b” = 12.1 Hz, H-6a”), 4.54-4.58 (m, 2H, H-4,
6b”), 4.95 (d, 1H, J1’,2’ = 11.0 Hz, H-1’), 5.22 (dd, 1H, H-4’), 5.50-5.55 (m, 2H, H-2’,
3’), 5.60-5.69 (m, 2H, H-3”, 4”), 5.71 (dd, 1H, J3,4 = 9.6 Hz, H-3), 5.77 (d, 1H, J1”,2” =
5.3 Hz, H-1”), 5.86 (dd, 1H, J2,3 = 9.7 Hz, H-2), 5.95 (d, 1H, J2”,3” = 9.5 Hz), 5.96 (d, 1H,
J1,2 = 10.3 Hz, H-1), 7.15-8.10 (m, 54H, aromatic); 13C NMR: δ, 60.6, 63.0, 63.3, 68.1,
68.6, 69.3, 69.5, 69.98, 70.8, 71.7, 72.4, 72.4, 73.2, 74.3, 76.7, 77.6, 77.7, 84.1, 97.8,
102.0, 110.3, 119.1, 121.1, 124.6, 124.8, 126.6, 128.2 (×2), 128.4 (×2), 128.4 (×2), 128.5
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(×4), 128.6 (×4), 128.8, 128.9, 129.0, 129.1, 129.1, 129.2, 129.4 (×3), 129.7, 129.8 (×2),
129.9 (×4), 130.0 (×4), 130.0 (×4), 130.0 (×4), 130.10 (×2), 130.3, 133.1, 133.2, 133.3
(×2), 133.4, 133.5, 133.6 (×2), 133.6, 134.4, 141.7, 152.0, 161.4, 164.5, 165.1, 165.2,
165.2, 165.4, 165.9, 166.0, 166.3 ppm; HR FAB MS [M+Na]+ calcd for C95H75NO26SNa
1700.4196, found 1700.4182. (See Appendix; Figure A-7, A-8, and A-9)

2,3,4-Tri-O-benzoyl-β-D-glucopyranosyl-(1→6)-O-2,3,4,6-tetra-O-benzoyl-β-Dglucopyranosyl)-(1→6)-O-(2,3,4-tri-O-benzoyl-β-D-glucopyranosyl)-(1→6)-2,3,4-triO-benzoyl-β-D-glucopyranosyl fluoride (3.20). This compound was obtained by
Method G from 3.17d and 2,3,4-tri-O-benzoyl-α-D-glucopyranosyl fluoride (3.19)31 in
87% yield. Rf = 0.42 (ethyl acetate/toluene, 1/9, v/v); [α]D25 = -2.02 (c = 1, CHCl3]; 1H
NMR: δ, 3.54 (m, 1H), 3.59 (m, 1H), 3.86 (m, 3H), 4.00 – 4.08 (m, 3H), 4.14 (dd, 1H, J
= 12.1 Hz), 4.34 (m, 1H), 4.46 (dd, 1H, J = 4.9, 11.4 Hz), 4.60 (dd, 1H, J = 11.8 Hz),
4.76 (d, 1H, J =7.7 Hz), 4.82 (d, 1H, J = 7.9 Hz), 5.11 (d, 1H, J = 7.8 Hz), 5.21 (dd, 1H, J
= 9.8), 5.28 (dd, 1H, J = 9.3 Hz), 5.34 (d, ½ H, J = 6.2 Hz), 5.40 (dd, 1H, J = 9.7 Hz),
5.46 (m, 1.5 H), 5.53 (dd, 1H, J = 9.5 Hz), 5.62 – 5.70 (m, 3H), 5.75 (dd, 1H, J = 9.6 Hz),
5.79 – 5.85 (m, 2H), 6.16 (dd, 1H, J = 9.6 Hz), 7.22 – 8.10 (m, 65H, aromatic) ppm; 13C
NMR: δ, 63.45, 68.14, 68.66, 68.91, 69.14, 69.67, 69.79, 70.24, 71.76, 71.98, 72.03,
72.40, 72.46, 72.78, 72.93, 73.03, 73.77, 74.24, 74.76, 100.87, 101.51, 101.71, 106.23,
128.36, 128.38, 128.46, 128.50, 128.52, 128.62, 128.67, 128.70, 128.73, 128.77, 128.83,
128.89, 128.92, 129.05, 129.07, 120.10, 129.16, 129.21, 129.57, 129.72, 129.80, 129.89,
129.96, 129.99, 130.02, 130.09, 130.18, 133.21, 133.25, 133.29, 133.35, 133.40, 133.44,
133.52, 133.65, 133.70, 133.77, 133.82, 134.05, 165.01, 165.11, 165.23, 165.26, 165.39,
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165.43, 165.46, 165.73, 165.80, 165.89, 165.91, 166.00, 166.10, 166.32 ppm;
HRFABMS [M+Na]+ calcd for C115H93FO33Na 2043.5481, found 2043.5452. (See
Appendix; Figure A-10, A-11, and A-12)

Ethyl O-(2,3,4-tri-O-benzoyl-β-D-glucopyranosyl)-(1→6)-O-2,3,4,6-tetra-O-benzoylβ-D-glucopyranosyl)-(1→6)-O-(2,3,4-tri-O-benzoyl-β-D-glucopyranosyl)-(1→6)-O(2,3,4-tri-O-benzoyl-β-D-glucopyranosyl)-(1→6)-2,3,4-tri-O-benzoyl-β-thio-Dglucopyranoside (3.22). This compound was obtained by Method H from glycosyl
fluoride 3.20 and ethyl 2,3,4-tri-O-benzoyl-thio-β-D-glucopyranoside (3.21)32 in 84%
yield. Rf = 0.46 (ethyl acetate/toluene, 1.5/8.5, v/v); [α]D26 = -9.32 (c = 1, CHCl3]; 1H
NMR: δ, 1.14 (t, 3H, SCH2CH3), 2.68 (m, 2H, SCH2CH3), 3.58 (m, 1H, J = 5.5, 6.2 Hz),
3.67 – 3.75 (m, 3H), 3.85 – 3.92 (m, 6H), 4.02 (dd, 1H, J = 10.8 Hz), 4.12 (m, 1H), 4.35
(m, 1H), 4.48 (dd, 1H, J = 5.5, 12.1 Hz), 4.57 (dd, 1H, J = 11.0 Hz), 4.70 (d, 1H, J = 10.0
Hz), 4.76 (d, 1H, J = 7.7 Hz), 4.86 (m, 2H), 5.16 (d, 1H, J = 7.9 Hz), 5.25 (dd, 1H, J =9.6
Hz), 5.33 (dd, 1H, J = 9.3 Hz), 5.39 (dd, 1H, J = 9.6 Hz), 5.43 – 5.56 (m, 7H), 5.70 (dd,
1H, J = 9.7 Hz), 5.76 – 5.87 (m, 2H), 5.90 – 5.95 (m, 2H), 6.23 (dd, 1H, J =9.7 Hz), 6.95
– 8.90 (m, 80H, aromatic) ppm;
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C NMR: δ, 14.88, 31.14, 63.48, 67.95, 68.03, 69.00,

69.29, 60.74, 69.91, 70.12, 70.19, 70.74, 70.95, 72.18, 72.28, 72.42, 72.47, 72.77, 72.87,
72.98, 73.05, 73.76, 74.16, 74.66, 83.73, 101.20, 101.27, 101.39, 101.80, 128.19, 128.28,
128.35, 128.45, 128.49, 128.60, 128.67, 128.74, 128.82, 128.92, 128.94, 129.01, 129.05,
129.11, 129.18, 129.24, 129.28, 129.52, 129.69, 129.74, 129.77, 129.79, 129.82, 129.90,
129.96, 129.99, 130.05, 130.08, 130.12, 133.08, 133.19, 133.27, 133.35, 133.49, 133.65,
133.82, 165.20, 165.27, 165.30, 165.34, 165.38, 165.43, 165.58, 165.61, 165.76, 165.89,
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165.91, 165.97, 166.29 ppm;

HRFABMS [M+Na]+ calcd for C144H120O41SNa

2559.6923, found 2559.6938. (See Appendix; Figure A-13, A-14, and A-15)

4-Pentenyl

O-(2,3,4-tri-O-benzoyl-β-D-glucopyranosyl)-(1→6)-O-2,3,4,6-tetra-O-

benzoyl-β-D-glucopyranosyl)-(1→6)-O-(2,3,4-tri-O-benzoyl-β-D-glucopyranosyl)
(1→6)-O-(2,3,4-tri-O-benzoyl-β-D-glucopyranosyl)-(1→6)-O-(2,3,4-tri-O-benzoyl-βD-glucopyranosyl)-(1→6)-2,3,4-tri-O-benzoyl-β-D-glucopyranoside

(3.24).

This

compound was obtained by Method E from thio pentasaccharide (3.22) and 4-pentenyl
2,3,4-tri-O-benzoyl-β-D-glucopyranoside (3.23)33 in 72% yield. Rf = 0.50 (ethyl
acetate/toluene, 2/8, v/v); [α]D22 = -10.54 (c = 1, CHCl3), 1H NMR; δ, = 1.41 – 1.58 (m,
4H), 1.89 (m, 2H), 3.28 (m, 1H), 3.55 (m, 2H), 3.71 (dd, 1H, J = 11.5 Hz), 3.75 – 3.81
(m, 5H), 3.90 - 4.07 (m, 7H), 4.12 (m, 1H), 4.31 (m, 1H), 4.47 (dd, 1H, J = 5.4, 12.1 Hz),
4.56 (dd, 1H, J = 2.6, 9.3 Hz), 4.64 (d, 1H, J = 7.9 Hz), 4.75 (d, 1H, J = 1.6 Hz), 4.79 4.87 (m, 6H), 5.12 (d, 1H, J = 7.8 Hz), 5.24 (dd, 1H, J = 9.7 Hz), 5.31 (dd, 1H, J = 1.8,
9.6 Hz), 5.38 - 5.55 (m, 9H), 5.58 – 5.63 (m, 1H), 5.68 (dd, 1H, J = 9.7 Hz), 5.67 (dd,
1H, J = 9.7 Hz), 5.86 (dd, 1H, J = 9.6 Hz), 5.90 -5.97 (m, 2H, J = 9.6 Hz), 6.06 (dd, 1H, J
= 9.6 Hz), 6.16 (dd, 1H, J = 9.7 Hz), 6.90 – 8.00 (m, 95H, aromatic) ppm; 13C NMR: δ,
28.71, 29.92, 30.01, 31.15, 63.04, 63.43, 67.64, 68.19, 69.80, 69.94, 70.09, 70.47, 70.51,
70.93, 72.12, 72.31, 72.26, 72.42, 72.85, 72.89, 72.99, 74.54, 89.86, 101.28, 101.30,
102.35, 101.44, 101.57, 115.02, 128.24, 128.34, 128.36, 128.41, 128.47, 128.50, 128.52,
128.65, 128.69, 128.75, 128.79, 128.98, 129.00, 129.02, 129.05, 129.08, 129.15, 129.18,
129.22, 129.28, 129.44, 129.72, 129.80, 129.82, 129.84, 129.86, 129.95, 129.99, 130.04,
130.08, 130.13, 130.16, 130.17, 165.23, 165,25, 165.27, 165.30, 165.37, 165.42, 165.46,
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165.49, 165.62, 165.65, 165.74, 165.90, 165.91, 165.95, 166.31 ppm; HRFABMS
[M+Na]+ calcd for C174H146O50Na 3057.8780, found 3057.8748. (See Appendix; Figure
A-16, A-17, and A-18)

3.4.3

Aglycone isolation

3-Benzyl-thiazolidine-2-thione (3.13). The title compound was isolated by column
chromatography from the reaction mixture resulted from glycosylation between 3.1 and
3.7.

Analytical data for 3.13 was reported previously.34 The structure of 3.13 was

confirmed by UV spectrometry with absorption maximum at 277 nm.

2-(Benzylthio)-benzoxazole (3.14).

The title compound was isolated by column

chromatography from the reaction mixture resulted from glycosylation between 3.3 and
3.7.

Analytical data for 3.14 was reported previously.35 The structure of 3.14 was

confirmed by UV spectrometry with two absorption maxima at 280 and 290 nm.36

3.4.5

HPLC Monitoring
The analyses were carried out on a Supelcosil LC-SI Semi Prep (250mm×10mm

i.d., 5μm) (Supelco, Bellefonte, PA, USA). The mobile phase was ethyl acetate/hexane
(30/70, v/v), under isocratic conditions. The sample analysis (injection volume 20 μL)
was performed for 60 min at rt with the flow rate 1.0 mL/min and UV detection at 254
nm.
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CHAPTER IV

On the stereoselectivity of glycosidation of thiocyanates, thioimidates and
thioglycosides
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4.1

Introduction
The stereocontrolled introduction of glycosidic linkages1,2 is arguably the most

challenging aspect in the synthesis of oligosaccharides3-9 and glycoconjugates.10-12 While
a 1,2-trans glycosidic linkage can be usually stereoselectively obtained by using the
anchimeric assistance from the participatory neighboring substituent at C-2 (most
commonly an ester13 or recently introduced picolinyl),14,15 the stereoselective formation
of a 1,2-cis linkage still remains a notable challenge,16 despite significant recent
improvements.17-19 In addition to the effect of protecting groups on the glycosyl donor, a
myriad of other factors is known to have effect on the stereoselectivity of the chemical
glycosylation;20 and the effect of conformation,21 solvent,22-24 temperature,25 metal
coordination,26 steric hindrance,27,28 and remote participation29-31 are only a few to
mention. It is commonly believed that a typical glycosylation follows the unimolecular
mechanism with the rate-determining step being the glycosyl acceptor attack on the
intermediate formed as a result of the leaving group departure.32 Nevertheless,
occasionally the effect of a leaving group itself may also have an influence on the
anomeric stereoselectivity. However, it is often unclear whether this effect is a result of a
bimolecular or close-ion pair rather than the unimolecular displacement mechanism, or
other factors affecting this complex process.
As part of a program to develop new protocols for stereocontrolled glycosylation,
we have been investigating various classes of sulfur-based leaving groups ranging from
conventional alkyl/aryl thioglycosides to relatively novel S-benzoxazolyl (SBox) or Sthiazolinyl (STaz) thioimidates. In particular, we were interested in a possible influence
that different leaving groups may have on the outcome of glycosylations. While on a
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number of occasions we managed to achieve very good to excellent stereoselectivities,
particularly with the SBox glycosides, these results have been occasionally outshadowed
by other classes of glycosyl donors. For example, glycosyl thiocyanates, introduced two
decades ago, have proven to be very effective glycosyl donors for what then appeared to
be “stereospecific 1,2-cis glycosylations”.33
Indeed, in a series of publications, Kochetkov et al., provided a convincing case
of the power of this class of glycosyl donors.33-37 Various hexose and pentose 1,2-trans
thiocyanate glycosyl donors were found to provide 1,2-cis glycosides completely
stereoselectively (or stereospecifically, as quoted in the original literature) with the only
failure reported when the method was applied to the synthesis of β-mannosides.38
Another attractive feature of this glycosylation approach is that the activation could be
performed in the presence of a catalytic amount of promoter and at ambient temperature.
While tritylated acceptors were used in most of the reported transformations, a
complementary procedure involving an unprotected hydroxyl group was also
developed.35 The major drawback of this technique was modest yields obtained during
both the synthesis of glycosyl thiocyanates and glycosidations thereof. This drawback
was arguably related to the propensity of thiocyanates to isomerize into the corresponding
isothiocyanates. The latter would remain inert under the glycosylation conditions leading
to average to modest yields, which could be further diminished by the migration of acetyl
substituents that have been used as protecting groups throughout the original reports.
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4.2

Results and Discussion
When 3,4,6-tri-O-acetyl-2-O-benzyl-β-D-glucopyranosyl-thiocyanate 4.137 was

allowed to react with glycosyl acceptor 4.239 in the presence of catalytic amount (0.2
equiv.) of triphenylmethyl perchlorate40 (TrClO4) in 1,2-dichloroethane (DCE) at ambient
temperature, the corresponding 1,2-cis linked disaccharide 4.537 was obtained with
complete stereoselectivity (conservative estimation α/β > 25:1, although no evidence of
the corresponding 1,2-trans anomer could be detected by 1H NMR) yet only in a modest
yield of 65% (Scheme 4.1).

AcO
AcO

OAc
O
BnO
1

PO
SCN + PO

OTr
O

AcO
AcO

OAc
O
O
BnO

TrClO4

1,2-DCE
PO
OMe

2 : P = Ac
3: P = Bz
4 : P = Bn

PO
PO

O

PO
OMe
5: P = Ac, 65%, α/β > 25/1
6 : P = Bz, 78%, α/β > 25/1
7 : P = Bn, 72%, α/β = 8.3/1

Scheme 4.1 Reaction of thiocyanate 4.1 with differently protected 6-O-trityl glycosyl
acceptors 4.2-4.4.

This result was in line with previously reported results for similar systems.37 We
assumed that the application of more stable benzoyl or benzyl protecting groups would
enhance the overall stability of the glycosyl acceptor by reducing the acyl migration.
Indeed, the disaccharide 4.6,41 derived from benzoylated glycosyl acceptor 4.3,42 was
isolated in a significantly improved yield of 78% and with complete 1,2-cis
stereoselectivity. However, when the structurally similar benzylated glycosyl acceptor 443
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was employed, the corresponding disaccharide 4.744 was obtained in a yield of 72%, but
as a mixture of diastereomers (α/β = 8.3:1). This notable decrease in the stereoselectivity
of glycosyl thiocyanates, which were previously described as glycosyl donors capable of
the concerted stereospecific displacement, was intriguing. To the best of our knowledge,
this was the first example wherein thiocyanate 4.1 of the D-gluco series gave the
anomeric mixture, although prior to this study the stereoselectivity of glycosyl
thiocyanates was only investigated with partially acetylated acceptors.37 Hence, this a
typical observation led us to a decision to reinvestigate glycosidations of thiocyanates in
a greater detail. In principle, the effect of protecting groups on the reactivity of glycosyl
acceptor has been noted.16,45-47 It has been observed that strongly electron withdrawing
ester protecting groups decrease electron density at the hydroxyl group (or
triphenylmethoxy as in the examples depicted in Scheme 1) thus lowering its
nucleophilicity and hence reactivity in glycosylation. However, still very little is
understood about the actual effect that the glycosyl acceptor protection may have on
stereoselectivity of glycosylation.48 Basic knowledge in this area implies that an
enhanced stereocontrol could be achieved with the less nucleophilic acceptors (such as
4.2 or 4.3). Occasionally, a mismatch between donor-acceptor pair may result in the
unexpected stereoselectivity outcome and/or reduced yields.49-53 Hence, at first, we
attributed the result obtained for disaccharide 4.7 to the increased reactivity of the
glycosyl acceptor 4.4, which implies that the glycosidation of glycosyl thiocyanate
donors follows unimolecular rather than the earlier proposed concerted push-pool
mechanism.33,37
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In order to extend this finding, we employed common benzoylated (4.10)42 and
benzylated (4.11)54 6-OH glycosyl acceptors that were subjected to systematic
investigation with the thiocyanate donor 4.1 along with a variety of other thioderivatives.
As previously reported,35 glycosyl thiocyanate 4.1 could be activated for reactions with
non-tritylated acceptors in the presence of catalytic amount of TMSOTf. However, these
rather sluggish reactions were commonly accompanied by the competing isomerization of
glycosyl donor 4.1 into the corresponding isocyanate, which was reflected in low
efficiency.35 Although excellent stereoselectivity (α/β = 10.2:1) was observed with the
benzoylated glycosyl acceptor 4.10, the disaccharide 4.6 was obtained in only 45% yield
(Entry 1, Table 1). The reaction with the more reactive glycosyl acceptor 4.11 was more
rapid (36 vs. 48 h), which was also reflected in the improved yield of disaccharide (69%)
yet displayed two-fold reduced stereoselectivity (Entry 2).
Since our key task was to compare glycosyl thiocyanates with other classes of
thioglycosyl donors, such as thioimidates, we decided to search for the universal
promoters of glycosylation that would activate both classes of glycosyl donors. If such
promoters were available, one could standardize the reaction conditions across the
spectrum of different classes of glycosyl donors to obtain comparable results by
excluding the possibility of the promoter effect. Based on our previous reports, the most
prominent results for glycosidation of S –benzoxazolyl (SBox, 4.8)41,55 and S-thiazolinyl
(STaz, 4.9)44,56 glycosides have been obtained in the presence of AgOTf as the promoter.
Hence, thiocyanate 4.1 was also investigated in the presence of stoichiometric amount of
AgOTf. Relatively clean and fast activations (5–15 min) resulted in good yields for the
coupling products 4.6 and 4.7 (78–84%, Entries 3 and 4). This result could serve as a
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promising new beginning of comparative glycosylation studies with thiocyanates and
thioimidates.

Table 4.1 Glycosylation of various glycosyl donors 4.1 (thiocyanate), 4.2 (Sbenzoxazolyl) and 4.9 (S-thiazolinyl) with glycosyl acceptor 4.10 and 4.11

AcO
AcO

OAc
O
R

+

OBn
1: R = SCN
8: R = SBox
9: R = STaz

PO
PO

OH
O

AcO
AcO

OAc
O
O

BnO

PO
OMe

O

PO
PO

PO
OMe

10 : P = Bz
11 : P = Bn

6: P = Bz
7 : P = Bn

Entry

Donor

Acceptor

Cond’s

Time

Product,
Yield (%)

Ratio α/β

1

1

10

A

48 h

6, 45%

10.2/1

2

1

11

A

36 h

7, 69%

5.0/1

3

1

10

B

5 min

6, 84%

7.5/1

4

1

11

B

15 min

7, 78%

2.2/1

5

8

10

B

1h

6, 92%

9.5/1

6

8

11

B

30 min

7, 84%

3.8/1

7

9

10

B

2h

6, 89%

7.4/1

8

9

11

B

1.5 h

7, 81%

2.7/1

Reagents and conditions: All glycosylations were performed in 1,2-dichloroethane under
argon at rt: A - TMSOTf (0.2 equiv); B - AgOTf (1.0 equiv for 1, 2.0 equiv for 8 and 9),
3Å molec. sieves

However, somewhat lower overall stereoselectivity was observed in comparison
to that seen in TMSOTf-promoted glycosidations (Entries 1 and 2). Nevertheless, the
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trend remained the same, and the disaccharide 4.6 derived from the benzoylated glycosyl
acceptor 4.10 was obtained in a notably higher α stereoselectivity than its benzylated
counterpart 4.7 from 4.11 (7.5:1 and 2.2:1, respectively). The latter result was particularly
surprising considering the sturdy common knowledge that thiocyanates are amongst the
most stereoselective glycosyl donors developed to date. Indeed, this example clearly
illustrated that the effect of glycosyl acceptor and promoter of glycosylation cannot be
underestimated and may have a prevailing effect on the reaction outcome.
When SBox or STaz glycosides (4.8 and 4.9, respectively) have been
investigated, a very similar trend has been observed, although these activations were
slower than those of glycosyl thiocyanate 4.1, and required at least 2.0 equivalents of
AgOTf. Again, disaccharide 4.6 derived from the benzoylated glycosyl acceptor 10 was
obtained with a much higher (approximately three-fold) α stereoselectivity (Entries 5 and
7) than its benzylated counterpart 4.7 from acceptor 4.11 (Entries 6 and 8). It should be
noted that the rate of the reaction did not clearly correlate with the stereoselectivity
observed: for example, slower glycosidations of the STaz derivative 4.9 provided lower
stereoselectivity than that of the SBox glycoside 4.8.
To gain a broader insight, a similar set of experiments have been performed using
a variety of standard secondary glycosyl acceptors with the uniform benzoyl and benzyl
protecting group pattern (4.12,57 4.14,58 4.16,57 4.18,59 4.20,60 and 4.2261). STaz glycosyl
donor 4.9 was used in this comparative evaluation. As evident from the results presented
in Table 4.2, the glycosylations of secondary glycosyl acceptors were in accordance with
the observation made for primary glycosyl acceptors 4.10 and 4.11. Thus, benzoylated
glycosyl acceptors (4.12, 4.16 and 4.20) gave consistently higher stereoselectivity (α/β~
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12:1, Entries 1, 3, and 5) for the formation of disaccharides (4.13, 4.17, and 4.21,
respectively) than their benzylated counterparts (4.14, 4.18, and 4.22) provided for
disaccharides 4.15,44 4.19, and 4.2344 (α/β ~ 6.5 - 9.3:1, Entries 2, 4, and 6).

Table 4.2 The glycosylation of secondary acceptor 4.12, 4.14, 4.16, 4.18, 4.20, and 4.22
with the STaz donor 4.9

Entry

Acceptor

Time

Product, yield

Ratio α/β

1

12

16 h

13, 89%

11.7/1

2

14

14 h

15, 90%

6.8/1

3

16

12 h

17, 87%

12.1/1

4

18

8h

19, 85%

6.5/1

5

20

12 h

21, 72%

12.0/1

6

22

6h

23, 87%

9.3/1

RO
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OMe
4.12:
4.13:
4.14:
4.15:

P=Bz, R=H
P=Bz, R=Sug
P=Bn, R=H
P=Bn, R=Sug

OP
O

PO
PO

PO
OMe
4.16:
4.17:
4.18:
4.19:

P=Bz, R=H
P=Bz, R=Sug
P=Bn, R=H
P=Bn, R=Sug

AcO
Sug = AcO

OP
O
RO
OMe

4.20:
4.21:
4.23:
4.23:

P=Bz, R=H
P=Bz, R=Sug
P=Bn, R=H
P=Bn, R=Sug

OAc
O
BnO

Since ethyl thioglycosides are inert in the presence of either TMSOTf or AgOTf,
direct comparison of them with thiocyanates and thioimidates was not possible.
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Nevertheless, we supposed that this general study may benefit from the indirect
comparison with a common ethyl thioglycosides, even though its activation required
entirely different activation protocol. Indeed, a very similar trend was achieved when
ethyl 3,4,6-tri-O-acetyl-2-O-benzyl-1-thio-β-D-glucopyranoside62 was glycosidated in
the presence of NIS–TfOH (or other common promoters for thioglycoside activation).63-66
For example, disaccharide 4.6 derived from the benzoylated glycosyl acceptor 4.10 was
obtained in a significantly higher α-stereoselectivity than its benzylated counterpart 4.7
(6.8:1 vs. 1.7:1, respectively). In addition, a very similar trend has been observed with
per-benzylated STaz and SEt glycosyl donors (these results are not shown herein and will
be reported elsewhere).

4.3

Conclusions
In conclusion, we observed that protecting groups on glycosyl acceptor have a

profound effect on stereoselectivity of glycosylation. The effect of protecting groups of
glycosyl acceptor on the stereoselectivity of glycosylation seemed very directly
correlated to their electron-withdrawal power. Thus, we demonstrated that much higher
α-stereoselectivity

can

be

obtained

with

glycosyl

acceptors

bearing

more

electronwithdrawing benzoyl substituents in comparison to that of their benzylated
conterparts. This improvement was consistently achieved with all classes of glycosyl
donors investigated (thiocyanates, thioimidates, and thioglycosides) and was practically
independent on the leaving group used. Both primary and secondary glycosyl acceptors
showed the same trend; and these results were in line with generally accepted principles
of the effect of protecting groups on glycosyl acceptor. The actual effect remains unclear,
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but it is possible that a variety of factors may have to be considered: dipole moments of
the entire molecule, dipole-dipole interactions, polarizability, donor-acceptor matchmismatch, the role of the promoter (and the activation mode), solvent, etc. Further
investigation of the protecting and leaving group effects on stereoselectivity of
glycosylation is currently underway in our laboratory.

4.4

Experimental part

4.4.1

General
Column chromatography was performed on silica gel 60 (EM Science, 70-230

mesh), reactions were monitored by TLC on Kieselgel 60 F254 (EM Science). The
compounds were detected by examination under UV light and by charring with 10%
sulfuric acid in methanol. Solvents were removed under reduced pressure at <40 oC. 1, 2Dichloroethane was distilled from CaH2 directly prior to application in glycosylations.
Molecular sieves (3Å or 4 Å), used for reactions, were crushed and activated in vacuo at
390 °C during 8 h in the first instance and then for 2-3 h at 390 °C directly prior to each
application. AgOTf (Acros) was co-evaporated with toluene (3 x 10 mL) and dried in
vacuo for 2-3 h directly prior to each application.
CDCl3 at 300 MHz,

13

1

H-NMR spectra were recorded in

C-NMR spectra were recorded at 75 MHz (Bruker Avance).

HRMS determinations were made with the use of JEOL MStation (JMS-700) Mass
Spectrometer.
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4.4.2

Typical glycosylation procedures

Method A. Typical AgOTf promoted glycosylation procedure: A mixture the glycosyl
donor (0.11 mmol), glycosyl acceptor (0.10 mmol), and freshly activated molecular
sieves (3 Å, 200 mg) in (ClCH2)2 (2mL) was stirred under argon for 1.5 h. Freshly
conditioned AgOTf (0.11-0.22 mmol) was added and the reaction mixture was monitored
by TLC. Upon completion (see Table), the reaction mixture was diluted with CH2Cl2 (20
mL), the solid was filtered-off and the residue was washed with CH2Cl2. The combined
filtrate (30 mL) was washed with 20% aq. NaHCO3 (15 mL), water (3 × 10 mL), and the
organic phase was separated, dried over MgSO4, and concentrated in vacuo. The residue
was purified by column chromatography on silica gel (ethyl acetate/toluene gradient
elution) to afford the corresponding disaccharide derivative.

Method B. TMSOTf promoted glycosylation procedure: A mixture the glycosyl donor
(0.11 mmol) and glycosyl acceptor (0.10 mmol) and freshly activated molecular sieves (4
Å, 200 mg) in (ClCH2)2 (2 mL) was stirred for 1.5 h under argon. TMSOTf (0.022
mmol) was added and the reaction mixture was monitored by TLC. Upon completion,
the reaction was quenched with a drop of pyridine. The reaction mixture was diluted
with CH2Cl2 (20 mL) and washed with 20% aq. NaHCO3 (15 mL) and water (3 × 10 mL).
The organic phase was separated, dried over MgSO4, and concentrated in vacuo. The
residue was purified by column chromatography on silica gel (ethyl acetate/toluene
gradient elution) to afford the corresponding disaccharide derivative.

148

Method C. NIS-TfOH promoted glycosidation of S-ethyl glycosides. A mixture of the
glycosyl donor (0.11 mmol), glycosyl acceptor (0.10 mmol), and freshly activated
molecular sieves (4 Å, 200 mg) in (ClCH2)2 (2 mL) was stirred for 1.5 h under argon.
NIS (0.22 mmol) and TfOH (0.022 mmol) were added and the reaction mixture was
monitored by TLC. Upon completion, the reaction mixture was diluted with CH2Cl2 (20
mL), the solid was filtered off and the residue was washed with CH2Cl2. The combined
filtrate (30 mL) was washed with 20% aq. Na2S2O3 (15 mL) and water (3 × 10 mL). The
organic phase was separated, dried over MgSO4, and concentrated in vacuo. The residue
was purified by column chromatography on silica gel (ethyl acetate–toluene gradient
elution) afford a disaccharide derivative.

Methyl

3-O-(3,4,6-tri-O-acetyl-2-O-benzyl-α/β-D-glycopyranosyl)-2,4,6-tri-O-

benzoyl-α-D-glucopyranoside (4.17) was obtained from 9 and 16 in 89% yield (α/β =
11.7/1). Analytical data for 17: Rf = 0.48 (ethyl acetate/toluene, 3/7, v/v); 1H NMR: δ,
1.76, 1.78, 2.02 (3s, 9H, 3 × COCH3), 3.27 (dd, 1H, J2’,3’ = 10.0 Hz, H-2’), 6.46 (s, 3H;
OCH3), 3.76-3.87 (m, 3H, H-6a’, 6b’, ½ CH2Ph), 4.06 (dd, 1H, J5’,6a’ = 10.4 Hz, J5’,6a’ =
5.3 Hz, H-5’), 4.17 (d, 1H, J2 = 12.7 Hz, ½ CH2Ph), 4.33 (m, 1H, H-5), 4.45 (dd, 1H,
J6a’,6b’ = 14.4 Hz, H-6a’), 4.56-4.62 (m, 2H; H-3, 6b’), 4.74 (dd, 1H, J4’,5’ = 9.8 Hz, H-4’),
5.06 (d, 1H, J1’,2’ = 3.7 Hz, H-1’), 5.10 (d, 1H, J1,2 = 3.4 Hz, H-1), 5.22 (dd, 1H, J3’,4’ = 9.6
Hz, H-3’), 5.36 (dd, 1H, J2,3 = 9.9 Hz, H-2), 5.68 (dd, 1H, J4,5 = 9.5 Hz, H-4), 6.91-8.06
(m, 20H, aromatic) ppm; 13C NMR: δ, 20.7, 20.8, 20.9, 55.8, 61.8, 63.3, 67.8 (x2), 68.3,
71.4, 71.7, 72.5, 72.6, 76.3, 77.4, 97.3, 98.0, 127.9 (×2), 128.5 (×2), 128.6 (×2), 128.7
(×3), 129.9, 130.0 (×2), 130.7 (×2), 130.2 (×2), 133.3, 133.5, 133.6, 164.9, 165.8, 166.5,
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169.7, 169.9, 170.8 ppm; HR-FAB MS: calcd for C47HB48O17Na [M+Na]+: 907.2789
found: 907.2790.

Methyl 3-O-(3,4,6-tri-O-acetyl-2-O-benzyl-α/β-D-glycopyranosyl)-2,4,6-tri-O-benzylα-D-glucopyranoside (4.19) was obtained from 9 and 18 in 90% yield (α/β = 6.8/1).
Analytical data for 19: Rf = 0.50 (ethyl acetate/toluene, 3/7, v/v); 1H NMR: δ, 1.91, 1.94,
2.06 (3s, 9H, 3 × COCH3), 3.35 (s, 3H, OCH3), 3.52-3.79 (m, 3H, H-2, 2’, 4), 3.76 (m,
1H, H-5), 3.89-3.93 (m, 2H, H-6a, 6b), 4.24 (dd, 1H, J3,4 = 9.3 Hz, H-3), 4.34-4.53 (m,
4H, H-6a’, 6b’, CH2Ph), 4.59-4.68 (m, 4H, H-5’, CH2Ph), 4.73 (d, 1H, J1,2 = 3.5 Hz, H-1),
4.84 (d, 1H, J2 = 12.0 Hz, ½ CH2Ph), 4.91 (dd, 1H, J4’,5’ = 10.3 Hz, H-4’), 5.49 (dd, 1H,
J3’,4’ = 9.8 Hz, H-3’), 5.60 (d, 1H, J1’,2’ = 3.5 Hz, H-1’), 6.90-7.35 (m, 20H, aromatic)
ppm;

13

C NMR: δ, 20.9, 21.0, 21.1, 55.3, 62.0, 67.3, 68.6, 68.8, 70.0, 72.4, 72.8, 73.5,

73.7 (x2), 76.4, 77.4, 78.3, 78.9, 97.1, 97.7, 126.6 (×2), 127.4, 127.8 (×2), 127.9 (×2),
128.1 (×2), 128.8, 128.5 (×4), 128.6 (×2), 128.6 (×2), 128.8 (×2), 137.7, 137.9, 138.0,
138.6, 170.1, 170.3, 171.0 ppm; HR-FAB MS: calcd for C47H48O17Na [M+Na]+: 907.2789
found: 907.2785.

Methyl

4-O-(3,4,6-tri-O-acetyl-2-O-benzyl-α/β-D-glycopyranosyl)-2,3,6-tri-O-

benzoyl-α-D-glucopyranoside (4.13) was obtained from 9 and 12 in 87% yield (α/β =
12.1/1). Analytical data for 13: Rf = 0.46 (ethyl acetate/toluene, 3/7, v/v); 1H NMR: δ,
1.97, 2.01, 2.02 (3s, 9H, 3 × COCH3), 3.37 (dd, 1H, J2’,3’ = 5.8 Hz, H-2’), 3.45 (s, 3H,
OCH3), 4.09 (m, 1H, H-5’), 4.16-4.26 (m, 3H, H-4, 6a’, 6b’), 4.08 (m, 1H, J5,6b = 2.7 Hz,
H-5), 4.66 (dd, 1H, H-6a), 4.78 (dd, 1H, J6a,6b = 12.0 Hz, H-6b), 4.85 (dd, 1H, J4’,5’ = 9.4
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Hz, H-4’), 5.14 (d, 1H, J1,2 = 2.1 Hz, H-1), 5.14-5.22 (m, 3H, H-1’, CH2Ph), 5.36 (dd, 1H,
J3’,4’ = 9.8 Hz, H-3’), 6.20 (dd, 1H, J3,4 = 8.5 Hz, H-3), 7.03-8.10 (m, 20H, aromatic) ppm;
13

C NMR: δ, 20.8 (×3), 55.7, 62.1, 63.6, 68.5, 68.6, 68.7, 71.7, 72.2, 72.4, 73.1, 75.7,

76.4, 77.4, 97.0, 98.0, 127.8 (×2), 128.0, 128.5 (×2), 128.6 (×3), 128.8 (×3), 129.2, 129.9
(×4), 130.1, 130.2 (×2), 133.3, 133.6 (×2), 137.7, 165.4, 166.3 (x2), 169.9, 170.0, 170.7
ppm; HR-FAB MS: calcd for C47H55O14 [M+H]+: 843.3592 found: 843.3594.

Methyl

2-O-(3,4,6-tri-O-acetyl-2-O-benzyl-α/β-D-glycopyranosyl)-3,4,6-tri-O-

benzoyl-α-D-glucopyranoside (4.21) was obtained from 9 and 20 in 72% yield (α/β =
12/1). Analytical data for 21: Rf = 0.40 (ethyl acetate/toluene, 3/7, v/v); 1H NMR: δ, 1.83
(s, 3H; COCH3), 1.99 (s, 6H; 2 × COCH3), 3.51 (s, 3H; OCH3), 3.53-3.60 (m, 2H, H-2’,
5’), 3.87 (dd, 2H, J6a’,6b’ = 9.5 Hz, H-6a’, 6b’), 3.94 (dd, 1H, J2,3 = 10.0 Hz, H-2), 4.39 (m,
1H, H-5), 4.46 (dd, 1H, J6a,6b = 12.1 Hz, H-6a), 4.57-4.60 (m, 2H, H-6b, ½ CH2Ph), 4.64
(d, 1H, J2 = 12.1 Hz, ½ CH2Ph), 4.85 (dd, 1H, J4’,5’ = 9.6 Hz, H-4’), 4.88 (d, 1H, J1’,2’ =
3.5 Hz, H-1’), 5.00 (d, 1H, J1,2 = 3.1 Hz, H-1), 5.33 (dd, 1H, J3’,4’ = 9.6 Hz, H-3’), 5.54
(dd, 1H, J4,5 = 9.9 Hz, H-4), 6.03 (dd, 1H, J3,4 = 9.7 Hz, H-3), 7.28-8.06 (m, 20H,
aromatic) ppm;

13

C NMR: δ, 20.7, 20.8, 21.0, 56.0, 61.3, 63.3, 67.8, 68.0, 68.1, 69.8,

71.6, 72.0, 73.4, 77.1, 97.5, 97.6, 128.1 (×3), 128.4, 128.6 (×6), 128.8 (×3), 129.1, 129.7,
129.9 (×4), 130.1 (×2), 133.3 (×2), 133.6, 137.9, 165.6, 165.7, 166.4, 169.9, 170.0, 170.7
ppm; HR-FAB MS: calcd for C47H48O17Na [M+Na]+: 907.2789 found: 907.2788
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CHAPTER V

Glycosidation of thioglycosides in the presence of bromine: mechanism, reactivity,
and stereoselectivity

__________________________________________________________________
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5.1

Introduction
Since the first glycosylation reactions were performed in the late 1800s,

carbohydrate chemistry has evolved into a broad area of research that has persistently
captured the interest of the scientific community. Nevertheless, the installation of the
glycosidic linkage remains cumbersome due to the lack of understanding the mechanistic
detail of glycosylation or the inability to translate such knowledge into practical
application.1,2

With significant recent advances in the rapidly expanding fields of

glycosciences, the demand for reliable and stereocontrolled glycosylation technologies
has increased. Owing to many recent breakthroughs in the field, the formation of many
glycosidic bonds can be readily achieved;3,4 however, it is the inability to effectively
control the stereoselectivity of glycosylation that has proven to be the major synthetic
hurdle.
Building upon our earlier discovery of the O-2/O-5 cooperative effect in
glycosidation of superdisarmed glycosyl donors bearing 2-benzyl-3,4,6-triacyl protecting
group pattern,5 herein we present our study for the development of a highly
stereocontrolled glycosylation using glycosyl bromides as glycosyl donors generated in
situ. It has been our belief that a carefully controlled reaction pathway helps to ensure
predictable, rather than serendipitous, outcome of chemical glycosylation, a remarkably
complex and multi-step reaction of very high scientific and industrial significance as a
vast majority of all sugars are bound via the glycosidic linkage.

There are many

complexities to consider when depicting the mechanism of the glycosylation reaction,
and often a clear delineation between SN1 and SN2 nucleophilic substitution reactions is
obscured.6,7 Nevertheless, today it is generally presumed that the reaction conditions
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favor that of a unimolecular SN1 mechanism, and the reaction is thought to proceed
through a total of four distinct steps: activation, dissociation, nucleophilic attack and
deprotonation.6
Glycosyl bromides are arguably the best known and the most studied glycosyl
donors to date.

Historically being the first glycosyl donors investigated, glycosyl

bromides are still in frequent use, particularly in glycosylations of simple aglycones. In
the recent years, however, their utility for oligosaccharide synthesis has been diminished
by the development of new classes of glycosyl donors. A very significant application of
the accrued mechanistic and kinetic knowledge was the halide-ion catalyzed
glycosylation developed by Lemieux et al. in 1975.8 Through extensive theoretical
studies, careful consideration of the reaction intermediates, and conformations thereof, it
was found that a rapid equilibrium could be established between a relatively stable αhalide A and its more reactive β-counterpart I, by adding tetraalkylammonium bromide
(Scheme 5.1). At first, the expulsion of α-halide A results in the formation of ion-pair B.
Since no inverted product (E) is formed herein, it was concluded that the ion-pair F
leading to the anomerized β-linked bromide I is a more energetically favorable pathway.
The existence of alternate conformations for intermediates G and H en route to/from I
was deemed necessary to form/activate the equatorial bond.9 At this point, the highly
unstable β-halide dissociates back into its ion pair (I→G), whereupon it quickly
undergoes nucleophilic attack (G→K) to form the 1,2-cis product L. As an end result,
nucleophilic substitution of the β-bromide I occurs favorably, whereas the α-bromide A
anomerizes before glycosylation can occur.
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Scheme 5.1 Lemieux’s in situ anomerization concept.

Does this concept offer a practical application to synthesis of glycosides and
oligosaccharides? Yes, but it lacks generality as it requires very reactive per-benzylated
bromides (or iodides)10 as glycosyl donors and provides satisfactory results mainly with
the highly reactive series, L-fucose and D-galactose.

5.2

Results and Discussion
In our hands, this procedure was found less effective and thorough investigation

of differently protected glucosyl bromides 5.1a-5.5a in reactions with glycosyl acceptor
5.6, showed it is it mainly applicable to glycosidation of per-benzylated glucosyl bromide
5.1a. Herein and below, index a or b is used to designate α- or β-anomeric configuration
in glycosyl donors, if known. Even then, the reaction was extremely sluggish and
proceeded only half-way in 120 h (entry 1, Table 1). The stereoselectivity obtained for
disaccharide 5.7 was good (α/β = 9/1), but far from being exclusive; and, in principle, the
application of such uniformly protected building blocks in oligosaccharide synthesis is
limited to the introduction of terminal units only.
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Our consecutive attempt to

differentiate the protecting group pattern by adding a single benzoyl substituent led to the
significant decrease in the rate of glycosylation and yields (entries 2 and 3).
Stereoselectivity and yields observed with 6-O-benzoyl bromide 5.2a and 4-O-benzoyl
bromide 5.3a differed drastically indicating that the effect of the electron-withdrawal is
very position dependable. Not surprisingly, all our attempts to activate the disarmed and
superdisarmed bromides 5.4a and 5.5a, respectively, under Lemieux’s inversion
conditions have failed (entries 4 and 5).

Table 5.1 Glycosidation of differently protected glucosyl bromides 5.1a-5.5a in the
presence of Bu4NBr.

Entry

Glycosyl donor

Intermediate

Product (yield, α/β ratio)

1

5.7 (50%, 9.0/1)

2

5.8 (43%, 24/1)

3

5.9 (15%, 6.2/1)
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5.10 (no reaction)

4

5

BzO
BzO

OBz
O

Br
BnO
5.5b (not formed)

5.11 (no reaction)

Interestingly, glycosyl bromide 5.5 generated from the corresponding βethylthio glycoside 5.12 in the presence of bromine reacted readily and provided
disaccharide 5.11 as the α-linked diastereomer only (entry 1, Table 5.2).

We also

observed that no reaction would take place if the acceptor 5.6 was added at the later
stage, when all thioglycoside 5.12 has been consumed. Strikingly, we also observed that
bromide 5.5a cannot be glycosidated directly by the addition of bromine (entry 2). These
observations led us to a working hypothesis that thioglycoside 5.12 is first converted into
a highly reactive β-bromide 5.5b that reacts readily with the glycosyl acceptor 5.6 to give
the α-linked disaccharide 5.11 exclusively. The literature precedent for this exists, and
the formation of β-bromide from thioglycosides or selenium glycosides has been
observed. In a majority of studies, however, the reaction of thioglycoside with bromine
is used to generate the corresponding glycosyl bromide, which is usually seen as the αanomer only upon isolation. Perhaps, in the absence of the glycosyl acceptor, the kinetic
β-bromide rapidly equilibrates into the thermodynamically more stable α-anomer. If the
glycosyl acceptor is present from the beginning, β-bromide 5.5b can undergo direct
nucleophilic displacement that arguably takes place via concerted bimolecular pathway
resulting in the formation of α-linked glycoside only. Since the disaccharide 5.11 was
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isolated in only 28% yield along with 63% of α-bromide 5.5a, we hypothesized that there
is a competition between β-bromide glycosidation and anomerization, with both reactions
being irreversible under these reaction conditions. The α-bromide 5.5a is stable under
these reaction conditions and cannot be glycosidated, which is significant as it helps to
ensure complete stereoselectivity of such transformation.

Table 5.2 Comparative glycosidations of β-thioglycosides and their corresponding αglycosyl bromides in the presence of bromine.

Entry

Glycosyl donor

Intermediate

1

2

5b (not formed)

3

4

4b (not formed)
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Time

Product
(yield, α/β ratio)

16 h

5.11
(28%, >25/1)

16 h

5.11
(no reaction)

16 h

5.10
(45%, β-only)

16 h

5.10
(no reaction)

5

6

5.1b

10 min

5.7
(71%, 2.2/1)

10 min

5.7
(67%, 1.5/1)

In a similar fashion, per-benzoylated thioglycoside 5.13b was glycosidated in
the presence of bromine to afford disaccharide 5.10 as β-linked product only in 45% yield
(entry 3). Since α-bromide 5.4a did not undergo glycosidation under these reaction
conditions (entry 4), we conclude that the formation of 5.10 also takes place via the
intermediacy of β-bromide 5.4b only. Differently, since bromide 5.4b is equipped with
the participating group at C-2, it undergoes a two-step displacement via bicyclic
acyloxonium ion (vide infra, see Scheme 3). Since no α-linked disaccharide formation
was detected; this appears to be the only feasible route leading to the products of
glycosylation, which copes well with the well-known effect of the neighboring protecting
groups.
When a similar glycosylation was set up with per-benzylated thioglycoside
5.14b, disaccharide 5.7 was readily obtained in a good yield of 71%, but as a mixture of
diastereomers (entry 5). Also the corresponding α-bromide 5.1a reacted readily under
these reaction conditions (entry 6) providing nearly identical outcome to that obtained
with thioglycoside 5.14b. Perhaps, this reaction proceeds via the classic SN1 pathway via
the intermediacy of the flattened oxacarbenium ion (vide infra) resulting in scrambled
stereoselectivity.7
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In order to improve an outcome of the reaction between the superdisarmed
thioglycoside 5.12b and acceptor 5.6 in the presence of bromine leading to complete
stereoselectivity, we attempted to delineate between two plausible reactions pathways, as
follows. First, it is possible that the rate of formation of the diastereomeric bromides
from the thioglycoside precursor are similar, but only the β-bromide then elaborates into
the glycoside product while the α-counterpart remains intact. Second, it is also possible
that the kinetic β-bromide forms exclusively first and then anomerizes into its
thermodynamically more stable α-counterpart concomitantly with glycosidation.

To

differentiate between these two anticipated scenarios by which the glycosylation reaction
may proceed we developed a toolkit for the reaction monitoring by 1H NMR. First, we
investigated the reaction of per-benzoylated β-thioglycoside 5.13b with bromine, as
depicted in Scheme 5.2. It was determined that α- and β-bromides 5.4a/5.4b form
rapidly (5 min) with a vast predominance of the latter (α/β = 1/11). This was followed by
a relatively slow anomerization of β-bromide 5.4b into its α-linked counterpart 5.4a
resulting in a nearly equal mixture of anomers with a slight predominance of 5.4a after 16
h (see also entry 1 in Table 5.3).
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Scheme 5.2 In situ NMR monitoring of the reaction of thioglycoside 5.13b with
bromine.

Certainly, the predominant formation of β-bromide 5.4b in this case can be
attributed to the assistance of the neighboring benzoyl substituent at C-2. Hence, it was
important to establish how the β-thioglycosides of the armed and superdisarmed series
5.14b and 5.12b, respectively, both bearing a non-participating 2-O-benzyl substituent,
react. The results of this study are summarized in Table 5.3. The reaction of perbenzylated thioglycoside 5.14b was very fast and by the time the first 1H NMR was
acquired, 5 min since the addition of bromine, α-bromide 5.1a was present exclusively
(entry 2, Table 5.3). Therefore, we attempted to perform the reaction monitoring at low
temperature, which was performed as follows. Thioglycoside 5.14b was dissolved in
CDCl3, placed in the standard 5 mm NMR tube equipped with a septum, which was then
placed into a dewar containing liquid nitrogen for 5 min. Bromine (1 equiv.) was added
via syringe, the external cooling was removed, and the NMR tube was placed
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immediately into the magnet and the spectrum was recorded (approximately 5 min since
Br2 addition). This approach allowed us to detect an anomeric mixture of bromides 5.1a
and 5.1b (α/β = 7.3/1), which then rapidly equilibrated into the pure α-bromide 5.1a
(entry 3, Table 5.3).
Next, the reaction of thioglycoside 5.12b equipped with the superdisarming
protecting group pattern (2-O-benzyl-3,4,6-tri-O-benzoyl) was investigated. As indicated
by NMR, room temperature reaction resulted in the formation of a 2.1/1 mixture of
bromides 5.4a/5.4b with predominance of α-anomer 5.4a. This mixture then began
equilibrating slowly, and further accumulation of the α-anomer was monitored (entry 4,
Table 5.3). The outcome of this study was that even though β-bromides only can react
under these reaction conditions, the predominate formation of the α-bromide is a serious
conceptual drawback of such an approach. This significantly diminishes the likelihood of
further improvement of this reaction. For example, if one assumes that the β-anomer in a
α/β = 2.1/1 mixture were to react entirely to form glycoside, the theoretical yield of such
transformation based on the starting material cannot exceed 32%. This maximum yield
correlates well with the actual observed yield of 28% for the formation of disaccharide
5.11 (see Table 5.2, entry 1), which corresponds to about 88% of conversion β-bromide
5.4b into 5.11 leaving about 12% as a tribute to the competing anomerization process.
This result is significant as it demonstrates that the glycosidation of 5.4b is significantly
faster than the competing anomerization into 5.4a. Further evidence was acquired during
the NMR-monitored glycosidation of 5.4a/5.4b with CD3OD as a glycosyl acceptor
(Figure 5.1).
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H-1 α-Br
H-5 β-Br

5 min

15
min

30
min

H-1 α-OCD3

1h

Figure 5.1 In situ NMR monitoring of the reaction of thioglycoside 5.12b with bromine
in presence of CD3OD.
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Table 5.3 Reactions of thioglycosides 5.12-5.14 with bromine: NMR monitoring of
glycosyl bromide formation and anomerization.

Entry

1

2

3

4
5

6

7

Reaction

13bÆ4a/4b

14bÆ1a/1b

14bÆ1a/1b

12bÆ5a/5b

14aÆ1a/1b

14aÆ1a/1b

12aÆ5a/5b

Temperature

rt

rt

Low (see text)

rt
rt

Low (see text)

rt
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Time recorded

Ratio α/β

5 min

1/10.7

15 min

1/10.3

30 min

1/9.0

3h

1/4.3

16 h

1/0.8

5 min

>25/1

5 min

7.3/1

10 min

8.9/1

20 min

10.2/1

30 min

12.7/1

5 min

2.1/1

15 min

2.2/1

1h

2.4/1

5 min

>25/1

5 min

1/>25

10 min

1/2.5

15 min

1/0.9

30 min

1/0.3

1h

>25/1

5 min

1/20

15 min

1/17.3

30 min

1/16.3

3h

1/11.5

16 h

1/4.5

Since no Lemieux-like equilibrium could be established with the bromides of
the unreactive series, the only possibility to improve the yield of glycosylation is to make
sure that β-bromide is generated preferentially. In case of thioglycosides equipped with
the neighboring participating group at C-2, such as 5.13, or schematically represented as
A in Scheme 5.3a, the β-thioglycoside undergoes a multi-step displacement via the
intermediacy of the bicyclic acyloxonium ion D. Thus, upon interaction of A with
bromine, active sulfonium intermediate B is generated. The promoter-assisted leaving
group departure then results in the formation of oxacarbenium intermediate C. The
leaving group departs as BrSEt that then disproportionates into ethyl disulfide (easily
detectable by NMR) and bromine.

Oxacarbenium ion C is then stabilized via the

anchimeric assistance of the neighboring benzoyl group resulting in the formation of
cyclic acyloxonium intermediate D. The formation of the latter can be used to explain
the preferential formation of β-bromide E as the bottom; α-face of the ring is blocked for
the bromide ion attack. In the case of β-thioglycosides 5.12 and 5.14, schematically
shown as F in Scheme 5.3b, there is no direct route that would lead to the stereoselective
formation of the corresponding β-bromides. This reaction proceeds via the formation of
oxacarbenium intermediate G and although β-bromide H is the kinetic product, our
results show that more thermodynamically stable α-bromide formation predominates,
with most β-bromide obtained in case of the superdisarmed series 5.5a/5.5b (α/β = 2.1/1,
see Table 5.3, entry 4).
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Scheme 5.3 Mechanistic rationale for the transformation of thioglycosides to bromides.

We conceptualized that the use of α-thioglycosides, generically shown as I in
Scheme 5.3, as the starting material may offer a more direct route to obtain β-bromide H.
Our modified working hypothesis that has been adjusted as more experimental data was
gathered is depicted in Scheme 5.3c. Thus, promoter-assisted activation of the leaving
group of α-thioglycode I with bromine will lead to the formation of α-sulfonium ion J.
Two possible pathways by which J may convert into bromides H can be assumed as
follows. First, the formation of β-Η takes place directly via the concerted nucleophilic (or
close ion-pair) displacement of BrSEt leading to the complete inversion. Second, upon
monomolecular departure of the activated leaving group in J, the reaction would proceed
via the intermediacy of the oxocarbenium ion G that will result in the formation of the
anomeric mixture of α/β-H, as it has been proven for reactions with β-thioglycosides F.
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To reveal the most likely reaction pathway by which α-ethylthio glycosides
may

elaborate

into

bromides,

we

obtained

per-benzylated

derivative

5.14a.

Disappointingly, an NMR experiment with 5.14a performed at room temperature led to
the formation of α-bromide 5.1a exclusively (entry 5, Table 5.3). Very differently
though, when this experiment was performed at low temperature (vide supra), β-bromide
5.1b was formed nearly exclusively (α/β > 1/25, entry 6) with some trace amount of
unreacted α-thioglycoside still remaining. After that, a rapid anomerization of 5.1b
resulted in complete anomerization into 5.1a within 1 h of the addition of bromine.
Assuming that the rate of this transformation would be very difficult to control, we
obtained thioglycoside 5.12a equipped with the super-disarming 2-benzyl-tri-benzoyl
protecting group pattern. We anticipated that 5.12a would provide the bromination and
anomerization reaction rates that would be easier to comprehend. This in turn, may lead
to the enhanced control of the subsequent glycosidation process.
Figure 5.2 shows a series of NMR spectra that have been acquired at different
times of reaction (see also the summary in entry 7, Table 5.3). After recording the
spectrum of the starting material 5.12a (Figure 5.2a), bromine (1 equiv) was injected into
the NMR tube. Subsequent NMR spectrum recorded at 5 min (Figure 5.2b) since the
addition of Br2 showed that bromides 5.5a/5.5b formed in a ratio of α/β = 1/20 favoring
the formation of β-anomer. The ratios were measured by comparison of the integral
intensity of the signals corresponding to H-1 of α-bromide 5.5a (6.48 ppm) and H-5 of βbromide 5.5b (4.20 ppm), which were clearly separable from the rest of the signals. At
this time, about 24% of the starting material 5.12a was still remaining, as judged by the
integral intensity of its H-3 signal (5.96 ppm). This result indicates that the formation of
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β-bromide takes place by the direct displacement of the activated leaving group (Figure
5.2c) rather than via the intermediacy of the oxacarbenium intermediate. Subsequent
NMR spectra recorded at 15 and 30 min time points since the addition of bromine
showed that the starting material was completely consumed (by 30 min), and the βbromide began slow anomerisation into its more stable α-counterpart (Figure 5.2b and
5.2c). This result indicates that anomerization of the superdisarmed bromide 5.5b is much
slower than that observed for its armed, per-benzylated counterpart 5.1b. Moreover, it
5.5b anomerizes even slower that per-benzoylated disarmed bromide 5.4b. Thus, the
super-disarmed 5.5b it is still present as the major anomer after 16 h (α/β = 1/4.5),
whereas 5.4b has been succeeded by 5.4a by the same time point (α/β = 1/0.8, see entry
1, Table 5.3).

Figure 5.2 NMR monitoring of the conversion of thioglycoside 5.12a into bromides
5a/5b at rt.
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Having established favorable reaction conditions for the formation of relatively
stable β-bromide 5.5b at room temperature, we turned our attention to studying its
glycosidation. For this purpose we obtained a number of glycosyl acceptors ranging from
simple aliphatic alcohols to secondary hydroxyls of monosaccharide acceptors. The
results summarized in Table 5.4 clearly indicate the correlation between the reactivity of
glycosyl acceptors and the yield: more reactive primary acceptors providing higher yields
in glycosylations. In all cases, α-linked glycosides have been formed exclusively.

Table 5.4 Glycosidation of thioglycoside 5.12a with various glycosyl acceptors

BzO
BzO

OBz
O
+ ROH

BnO
SEt
5.12a

Entry
1

ROH
MeOH

Br2

BnO

(see Table)

Time

Product
BzO
BzO

16 h

5.18

2

BnOH

OBz
O

BzO
BzO

OBz
O
BnO

OR

%yield,
α/β ratio
78%, >25/1Pa

OMe

16 h

75%, >25/1

3

16 h

67%, >25/1

4

48 h

35%, >25/1
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a

5

48 h

27%, >25/1

6

24 h

42%, >25/1

– conservative estimation, no traces of β-linked glycosides could be detected by NMR.

Having achieved this promising outcome, we conceptualized that if an efficient
equilibrium could be established between stable α-anomeric bromide 5.5a and its more
reactive b-linked counterpart 5.5b, this would lead to the further improvement. Since the
bromide 5.5a cannot be anomerized in the presence of Bu4NBr or Br2 at room
temperature (see Tables 5.1 and 5.2), it might be possible to anomerize it with the
assistance of a metal-based promoter. As discovered in 1901 by Koenigs and Knorr11
(and independently by Fischer and Armstrong12), glycosyl halides can be activated in the
presence of Ag2CO3 or Ag2O. The silver salt was used with the primary intention to
scavenge the hydrogen halide by-product, and it was not until the early 1930’s when it
was realized that it plays an active role by assisting in leaving group departure.13 This
mild assistance resulted in the Koenigs-Knorr glycosylation reaction being very
stereoselective and being one of the rare examples wherein a concerted bimolecular
displacement occurs. Even in case of α-bromide equipped with the neighboring
participating group, as noticed by Isbell,14 the inversion product was obtained as a result
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of concerted displacement, not participation due to the lack of the 1,2-orthoester
formation.

Table 5.5 Attempts to anomerize unreactive α-bromide 5a into its more reactive βcounterpart 5b.

BzO
BzO

OBz
O

+

OH
O

BnO
BnO

BnO
Br
5.5a

BnO
OMe
5.6

see

BzO
BzO

OBz
O
BnOO

table
BnO
BnO
5.7

O
BnO
OMe

Entry

Promoter (equiv.)

Time

%yield, α/β ratio

1

TBAB (0.5-5)

72 h

No reaction

2

AgCO3/TBAB (1-3/0.5-2)

72 h

No reaction

3

TBAB, 80 oC (1.0)

16 h

52% 5.6/1

4

80 oC

72 h

84% 7/1

5

KBr/18-crown-6 (1/0.5)

72 h

No reaction

6

HgBr2 (1.0)

12 h

77% 9.3/1

7

HgBr2/TBAB (1.0/0.5)

12 h

81% 9.5/1

It is possible that the anomerization can be achieved by using other heavy metal
salt-based systems, although a delicate balance between reactivity and stereoselectivity
should be kept in place to ensure success of this study. As shown by Helferich et al.,15-17
mercury(II) salts offer a potent assistance for the leaving group departure. On the other
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hand, Helferich’s study serves as an important lesson to necessitate caution and find a
balance between the reactivity and stereoselectivity as it was noted that faster reactions
often result in a decreased stereoselectivity. Nevertheless, investigation of mercurybased reagents, such as mercury (II) bromide, seemed attractive as this reagent is capable
of both assisting the leaving group departure and providing Br-. In order to prove the
concept, we performed glycosidation of 5.5a with 5.6 in the presence of HgBr2 (1 equiv.)
and obtained the expected disaccharide in 73% yield. Importantly, along with the notable
increase of the yield, stereoselectivity remained high.

5.3

Conclusions

The conceptual similarity between this approach and the Lemieux method that
was introduced in 1975 is undeniable. However, because no equilibrium between 5.5a
and 5.5b can be established by the addition of tetraalkylammonium bromide, we believe
that the concept described herein offers a novel complementary approach to glycosidation
of relatively unreactive alkyl halides. The fact that α-bromide was found to be totally
unreactive with glycosyl acceptors under these reaction conditions is a very significant
result as it guarantees that its β-counterpart will be the only species en route to the
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product. The yields achieved are similar to (or surpass) those achieved using traditional
Lemieux method (see results in Table 5.1), but the complete stereoselectivity observed
here is unmatched. Significantly, both simple aliphatic alcohols and the less reactive
sugar acceptors provided complete α-stereoselectivity.

5.4

Experimental part

5.4.1

General
Column chromatography was performed on silica gel 60 (EM Science, 70-230

mesh), reactions were monitored by TLC on Kieselgel 60 F254 (EM Science). Preparative
layer chromatography was performed on PLC silica gel 60 glass plates, Kieselgel 60 F254,
1 mm (Merck). The compounds were detected by examination under UV light and by
charring with 10% sulfuric acid in methanol. Solvents were removed under reduced
pressure at < 40 oC. CH2Cl2 and ClCH2CH2Cl were distilled from CaH2 directly prior to
application. Pyridine was dried by refluxing with CaH2 and then distilled and stored over
molecular sieves (3 Å). Molecular sieves (3 Å), used for reactions, were crushed and
activated in vacuo at 390 °C during 8 h in the first instance and then for 2-3 h at 390 °C
directly prior to application. Optical rotations were measured at ‘Jasco P-1020’
polarimeter. 1H-n.m.r. spectra were recorded in CDCl3 at 300 and 500 MHz,

13

C-NMR

spectra were recorded in CDCl3 at 75 and 125 MHz (Bruker Avance). HR FAB-MS
determinations were made with the use of JEOL MStation (JMS-700) Mass
Spectrometer, matrix m-nitrobenzyl alcohol, with NaI as necessary.
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5.4.2

Synthesis of glycosyl donors

6-O-benzoyl-2,3,4-tri-O-benzyl-α-D-glucopyranosyl bromide (5.2a)
The solution of ethyl 2,3,4-tri-O-benzyl-6-O-benzoyl-1-thio-β-D-galactopyranoside (0.5
g, 0.83 mmol) and activated molecular sieves (3 Å, 0.40 g) in CH2Cl2 12.5 mL) was
stirred under argon for 1 h. Freshly prepared solution of Br2 in CH2Cl2 (8 mL, 1/165, v/v)
was then added and the reaction mixture was kept for 15 min at rt. After that, the solid
was filtered-off and the filtrate was concentrated in vacuo at rt. The residue was purified
by silica gel flash column chromatography (ethyl acetate-toluene gradient elution) to
obtain compound 2a as a white syrup in 59% yield (0.31 g, 0.50 mmol). Rf = 0.43 (ethyl
acetate - hexane, 2/8, v/v); [α]D24 +122.56 (c = 1.0, CHCl3); 1H NMR: δ, 3.56 (ddd, 1H,
J1,2 = 3.8 Hz, J2,3 = 9.2, H-2), 3.73 (dd, 1H, J4,5 = 9.1 Hz, H-4), 4.11 (dd, 1H, J3,4 = 9.1
Hz, H-3), 4.27 (m, 1H, J5,6a = 3.02 Hz, H-5), 4.50-5.02 (m, 8H, 3×CH2Ph, H-6a, 6b), 6.41
(d, 1H, J1,2 = 3.8 Hz, H-1), 7.20-7.60 (m, 18H, aromatic), 7.90 (d, 2H, aromatic) ppm; 13C
NMR: δ, 62.6, 72.9, 73.9, 75.5, 76.1, 76.2, 77.6, 80.0, 82.2, 91.1, 128.1, 128.2 (×3),
128.3(×2), 128.4 (×3), 128.6 (×2), 128.7 (×4), 128.8 (×2), 129.8 (×3), 164.1 ppm. HR
FAB MS [M+Na]+ calcd for C34H33O6BrNa 639.1358, found 639.1332.

4-O-benzoyl-2,3,6-tri-O-benzyl-α-D-glucopyranosyl bromide (5.3a)
The solution of ethyl 2,3,6-tri-O-benzyl-4-O-benzoyl-1-thio-β-D-galactopyranoside (0.5
g, 1.59 mmol) and activated molecular sieves (3 Å, 0.40 g) in CH2Cl2 (12.5 mL) was
stirred under argon for 1 h. Freshly prepared solution of Br2 in CH2Cl2 (8 mL, 1/165, v/v)
was then added and the reaction mixture was kept for 15 min at rt. After that, the solid
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was filtered-off and the filtrate was concentrated in vacuo at rt. The residue was purified
by silica gel flash column chromatography (ethyl acetate-toluene gradient elution) to
obtain compound 3a as a white syrup in 70% yield (0.36 g, 0.58 mmol). Rf = 0.42 (ethyl
acetate - hexane, 2/8, v/v); [α]D24 +110.56 (c = 1.0, CHCl3); 1H NMR: δ, 3.55-3.72 (m,
3H, H-2, 6a, 6b), 4.16 (dd, 1H, J3,4 = 9.3 Hz, H-3), 4.34 (m, 1H, J5,6a = 3.7 Hz, H-5), 4.51
(dd, 2H, J = 2.5, 12.0 Hz, CH2Ph), 4.77 (dd, 2H, J = 12.7 Hz, CH2Ph), 4.88 (d, 1H, J2 =
11.2 Hz, ½ CH2Ph), 5.56 (dd, 1H, J4,5 = 12.0 Hz, H-4), 4.47 (d, 1H, J1,2 = 3.7 Hz, H-1),
7.13-7.50 (m, 17H, aromatic), 7.62 (m, 1H, aromatic), 8.00 (d, 2H, aromatic) ppm;

13

C

NMR: δ, 67.9, 69.4, 73.1, 73.7, 74.1, 75.5, 79.3, 79.5, 91.4, 127.7, 127.8, 128.0 (×2),
128.2 (×3), 128.3 (×3), 128.3 (×4), 128.4 (×2), 128.5 (×2), 128.7 (×3), 129.6, 129.9 (×2),
133.4, 137.4, 137.5, 137.9, 165.2 ppm. HR FAB MS [M+Na]+ calcd for C34H29O8BrNa
639.1358, found 639.1343.

3,4,6-tri-O-benzoyl-2-O-benzyl-α-D-glucopuranosyl bromide (5.5a)
The solution of ethyl 2-O-benzyl-3,4,6-tri-O-benzoyl-1-thio-β-D-galactopyranoside (1.0
g, 1.59 mmol) and activated molecular sieves (3 Å, 0.79 g) in CH2Cl2 (24 mL) was stirred
under argon for 1 h. Freshly prepared solution of Br2 in CH2Cl2 (15 mL, 1/165, v/v) was
then added and the reaction mixture was kept for 15 min at rt. After that, the solid was
filtered-off and the filtrate was concentrated in vacuo at rt. The residue was re-dissolved
in CH2Cl2 and then washed with distill water. The organic phase was concentrated in
vacuo at rt and then the residue was purified by silica gel column chromatography (ethyl
acetate-toluene gradient elution) to obtain compound 1 as a white solid in 71% yield
(0.76 g, 1.18 mmol). Rf = 0.52 (ethyl acetate - hexane, 4/6, v/v); [α]D23 +65.21 (c = 1.0,
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CHCl3); 1H NMR: δ, 3.78 (ddd, 1H, J1,2 = 3.9 Hz, J2,3 = 9.6 Hz, H-2), 4.45 (dd, 1H, J5,6a =
4.7 Hz, J6a,6b = 12.3 Hz, H-6a), 4.54-4.70 (m, 4H, H-5, 6b, CH2Ph), 5.60 (dd, 1H, J4,5 =
9.9 Hz, H-4), 6.03 (dd, 1H, J3,4 = 9.6 Hz, H-3), 6.48 (d, 1H, J1,2 = 3.9 Hz, H-1), 7.22 –
7.57 (m, 14H, aromatic), 7.93 (dd, 4H, aromatic), 8.03 (dd, 2H, aromatic) ppm;

13

C

NMR: δ, 62.3, 68.3, 72.3, 72.7, 76.7, 89.2, 128.1 (×2), 128.4 , 128.5 (×2), 128.5 (×2),
128.6 (×3), 128.7 (×3), 128.8, 129.5, 129.7, 129.9 (×4), 130.1 (×2), 133.3, 133.4,
133.7, 136.8, 165.4, 165.6, 166.3 ppm; HR FAB MS [M+Na]+ calcd for C34H29O8BrNa
667.0943, found 667.0970.

3,4,6-tri-O-benzoyl-2-O-benzyl-β-D-glucopyranosyl bromide (5.5b)
The solution of ethyl 2-O-benzyl-3,4,6-tri-O-benzoyl-1-thio-α-D-glucopyranoside (0.03
mg, 0.04 mmol) in CD3Cl (0.5 mL) in NMR tube was frozen in liquid nitrogen. After
that, bromine solution 98% (2.4 μL, 0.04mol) was added directly to NMR tube. 1H NMR
was recorded immediately. Selected analytical data for the β-isomer; 1H NMR: δ, 4.07
(dd, 1H, J2,3 =7.8 Hz, H-2), 4.20 (m, 1H, H-5), 4.46 (dd, 1H, J5,6a = 5.1 Hz, J6a,6b = 12.4
Hz, H-6a), 4.57 (dd, 1H, J5,6b = 3.1 Hz, H-6b), 4.72 (d, 1H, J2 = 10.7 Hz, ½ CH2Ph), 4.91
(d, 1H, J2 = 10.77 Hz, ½ CH2Ph), 5.67-5.81 (m, 3H, H-1, 3, 4), 7.19-8.05 (m, 20H,
aromatic) ppm;

13

C NMR: δ, 63.0, 68.8, 74.8, 75.3, 76.4, 81.7, 82.6, 128.2, 128.4 (×2),

128.5 (×5), 128.6 (×4), 129.2, 129.6, 129.9 (×2), 130.0 (×3), 130.1 (×2), 136.9, 165.3,
165.6, 166.2 ppm.
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5.4.3

General Glycosylation Procedures

Method A: typical TBAB (tetrabutyl ammonium bromide) promoted glycosylation
procedure
A mixture of the glycosyl donor (0.11 mmol), glycosyl acceptor (0.10 mmol), and freshly
activated molecular sieves (3Å, 200 mg) in (ClCH2)2 (2 mL) was stirred under argon for 1
h., then TBAB (0.11 mmol) was added. The reaction mixture was stirred at rt and
monitored with TLC. Upon completion, the reaction mixture was diluted with
dichloromethane, the solid was filtered-off and the residue was washed with
dichloromethane. The combined filtrate was washed with 20% aq. NaHCO3 and water,
the organic phase was separated, dried with MgSO4 and concentrated in vacuo. The
residue was purified by column chromatography on silica gel (ethyl acetate/hexane
gradient elution) to allow the corresponding disaccharide. Anomeric ratios (if applicable)
were determined by comparison of the integral intensities of relevant signals in 1H-n.m.r.
spectra.

Method B: typical Br2 promoted glycosylation procedure
A mixture of the glycosyl donor (0.11 mmol), glycosyl acceptor (0.10 mmol), and freshly
activated molecular sieves (3Å, 200 mg) in (ClCH2)2 (2 mL) was stirred under argon for 1
h., then bromine solution, 99.8% (0.11 mmol) was added. The reaction mixture was
stirred at rt and monitored with TLC. Upon completion, the reaction mixture was diluted
with dichloromethane, the solid was filtered-off and the residue was washed with
dichloromethane. The combined filtrate was washed with 20% aq. NaHCO3 and water,

182

the organic phase was separated, dried with MgSO4 and concentrated in vacuo. The
residue was purified by column chromatography on silica gel (ethyl acetate/hexane
gradient elution) to allow the corresponding disaccharide. Anomeric ratios (if applicable)
were determined by comparison of the integral intensities of relevant signals in 1H-n.m.r.
spectra.

Method C: typical Br2 pre-activation glycosylation procedure
A mixture of the glycosyl donor (0.1 mmol) freshly activated molecular sieves (3Å, 200
mg) in (ClCH2)2 (2 mL) was stirred under argon for 1 h. Bromine solution 98% (0.1 mol)
was added and the reaction mixture was stirred for 10 min at rt. After that, the solvent
was removed out under vacuo at rt and dried in vacuo for 1 h. The solution of glycosyl
acceptor (0.15 mmol of glycosyl in 2 mL (ClCH2)2 was added into the glycosyl flask and
the reaction was stirred under argon for 3-5 days at rt. Upon completion, the reaction
mixture was diluted with dichloromethane, the solid was filtered-off and the residue was
washed with dichloromethane. The combined filtrate was washed with 20% aq. NaHCO3
and water, the organic phase was separated, dried with MgSO4 and concentrated in
vacuo. The residue was purified by column chromatography on silica gel (ethyl
acetate/hexane gradient elution) to allow the corresponding disaccharide. Anomeric ratios
(if applicable) were determined by comparison of the integral intensities of relevant
signals in 1H-n.m.r. spectra.

Methyl

6-O-(6-O-benzoyl-2,3,6,-tetra-O-benzyl-α/β-D-glucopyranosyl)-2,3,4-tri-O-

benzyl-α-D-glucopyranoside (5.8)
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This compound was obtained by Method B from compound 2a and compound 6 in 45%
yield as a white syrup (α/β = 24/1), Rf = 0.41 (ethyl acetate/hexane, 3/7, v/v); selected
analytical data 1H NMR: δ, 3.32 (ddd, 1Η, J1’,2’ = 3.6 Ηz, J2’,3’ = 9.6 Hz, H-2’), 3.46-3.54
(m, 3H, H-2, 4, 4’), 3.62 (m, 1H, J6a,6b = 10.1 Hz, H-6a), 3.72 (m, 2H, H-5, 6b), 3.90 (m
3H, J =9.8 Hz, H-3, 3’,5’), 4.31 (dd, 1H, J5’,6a’ = 4.4 Hz, J6a’,6b’ = 11.9 Ha, H-6a’), 4.43
(dd, 1H, J5’,6b’ = 2.0 Hz), 4.47-4.64 (m, 7H, J1’,2’ = 3.3 Hz, H-1’, 3×CH2Ph), 4.70-4.75 (m,
2H, CH2Ph), 4.81-4.93 (m, 5H, J1,2 = 3.56 Hz, H-1, 3×CH2Ph) ppm; δ, 13C NMR : δ,
55.4, 63.6, 66.2, 69.1, 70.6.72.6, 73.5, 75,2 (×2), 75.9 (×2), 77.4, 78.0, 80.3, 80.4, 81.9,
82.3, 97.1, 98.1, 127.8 (×3), 127.9 (×2), 127.9 (×3), 127.9 (×2), 128.0 (×2), 128.1 (×2),
128.2 (×4), 128.4 (×3), 128.5 (×3), 128.5 (×3), 128.6 (×4), 129.8 (×3), 130.2, 133.2,
138.2, 138.3, 138.5 (×2), 138.7, 139.0, 166.4 ppm; HRFABMS [M+Na]+ calcd for
C62H54O12Na 1023.4295, found 1023.4257.

Methyl

6-O-(4-O-benzoyl-2,3,4,-tetra-O-benzyl-α/β-D-glucopyranosyl)-2,3,4-tri-O-

benzyl-α-D-glucopyranoside (5.9)
This compound was obtained by Method B from compound 3a and compound 6 in 15%
yield as white syrup (α/β = 6.2/1), Rf = 0.41 (ethyl acetate/hexane, 3/7, v/v); Selected
analytical data for the α-isomer 1H NMR: δ, 3.38 (s, OCH3), 3.47 (m, 2H, H-2’, 4), 3.984.11 (m, 3H, H-3, 3’, 5), 4.59 (d, 1H, J1’,2’ = 3.8 Hz, H-1’), 4.96 (d, 1H, J1,2 = 2.5 Hz, H1), 5.31 (dd, 1H, J4’,5’ = 9.45 Hz, H-4’) ppm; 13C NMR : δ, 55.3, 69.1, 69.3, 70.6, 71.1,
72.7, 73.6, 73.7, 75.1, 75.2, 75.9, 77.4, 78.1, 78.4, 79.9, 80.3, 82.4, 127.5 (×2), 127.6
(×2), 127.8, 127.8 (×3), 127.9 (×3), 128.1 (×2), 128.2 (×2), 128.2 (×2), 128.3 (×2), 128.3,
128.4, 128.5 (×3), 128.6 (×2), 128.6 (×3), 129.9 (×2), 130.1, 133.2, 138.0, 138.3, 138.5,

184

138.7, 139.0, 165.46 ppm; HRFABMS [M+Na]+ calcd for C62H54O12Na 1023.4295,
found 1023.4337.

Benzyl 3,4,6-tri-O-benzoyl-2-O-benzyl-α-D-glucopyranoside (5.19) was obtained by
method B from glycosyl donor

and benzyl alcohol, as a clear film in 75% yield.

Analytical data for 5.19 : Rf = 0.35 (ethyl acetate-toluene, 0.5/9,.5 v/v); [α]D26 +29.30 (c =
1.0, CHCl3); 1H NMR (CDCl3): δ, 3.78 (ddd, 1H, J1,2 = 3.6 Hz, J2,3 = 9.9 Hz, H-2), 4.374.51 (m, 6H, CH2Ph, H-5, 6a, 6b), 4.62 (d, 1H, J2 = 12.3 Hz, ½ CH2Ph), 4.98 (d, 1H, J1,2
= 3.5 Hz, H-1), 4.99 (d, 1H, J2 = 15.0 Hz, ½CH2Ph), 5.49 (dd, 1H, J4,5 = 9.93 Hz, H-4),
6.03 (dd, 1H J3,4 = 9.7 Hz, H-3), 7.14-7.60 (m, 19H, aromatic), 7.91 (m, 4H, aromatic),
8.02 (d, 2H, aromatic) ppm; 13C NMR (CDCl3): δ, 31.4, 63.4, 68.1, 69.6, 70.1, 72.2, 77.4,
72.8, 95.5, 128.0 (×2), 128.1, 128.2, 128.4 (×2), 128.5 (×2), 128.6 (×5), 128.7 (×3),
128.8, 129.1, 129.9 (×3), 130.0 (×3), 130.1 (×2), 133.2, 133.3, 133.5, 136.9, 137.7, 165.7,
165.9, 166.4 ppm; HR-FAB MS calcd. for C41H36O9Na 695.2257, found 695.2244.

Ethyl 6-O-(2-O-benzyl-3,4,6-tri-O-benzoyl-α-D-glucopyranosyl)-2,3,4-tri-O-benzoylthio-β-D-glucopyranoside (5.22)
This compound was obtained by Method B from ethyl 2-O-benzyl-3,4,6-tri-O-benzoyl-1thio-α-D-glucopyranoside and ethyl 2,3,4-tri-O-benzoyl-1-thio-β-D-glucopyranoside in
42% yield as a white syrup, Analytical data for 5.22 : Rf = 0.62 (ethyl acetate/toluene, 1/9,
v/v); [α]D25 +28.06 (c = 1.0, CHCl3); 1H NMR: δ, 1.39 (t, 3H, J = 7.4 Hz, CH3CH2S),
2.83 (m, 2H, CH3CH2S), 3.37 (d, 1H, J6b,6a = 10.7 Hz, H-6b), 3.79 (ddd, 1H, J1’,2’ = 3.3
Hz, J2’,3’ = 9.9 Hz, H-2’), 4.00 (dd, 1H, J6a,6b = 10.4 Hz, H-6a), 4.19 (dd, 1H, J5,6a = 8.3
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Hz, H-5), 4.36 (dd, 1H, J5’,6a’ = 5.6 Hz, J6a’,6b’ = 12.1 Hz, H-6a’), 4.51–4.53 (m, 2H, H-5’,
6b’), 4.56 (d, 1H, J2 = 12.53 Hz, ½ CH2Ph), 4.64 (d, 1H, J2 = 12.54 Hz, ½ CH2Ph), 4.85
(d, 1H, J1’,2’ = 3.3 Hz, H-1’), 4.88 (d, 1H, J1,2 = 10.0 Hz, H-1), 5.39 (dd, 1H, J4’,5’ = 9.6
Hz, H-4’), 5.48 (dd, 2H, J = 10.0 Hz, H-2, 4), 5.92 (dd, 1H, J3’,4’ = 9.4 Hz, H-3’), 6.0 (dd,
1H, J3,4 = 9.8 Hz, H-3), 7.10–7.98 (m, 35H, aromatic) ppm; δ, 13C NMR : δ, 14.3, 24.9,
63.1, 67.2, 68.1, 69.7, 69.9, 70.9, 72.1, 73.3, 74.3, 84.1, 89.6, 96.6, 125.5, 128.1 (×3),
128.4, 128.5 (×3), 128.5 (×4), 128.6 (×3), 128.6 (×2), 128.7 (×3), 128.9, 129.1, 129.2,
129.4, 129.8, 129.9 (×3), 130.0 (×2), 130.1 (×3), 130.1 (×3), 133.2, 133.3, 133.4, 133.4,
133.5, 133.7, 137.7 (×2), 165.3, 165.4, 165.6, 165.8, 165.9, 166.2 ppm; HRFABMS
[M+Na]+ calcd for C63H56NO16SNa 1123.3187, found 1123.3198.

Deuterated methoxy 2-O-benzyl-3,4,6-tri-O-benzoyl-α-D-glucopyranoside
This compound was obtained by Method A from ethyl 2-O-benzyl-3,4,6-tri-O-benzoyl-1thio-α-D-glucopyranoside (1 equiv) and deuturated methanol (2 equiv) in 74 % yield as a
white syrup, Rf = 0.5 (ethyl acetate/hexane, 4/6, v/v); [α]D25 +7.7 (c = 1.0, CHCl3); 1H
NMR: δ, 3.83 (ddd, 1H, J1,2 = 3.5 Hz, J2,3 = 9.9 Hz, H-2), 4.37 (m, 1H, H-5), 4.47 (dd,
1H, J6a,6b = 12.01 Hz, J5,6a = 5.5 Hz, H-6a), 4.58 (dd, 1H, H-6b), 4.67 (dd, J = 3.09, 12.49
Hz, CH2Ph), 4.90 (d, 1H, J1,2 = 3.5 Hz, H-1), 5.48 (dd, 1H, J4,5 = 9.8 Hz, H-4), 6.02 (dd,
1H, J3,4 = 9.7 Hz, H-3), 7.30 (m, 4H, aromatic), 7.45 (m, 7H, aromatic), 7.55 (m, 3H,
aromatic), 7.97 (m, 4H, aromatic), 8.05 (d, 2H, aromatic) ppm; 13C NMR.: δ, 63.4, 67.8,
70.1, 72.1, 73.3, 98.1, 128.1 (×3), 128.2, 128.5 (×2), 128.5 (×4), 128.6 (×2), 129.2, 129.8
(×3), 129.9 (×2), 130.0 (×2), 130.1 (×2), 133.2, 133.3, 133.5, 165.7, 165.8, 166.3 ppm;
HR FAB MS [M+Na]+ calcd for C35D3H29O9Na 622.2129, found 622.2132.
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CHAPTER VI

Development of CD14-targeting therapeutics: synthesis and evaluation of
glucopyranoside-spacer-amino acid motifs

__________________________________________________________________
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6.1

Introduction
Septicemia is a serious world-wide health problem associated with mortality rates

of 40-60%.1 It has been estimated that 1% of hospital patients and 20-30% of ICU
patients develop sepsis. The cardiovascular consequences of septic shock resulting from
bacterial infections include myocardial dysfunction that develops in nearly all patients,2
vascular tone and permeability abnormalities, as well as abnormal oxygen delivery and
metabolism. As a result, vital organs, such as the brain, heart, kidneys, and liver may be
affected or may fail, and this is reflected in over 100,000 deaths annually in the US.1 It is
well established that septic shock is initiated by movement of bacterial endotoxin (or
lipopolysaccharide, LPS) into the blood stream. LPS, a vital component of the outer
leaflet of the gram-negative outer membrane, has been shown to be a principle mediator
of the depression of left ventricular function and myocardial contractility.3 LPS is
comprised of three structural regions (O-antigen, core-oligosaccharide, and Lipid A), the
Lipid-A region of which consists of a polyacylated glucosamine disaccharide and is
largely responsible for the toxic activity.4 The results of recent studies suggest that
concurrent evidence of a proinflammatory response to LPS is by far more important than
detection of LPS in circulation.5,6 The effects of LPS are initiated after it interacts with a
plasma LPS-binding protein (LBP), which has strong affinity for both the Lipid-A region
of endotoxin and glycosylphosphatidyl inositol-anchored LPS receptor CD14 on
mononuclear phagocytes. When LPS-LBP complex interacts with CD14 (and then TLR4), the cells produce proinflammatory factors, such as tumor necrosis factor α (TNFα)
(Figure 6.1).
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Due to recent advances in the understanding of structure-function relationships for
LPS, some generalizations regarding the most important structural determinants that
result in the endotoxic activity of Lipid-A were made.7 These determinants include the
number and chain length of fatty acids (lipids). Typically, 1,4’-diphosphate disaccharides
of the E. coli type are used (6.1, Figure 6.1), but their fair stability (chemical or in vitro)
has been a major drawback in their synthesis and application. Although the exact role of
the phosphate moieties is still unknown, the findings that showed 1-hydroxyl-4’-Ophosphate derivative as inactive gave rise to a belief that omitting at least one phosphate
results in the entire loss of activity.7,8
In an effort to explore molecules that will bind with high affinity to CD14 without
activating the inflammatory cascade, our laboratories have been designing simplified
Lipid A analogs that lack the complexity of the highly lipidated diphosphorylated
disaccharide core yet still maintain potent antagonistic activity against LPS. Herein we
present the synthesis and unprecedented LPS-antagonistic activity of the methyl
glucopyranoside-amino acid conjugates. This project was inspired by observations that
structurally modified or totally unrelated to Lipid A can still exhibit potent antagonistic
activity. Amongst a myriad of research articles that have been disseminated in the past
years, the following three groundbreaking discoveries appeared to us to be of a particular
inspiration and relevance to our own attempts.
First, as reported by Boons et al. strong binding and antagonistic effect was
achieved even with ‘phosphateless’ Rhizobium syn-1 disaccharide 6.2, which bears a
lactone moiety at the reducing end (Figure 6.1).9,10 This finding shows that one could
avoid hurdles associated with labile phosphate group installation, handling, and storage.
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Second, Shiozaki et al. showed that strong anti-LPS antagonistic response can be
achieved even with disaccharide 6.3, in which the non-reducing glucosamine is replaced
with glucose. In addition, instead of chiral β-hydroxy/acyl esters, relatively simple alkyl
chains were used at C-3 and 3’ positions, whereas a β-ketoamide moiety is used at C-2.8

Figure 6.1 Structure of monsaccharide and disaccaharide Lipid A analogs

Third, Peri et al. demonstrated that even simple methyl glycoside-heterocycle
conjugates 6.4 and 6.5 bearing alkyl chains instead of traditional lipids provide
antagonistic activity.11 To this end, we found it attractive to develop molecules that
contain the following: a methyl glucoside core to simplify the synthesis, hydrophobic
chains to facilitate membrane intercalation, and amino acids to provide an ionic character.
Here we report a highly efficient synthesis of molecules of this type and biological
studies of their endotoxic activity in vitro.
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6.2

Results and Discussion
The synthesis began with the conversion of commercially available methyl α-D-

glucopyranoside 6.6 into methyl 2,3-di-O-benzyl-α-D-glucopyranoside 6.7 via sequential
4,6-benzylidene acetal formation, 2,3-dibenzylation, and acetal cleavage accomplished in
67% overall yield (Scheme 6.1). 4,6-Diol 6.7 was then succinoylated at the primary
position with succinic anhydride in the presence of 4-dimethylaminopyridine (DMAP) in
pyridine to afford derivative 6.8 in 71 % yield. The carboxyl moiety of the linker was
then coupled with 3-hydroxyl of protected L-serine derivative 6.9. This was
accomplished using N,N'-diisopropylcarbodiimide (DIC) as the coupling reagent in the
presence of DMAP in pyridine to afford conjugate 6.10 in 80% yield. Having obtained
the key construct 6.10, we decided to pursue further protecting group transformations.
The main driving force for these synthetic manipulations was to obtain a series of simple
analogs that would allow us to investigate the effect of cationic and anionic character on
LPS-antagonistic activity in vitro. With this objective in mind, carboxylated compound
6.11 was obtained from 6.10 by cleavage of tert-butyl ester in presence of TFA/DCM in
81% yield.

Alternatively, the Fmoc protecting group could also be removed from

compound 6.10 with piperidine in DMF to afford free amine 6.12. Subsequently, we also
obtained compound 6.13 having both carboxyl and amine groups unprotected. This was
accomplished by the treatment of compound 6.12 with TFA/CH2Cl2 to give derivative
6.13 in 75% yield.
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Scheme 6.1 Synthesis of monosaccharide Lipid analog 6.10-6.13

The

inhibitory

activity

of

compounds

6.10-6.13

on

LPS-induced

TNFα production was investigated in vitro using THP-1 macrophages. Compounds 6.10,
6.12, and 6.13 exhibited no inhibitory activity against LPS-induced TNFα production in
the concentration range of 0.1 nM to 10 µM (Figure 6.2A-C). These compounds were
also tested in the absence of LPS and demonstrated no agonist activity (data not shown).
Compound 6.11 which has a free carboxylic group was able to significantly inhibit LPSinduced TNFα production at concentrations greater than 10 μM (Figure 6.3).
Unfortunately, cell viability measurements using an XTT reduction assay indicated that
compound 6.11 was toxic to the cells in the 30-100 µM range. Although there was a gap
between inhibition and toxicity at 30 and 50 µM, the similarities between the inhibition
and toxicity curves suggested that much of the antagonistic activity by 6.11 was related to
toxicity.
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compound 6.10

compound 6.12

compound 6.13

Figure 6.2 Antagonistic activity of compound 6.10, 6.12 and 6.13 (Experimental work
and data analysis done by Maria Udan in the laboratory of Dr. MR Nichols)
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Figure 6.3 Antagonistic activity and toxicity of compound 6.11(Experimental work and
data analysis done by Geeta Paranajape in the laboratory of Dr. MR Nichols)
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With the purpose of gaining further insight into the effect of various substituents
on endotoxic activity of monosaccharide-amino acid conjugates we obtained an analog of
compound 6.11 in which benzyl groups have been replaced with acyl (myristoyl, C14)
fatty acid chains. The synthesis of lipidated analog 6.19 was accomplished as depicted in
Scheme 6.2.

Scheme 6.2 Synthesis of monosaccharide Lipid A analog 6.19

Methyl glycoside 6.6 was protected as 4,6-O-(p-methoxybenzylidene) acetal 6.14
by treatment with anisaldehyde dimethylacetal in presence of camphorsulfonic acid in
89% yield. The acylation of 6.14 with myristoyl chloride in the presence of pyridine
furnished compound 6.15 in 85% yield. The benzylidene ring in 6.15 was reductively
opened by treatment with BH3-THF catalyzed with Cu(OTf)2 to obtain unexpected
product 6.16 lacking the C-2 acyl chain in 67% yield. The loss of the acyl chain was
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rather unexpected, but this glitch was overcome by regioselective succinoylation with
succinic anhydride in pyridine at the primary C-6 position followed by C-2 acylation with
miristoyl chloride. This two-step one-pot procedure allowed us to obtain compound 6.17
in 79% yield. L-serine derivative 6.9 was linked to the carboxyl group of 6.17 of via
DIC-mediated coupling in the presence of DMAP. The target monosaccharide-amino
acid conjugate 6.18 was obtained in 83% yield. Acid treatment of the fully protected
compound 6.18 led to concomitant cleavage of the p-methoxybenzyl (PMB) group at C-4
and tert-butyl ester. As a result, compound 6.19 was isolated in 75% yield.
The synthesis of alkylated analog 6.24 was accomplished as depicted in Scheme
6.3.

Intermediate 6.14 was di-alkylated at C-2 and C-3 with myristyl bromide in

presence of NaH to afford compound 6.20 in 72% yield. The benzylidene ring in 6.20
was reductively opened by treatment with BH3-THF catalyzed with Cu(OTf)2 to obtain
product 6.22 in 87%. Acylation of 6.22 with succinic anhydride led to compound 6.22 in
89% yield. L-serine derivative 6.9 was then linked to the carboxyl group of 6.22 via
DIC-mediated coupling in the presence of DMAP. The resulting monosaccharide-amino
acid conjugate 6.23 was obtained in 79% yield. Acid treatment of the fully protected
compound 6.23 led to concomitant cleavage of the p-methoxybenzyl (PMB) group at C-4
and tert-butyl ester. As a result, target compound 6.24 was isolated in 81% yield.
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Scheme 6.3 Synthesis of monosaccharide Lipid A analog 6.24

Having obtained compounds 6.19 and 6.24, a lipidated and alkylated analogs of
compound 6.11, respectively, we were well positioned to perform comparative studies. In
addition, as the comparison point, we obtained the standard positive control compound
6.4 as described by Peri et al.11 A marked improvement in LPS-antagonistic ability was
observed with the lipidated compound 6.19. Inhibition of LPS-induced TNFα was found
to begin at 550 nM. A reproducible biphasic response was consistently observed in the
activity of 6.19. This may indicate multiple binding sites on the macrophages, both higher
and lower affinity for the antagonist compound. Eighty percent of the LPS response was
blocked at 5 µM compound 6.19 with no observable toxicity. Cell viability began to be
compromised at 10 µM and some agonist activity was found in the 10-30 µM range
(Figure 6.4).
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Figure 6.4 Biological activity test of compound 6.19 (Experimental work and data
analysis done by Geeta Paranajape and Shana E. Terrill,in the laboratory of Dr. MR
Nichols)

Compound 6.24 with alkyl chains rather than lipid chains as in 6.19 was found to
be a very effective inhibitor of LPS-induced TNFα production in human macrophages.
Seventy percent inhibition was observed at 1 µM and overall inhibition reached 90% at
40 µM. Compound 6.24 exhibited no toxicity or agonist activity in the tested 0.2 to 40
µM range. Curve fitting of the inhibition data in Figure 6.5 produced an IC50 value of 470
nM. These results were superior to those obtained with compound 6.4

11

which had an

inhibition range from 3-10 µM and began to show agonist activity at concentrations >10
µM (Figure 6.6). Compound 6.4 was only toxic at high concentrations.
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Figure 6.5 Biological activity test of compound 6.24 (Experimental work and data
analysis done by Geeta Paranajape and Shana E. Terrill,in the laboratory of Dr. MR
Nichols
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Figure 6.6 Biological activity test of compound 6.4 (Experimental work and data
analysis done by Geeta Paranajape and Shana E. Terrill,in the laboratory of Dr. MR
Nichols
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6.3

Conclusions
In summary, studies described herein provide new information regarding

structure-activity relationship of novel class of compounds mimicking classic Lipid-A
analogs, and the scientific basis for future studies to prevent the deleterious effects of
endotoxemia. We believe that the results of these studies will have far reaching impacts
on the treatment of patients diagnosed with endotoxemia. As a consequence, we can
foresee additional efforts to investigate the molecular mechanisms responsible for the
antagonistic actions of the synthetic Lipid A analogs.

6.4

Experimental Section

6.3.1. General. Column chromatography was performed on silica gel 60 (EM Science,
70-230 mesh) and reactions were monitored by TLC on Kieselgel 60 F254 (EM Science).
The compounds were detected by examination under UV light and by charring with 10%
sulfuric acid in methanol. Solvents were removed under reduced pressure at < 40 oC.
CH2Cl2 was freshly distilled from CaH2 prior to application. The solvent was kept in
contact with the alloy until distilled for use. N,N'-Diisopropylcarbodiimide, 4dimethylaminopyridine, trifluoroacetic acid, anhydrous N,N-dimethylformamide were
purchased from Sigma-Aldrich and used as is. Pyridine was dried by refluxing with CaH2
and then distilled and stored over. Optical rotations were measured using ‘Jasco P-1020’
polarimeter. Unless noted otherwise, 1H-NMR spectra were recorded in CDCl3 at 300
MHz (Bruker Avance) or at 500 MHz (Bruker ARX-500),

13

C-NMR spectra and two-

dimensional experiments were recorded in CDCl3 at 75 MHz (Bruker Avance) or at 125
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MHz (Bruker ARX-500). HRMS determinations were made with the use of JEOL
MStation (JMS-700) Mass Spectrometer.

Methyl 2,3-di-O-benzyl-6-O-(3-carboxypropanoyl)-α-D-glycopyranoside (6.8).
DMAP (32 mg, 0.26 mmol) and succinic anhydride (0.16 g, 1.56 mmol) were added to a
stirred solution of methyl 2,3-di-O-benzyl-α-D-glucopyranoside 6.7 (0.5 g, 1.3 mmol) in
dry pyridine (5 mL) at room temperature under argon. The reaction mixture was stirred
for 16 h at room temperature under argon. After that, the reaction mixture was
concentrated under the reduced pressure, the residue was dissolved in CH2Cl2 (30 mL)
and washed successively with water (3 × 15 mL). The organic phase was dried over
MgSO4, filtered and concentrated in vacuo. The residue was purified by column
chromatography on silica gel (ethyl acetate-hexane gradient elution) to give compound
6.8 (0.45 g, 0.95 mmol) as a colorless syrup in 71% yield. Analytical data for 6.8: Rf =
0.43 (ethyl acetate); [α]D22 +7.19 (c = 1.0, CHCl3); 1H NMR (300 MHz, CDCl3): δ, 2.60
(m, 4H, 2×CH2), 3.38 (s, 3H, OCH3), 3.44 (dd, 1H, J2,3 = 9.5 Hz, H-2), 3,51 (ddd, 1H, J =
3.5, 9.5 Hz, H-4), 3.73 (m, 1H, J5,6b = 4.8 Hz, H-5), 3.80 (dd, 1H, J2,3 = 9.2 Hz, H-3),
4.26 (dd, 1H, J6a,6b = 10.0 Hz, H-6a), 4.42 (dd, 1H, H-6b), 4.61 (d, 1H, J1,2 = 3.5 Hz, H1), 4.65 (d, 1H, J2 = 12.1 Hz, ½ CH2Ph), 4.74-4.79 (m, 2H, CH2Ph), 4.99(d, 1H, J =
11.31 Hz, ½ CH2Ph), 7.26-7.36 (m, 10H, aromatic) ppm; 13C NMR (75 MHz, CDCl3): δ,
55.39, 3.73, 69.37, 69.99, 73.34, 75.34, 79.65, 81.34, 98.26, 128.02, 128.12, 128.24,
128.49, 128.62, 128.68, 138.08, 138.63, 172.64, 177.19 ppm; HR FAB MS [M+Na]+
calcd for C25H30O9Na 497.1788, found 497.1770.
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Methyl 2,3-di-O-benzyl-6-O-(4-((S)-2-(9-fluorenylmethoxycarbonyl)amino-3-(tertbutoxy)-3-oxopropyl)oxy-4-oxobutanoyl)-α-D-glycopyranoside (6.10).
DMAP (12.7 mg, 0.01 mmol) and DIC (0.16 mL, 1.04 mmol) were added to a stirred
solution of the O-tert-butyl-N-fluorenylmethoxycarbonyl-L-serine 6.9 (0.19 g, 0.52
mmol) in CH2Cl2 (4 mL). After 1 h, the carboxylic acid derivative 6.8 (0.29 g, 0.62
mmol) was added and the reaction was stirred for 5-9 h when TLC indicated no further
conversion of starting material. The reaction was diluted with CH2Cl2 (20 mL), washed
with distill water (2 × 15 mL) and brine (15 mL). The organic phase was dried over
MgSO4, filtered and concentrated in vacuo. The residue was purified by column
chromatography on silica gel (ethyl acetate-hexane gradient elution) to obtain compound
6.10 (0.34g, 0.41 mmol) as a white powder in 80 % yield. Rf = 0.34 (ethyl acetate-hexane
1/1, v/v); [α]D27 +12.05 (c = 1.0, CHCl3); 1H NMR (300 MHz, CDCl3) : δ = 1.48 (s, 9H, tBu), 2.53 (broad s, OH), 2.66 (m, 4H, 2×CH2), 3.37 (s, 3H, OCH3), 3.42 (d, 1H, J2,3 =
9.0, H-2), 3.73 (m, 1H, H-5), 3.78 (dd, 1H, J3,4 = 9.1 Hz, H-3), 4.25 (m, 2H, H-6b, SerCβH), 4.38 (m, 2H, H-6ª, SerCβ-H), 4.44 (m, 2H, CH2Fmoc), 4.52 (m, 1H, SerCα-H), 4.61
(d, 1H, J1,2 = 3.2 Hz, H-1), 4.64 (d, 1H, J2 = 12.1 Hz, ½ CH2Ph), 4.75 (dd, 2H, J = 12.0
Hz, CH2Ph), 4.98 (d, 1H, J2 = 11.33 Hz, ½ CH2Ph), 4.75 (d, 1H, JNH,CH = 8.00 Hz, SerNH), 7.27-7.42 (m, 14H, aromatic), 7.62 (d, 2H, J = 7.4 Hz, aromatic), 7.77 (d, 2H, J =
7.5 Hz, aromatic) ppm;
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C NMR (125 MHz, CDCl3): δ = 28.12, 29.09, 29.11, 47.30,

54.07, 55.48, 63.85, 64.81, 67.41, 69.38, 70.11, 73.40, 75.71, 79.74, 81.31, 83.29, 98.39,
120.17, 125.35, 125.40, 127.28, 127.91, 128.06, 128.16, 128.27, 128.68, 128.76, 138.18,
138.86, 141.48, 144.01, 144.05, 156.00, 168.51, 171.80, 172.60 ppm; HR FAB MS
[M+Na]+ calcd for C47H53NO13Na 862.3415, found 862.3432.
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Methyl

2,3-di-O-benzyl-6-O-(4-((S)-2-(9-fluorenylmethoxycarbonyl)amino-2-

carboxyethyl)oxy-4-oxobutanoyl)-α-D-glycopyranoside (6.11).
Methyl glucoside derivative 6.10 (0.25g, 0.29 mmol) was dissolved in TFA/CH2Cl2 (1/5
v/v, 2mL) and stirred for 2 h. Upon completion as assessed by TLC analysis, solvents
were evaporated in vacuo. The residue was dissolved in CH2Cl2 (5 mL) and neutralized
with triethylamine (TEA). The solvent was removed under the reduced the pressure. The
residue was subjected to column chromatography on silica gel (ethyl acetate-hexane 1/1,
v/v) to afford carboxylic derivative 6.11 (0.18g, 0.24 mmol) as white foam in 81% yield.
Rf = 0.5 (methanol-ethyl acetate 2/8, v/v) ); [α]D26 +22.48 (c = 1.0, CHCl3); 1H NMR (500
MHz, CDCl3:(CD3)2SO 4:2 ) : δ = 2.49 - 2.54 (m, 4H), 3.26 (s, 3H, OCH3), 3.39 (m,2H),
3.57 (m,2H), 4.01 (broad s, 1H), 4.12 (m, 2H), 4.22 (m, 2H), 4.32 (dd, 2H, J = 6.6 Hz),
4.43 (d, 1H, J = 5.1 Hz), 4.60 (s, 2H), 4.76 (m, 2H), 7.24 – 7.43 (m, 10H, aromatic), 7.68
(d, 2H, J = 4.38 Hz, aromatic), 7.93 (d, 2H, J = 4.89 Hz, aromatic) ppm; 13C NMR (75
MHz, CDCl3:(CD3)2SO 4:2): δ = 28.84, 28.99, 31.06, 47.03, 54.71, 54.83, 63.42, 63.90,
65.31, 65.92, 69.85, 70.20, 71.85, 74.50, 79.36, 81.46, 97.29, 120.47, 125.56, 127.44,
127.49, 127.87, 127.83, 127.90, 127.98, 128.33, 128.52, 138.94, 139.62, 141.06, 144.23,
156.05, 172.16, 172.23 ppm; HR FAB MS [M+Na]+ calcd for C43H45NO13Na 806.2789,
found 806.2780. (See Appendix; Figure A-22, and A-23)

Methyl

2,3-di-O-benzyl-6-O-(4-((S)-2-amino-3-(tert-butoxy)-3-oxopropyl)oxy-4-

oxobutanoyl)-α-D-glycopyranoside (6.12).
Piperidine (0.5 mL) was added dropwise to stirred solution of monosaccharide 6.10 (0.1
g, 0.12 mmol) in DMF (2.0 mL). After stirred for 20 min, TLC indicated complete
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conversion of starting material. The solvents were removed in vacuo (co-evaporation
with toluene). The residue was purified by flash column chromatography (ethyl acetatehexane 1/1) to give the amine derivative 6.12 (67 mg, 0.1 mmol) as yellow syrup in 92%
yield. Rf = 0.62 (methanol-ethyl acetate 1/9, v/v) ); [α]D26 +17.33 (c = 1.0, CHCl3); 1H
NMR (500 MHz, CDCl3) : δ = 1.49 (s, 9H, t-Bu), 2.52 – 2.66 (m, 3H), 2.73 – 2.78 (m,
1H), 3.02 (broad s, 1H, OH), 3.38 (s, 3H, OCH3), 3.46 (d, 1H, J2,3 = 9.4 Hz, H-2), 3.50
(ddd, 1H, J4,5 = 9.5 Hz, H-4), 3.75 (m, 2H, H-5, Ser-CβH), 3.80 (m, 2H, H-3, Ser-CβH),
4.18 (dd, 1H, J6a,6b = 10.19 Hz, H-6a), 4.46 (m, 1H, Ser-CαH), 4.52 (dd, 1H, J5,6b = 4.19
Hz, H-6b), 4.61 (d, 1H, J1,2 = 3.53 Hz, H-1), 4.65 (d, 1H, J2 = 12.5 Hz, ½ CH2Ph), 4.77
(dd, 2H, J = 11.5 Hz, CH2Ph), 4.99 (d, 1H, J2 = 9.0 Hz, ½ CH2Ph,) 6.49 (d, 1H, JNH,CH =
6.95 Hz, Ser-NH), 7.27 - 7.31 (m, 10H, aromatic) ppm; 13C NMR (125 MHz, CDCl3): δ =
28.18, 29.76, 31.05, 31.11, 55.51, 55.68, 63.35, 63.63, 69.46, 69.88, 73.49, 75.98, 79.83,
81.50, 83.01, 98.47, 128.09, 128.17, 128.30, 128.41, 128.68, 128.72, 138, 22, 128.73,
169.60, 172.05, 173.06 ppm; HR FAB MS [M+Na]+ calcd for C32H43NO11Na 640.2734,
found 640.2841.

Methyl 2,3-di-O-benzyl-6-O-(4-((S)-2-amino-2-carboxyethyl)oxy-4-oxobutanoyl)-αD-glycopyranoside (6.13)
Methyl glucoside derivative 6.12 (0.1 g, 0.12 mmol) was dissolved in TFA/CH2Cl2 (1/5
v/v, 2 mL) and stirred for 2 h. Upon completion as assessed by TLC analysis, solvents
were evaporated in vacuo. The residue was dissolved in CH2Cl2 (5 mL) and neutralized
with triethylamine (TEA). Solvents were removed under the reduced the pressure. The
residue was subjected to column chromatography on silica gel (methanol-ethyl acetate
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gradient elution) to obtain product 6.13 (50 mg, 0.09 mmol) as white foam in 75% yield.
Rf = 0.5 (methanol-ethyl acetate 2/8, v/v) ); 1H NMR (500 MHz, D2O ) : δ = 1.68 (m,
2H), 1.82 (m, 3H), 2.73 (m, 4H), 3.19 (dd, 3H, J = 5.7 Hz), 3.4 (s, 3H, OCH3), 3.58 (ddd,
2H, J = 9.5, 10.0 Hz), 3.80 (dd, 1H, J = 9.2 Hz), 3.87 (d, 3H, J = 4.7 Hz), 4.33 - 4 .37
(m, 2H, J = 4.7 Hz), 4.54 (d, 1H, J = 10.9 Hz), 7.44 (s, 10H, aromatic) ppm; 13C NMR
(125 MHz, D2O): δ = 21.87, 22.608, 29.54, 30.46, 44.94, 55.38, 62.43, 69.78, 73.36,
75.74, 79.13, 81.08, 97.82, 128.69, 128.78, 129.02, 129.11, 137.73, 137.96, 174.53,
175.12, 176.23 ppm; HR FAB MS [M+Na]+ calcd for C28H35NO11Na 584.2108, found
584.2104.

Methyl 4,6-O-(p-methoxybenzylidene)-2,3-di-O-tetradecanoyl-α-D-glucopyranoside
(6.15).
Myristoyl chloride (2.34 mL, 8.67 mmol) and DMAP (70 mg, 0.57 mmol) were added to
a stirred solution of methyl 4,6-O-p-anisylidene-α-D-glucoside 6.141 (1 g, 2.89 mmol) in
pyridine (15 mL) at 0°C. The mixture was stirred under an atmosphere of argon for 16 h.
Upon completion, the reaction mixture was concentrated in vacuo. The residue was
dissolved in CH2Cl2 (30 mL), and washed with 1N HCl (2 × 15 mL), distill water (2 ×
15 mL) and brine (15 mL). The organic phase was dried over MgSO4, filtered and
concentrated in vacuo. The residue was purified by column chromatography on silica gel
(ethyl acetate-hexane gradient elution) to afford derivative 6.15 (1.81 g, 2.48 mmol) as a
white foam in 86% yield. Rf = 0.47 (ethyl acetate-hexane 3/7, v/v) ); [α]D23 +23.56 (c =
1.0, CHCl3); 1H NMR (300 MHz, CDCl3) : δ = 0.88 (t, 6H, J = 7.02 Hz, 2×CH3), 1,26
(broad s, 40H, 20×CH2), 1.59 (m, 4H, 2×CH2), 2.29 (m, 4H, 2×CH2), 3.40 (s, 3H, OCH3),
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3.62 (dd, 1H, J4,5 = 9.7 Hz, H-4), 3.75 (dd, 1H, J6a,6b = 10.2 Hz, H-6a), 3.78 (s, 3H,
OCH3), 3.92 (m, 1H, H-5), 4.28 (dd, 1H, J5,6b = 4.7 Hz, H-6b), 4.82 – 2.94 (m, 2H, H-1,
2), 5.46 (s, 1H, >CHPh), 5.60 (dd, 1H, J3,4 = 9.7 Hz, H-3), 6.86 (d, 2H, J = 8.8 Hz,
aromatic), 7.25 (d, 2H, J = 8.7 Hz, aromatic) ppm;

13

C NMR (75 MHz, CDCl3): δ =

14.28, 22.86, 25.09, 25.28, 29.18, 29.22, 29.44, 29.47, 29.53, 29.63, 29.66, 29.83, 29.86,
32.09, 34.26, 34.46, 55.37, 55.49, 62.53, 68.76, 68.95, 71.58, 76.80, 77.23, 77.65, 79.46,
97.84, 101.62, 113.67, 127.59, 129.62, 160.22, 172.64, 173.39 ppm; HR FAB MS
[M+Na]+ calcd for C43H72O9Na 755.5074, found 755.5090.

Methyl 4-O-p-methoxybenzyl-3-O-tetradecanoyl-α-D-glucopyranoside (6.16).
A 1 M solution of borane/tetrahydrofuran complex in tetrahydrofuran (5 mL, 5 mmol)
was added to a benzylidene acetal 6.15 (0.75 g, 1.02 mmol) at room temperature under
nitrogen. The mixture was stirred for 10 min, and freshly dried copper (II)
trifluoromethanesulfonate (18 mg, 0.05 mmol) was added to the solution. After stirring
for 2 hours the mixture was cooled down to 0 °C, and the reaction was quenched by
sequential additions of triethylamine (TEA) (0.14 mL, 1 mmol) and methanol (1.8 mL).
The resulting mixture was concentrated at reduced pressure followed by co evaporation
with methanol. The residue was purified by flash column chromatography on silica gel to
give compound 6.16 (0.35g, 0.67 mmol) as white solid in 67% yield. Rf = 0.40 (ethyl
acetate-hexane 7/3, v/v) ); [α]D21 +78.50 (c = 1.0, CHCl3); 1H NMR (300 MHz, CDCl3) :
δ = 0.88 (t, 3H, J= 7.02 Hz, CH3), 1.24 (broad s, 20H, 10×CH2), 1.63 (m, 2H, CH2), 1.97
(broad s, 1H, OH), 2.23 – 3.82 (m, 3H, CH2, OH), 3.41 (s, 3H, OCH3), 3.52 -3.82 (m, 5H,
H-2, 4, 5, 6a, 6b), 3.79 (s, 3H, OCH3), 4.57 (dd, 2H, J = 12.4 Hz, CH2Ph), 4.75 (d, 1H,
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J1,2 = 3.7 Hz, H-1), 5.30 (dd, 1H, J = 9.1 Hz, H-3), 6.85 (d, 2H, J = 8.6 Hz, aromatic),
7.20 (d, 2H, J = 8.6 Hz, aromatic) ppm;
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C NMR (75 MHz, CDCl3): δ = 14.30, 22.86,

25.07, 29.31, 29.48, 29.52, 29.64, 29.79, 29.82, 29.85, 32.09, 34.68, 55.41, 55.53, 61.67,
71.04, 71.87, 74.33, 74.96, 99.65, 114.02, 129.63, 130.10, 159.54, 174.29 ppm; HR FAB
MS [M+Na]+ calcd for C29H48O8Na 547.3247, found 547.3254.

Methyl 6-O-(3-carboxypropanoyl)-4-O-p-methoxybenzyl-2,3-di-O-tetradecanoyl-αD-glucopyranoside (6.17).
DMAP (8.1 mg, 0.06 mmol) and succinic anhydride (67 mg, 0.67 mmol) were added to a
stirred solution of partially protected derivative 6.16 (0.35g, 0.67 mmol) in dry pyridine
(5 mL) at room temperature under argon. The reaction mixture was stirred for 16 h at
room temperature under argon. After 16 h, TLC indicated no further conversion of the
starting material. Myristoyl chloride (0.21 ml, 0.80 mmol) was added dropwise to the
reaction mixture. The reaction mixture was stirred for 2 h. Upon completion, the reaction
mixture was concentrated under reduced pressure, then the residue was dissolved in
CH2Cl2 (30 mL) and washed with 1N HCl (2 × 15 mL), distill water (2 × 15 mL) and
brine (15 mL). The organic phase was dried over MgSO4, filtered and concentrated in
vacuo. The residue was purified by silica gel column chromatography (ethyl acetatehexane gradient elution) to give compound 6.17 (0.43 g, 0.52 mmol) as white syrup in
79% yield. Rf = 0.55 (ethyl acetate-hexane 1/1, v/v); [α]D24 +42.45 (c = 1.0, CHCl3); 1H
NMR (300 MHz, CDCl3) : δ = 0.87 (t, 6H, 2×CH3), 1.25 (broad s, 40H, 20×CH2), 1.59
(m, 4H, 2×CH2), 2.26 (m,2H, CH2), 2.33 (m, 2H, CH2), 2.61 (m, 4H, 2×CH2), 3.36 (s,
3H, OCH3), 3.59 (dd, 1H, J4,5 = 9.5 Hz, H-4), 3.90 (m, 1H, H-5), 4.25 – 4.31 (dd, 2H,
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J5,6b = 4.4 Hz, J6a,6b = 11.5 Hz, H-6a, 6b), 4.44 (d, 1H, J2 = 10.65 Hz, ½ CH2Ph), 4.54 (d,
1H, J2 = 10.65, ½ CH2Ph), 4.87 (m, 2H, H-1, 2), 5.55 (dd, 1H, J3,4 = 9.5 Hz, H-3), 6.84
(d, 2H, J = 8.7 Hz, aromatic), 7.16 (d, 2H, J = 8.6 Hz, aromatic) ppm;
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C NMR (75

MHz, CDCl3): δ = 14.28, 22.85, 25.07, 28.82, 29.22, 29.35, 29.41, 29.45, 29.52, 29.60,
29.65, 29.81, 32.08, 34.20, 34.49, 34.30, 34.49, 55.37, 62.56, 68.56, 71.78, 71.89, 74.28,
75.72, 96.87, 114.04, 129.53, 129.76, 159.62, 171.67, 172.82, 173.68 ppm; HR FAB MS
[M+Na]+ calcd for C47H78O12Na 857.5391, found 857.5410.

Methyl 6-O-(4-((S)-2-(9-fluorenylmethoxycarbonyl)amino-3-(tert-butoxy)-3oxopropyl)oxy-4-oxobutanoyl)-2,3-di-O-tetradecanoyl-α-D-glucopyranoside (6.18).
DMAP (9.5 mg, 0.07 mmol) and DIC (0.12 mL, 0.78 mmol) were added to a stirred
solution of the O-tert-butyl-N-fluorenylmethoxycarbonyl-L-serine 6.9 (0.15 g, 0.39
mmol) in CH2Cl2 (3 ml). After 1 h, the carboxylic acid derivative 6.17 (0.39 g, 0.46
mmol) was added and the reaction was stirred for 5-9 h when TLC indicated no further
conversion of starting material to the major product. The reaction was diluted with
CH2Cl2 (20 mL), washed with distill water (2 × 10 mL) and brine (10 mL). The organic
phase was dried over MgSO4, filtered and concentrated in vacuo. The residue was
purified by silica gel flash column chromatography (ethyl acetate-hexane gradient
elution) to obtain compound 6.18 (0.38 g, 0.32 mmol) as white solid in 83 % yield. Rf =
0.5 (ethyl acetate-hexane 3/7, v/v) ); [α]D24 +25.72 (c = 1.0, CHCl3); 1H NMR (300 MHz,
CDCl3) : δ = 0.88 (t, 6H, J = 6.4 Hz, 2×CH3), 1.25 (broad s, 40H, 20×CH2), 1.49 (s, 9H,
t-Bu), 1.59 (m, 4H, 2×CH2), 1.59 (m, 4H, 2×CH2), 2.30 (m, 4H, 2×CH2), 3.37 (s, 3H,
OCH3), 3.48 (dd, 1H, J4,5 = 9.5 Hz, H-4), 3.76 (s, 3H, OCH3), 3.90 (m, 1H, H-5), 4.16-
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4.26 (m ,3H, H-6a, 6b, Ser-CβH), 4.35 – 4.55 (m, 6H, CH2Ph, Ser-CαH, Ser-CβH,
CH2Fmoc), 4.90 (m, 2H, H-1, 2), 5.58 (dd, 1H, J3,4 = 9.7 Hz, H-3), 5.82 (d, 1H, JNH,CH =
8.3 Hz, Ser-NH), 6.18 (d, 2H, J = 8.5 Hz, aromatic), 7.12 (d, 2H, J = 8.5 Hz, aromatic),
7.32 – 7.43 (m, 5H, aromatic), 7.63 (m, 2H, aromatic), 7.77 (d, 2H, J = 8.5 Hz, aromatic)
ppm;
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C NMR (75 MHz, CDCl3): δ = 14.25, 22.81, 25.00, 28.03, 28.76, 28.97, 29.27,

29.35, 29.43, 29.47, 29.62, 29.77, 32.04, 34.19, 34.44, 47.22, 54.02, 55.30, 62.58, 67.37,
68.53, 71.68, 71.88, 74.27, 83.04, 96.83, 113.95, 120.09, 25.40, 127.23, 127.84, 129.28,
129.62, 141.39, 143.98, 155.98,159.54, 168.44, 171.50, 172.72, 173.53 ppm; HR FAB
MS [M+Na]+ calcd for C69H101NO16Na 1222.7018, found 1222.7023.

Methyl

6-O-(4-((S)-2-(9-fluorenylmethoxycarbonyl)amino-2-carboxyethyl)oxy-4-

oxobutanoyl)-2,3-di-O-tetradecanoyl-α-D-glucopyranoside (6.19).
Methyl glucoside derivative 6.18 (0.2 g, 0.16 mmol) was dissolved in TFA/CH2Cl2 (1/5
v/v, 4 mL) and stirred for 2 h. Upon completion as assessed by TLC analysis, solvents
were evaporated in vacuo. The residue was dissolved in CH2Cl2 (5 mL) and neutralized
with triethylamine (TEA). Solvent were removed under the reduced the pressure. The
residue was subjected to column chromatography on silica gel (ethyl acetate-hexane 1/1,
v/v) to obtain product 6.19 (0.13 g, 0.12 mmol) as white foam in 75% yield. Rf = 0.5
(methanol-ethyl acetate 1/9, v/v) ); 1H NMR (300 MHz, CDCl3 ) : δ = 0.88 (t, 6H, J =
5.70 Hz, 2×CH3), 1.25 (broad s, 40H, 20×CH2), 1.58 (m, 4H, 2×CH2), 2.33 (m, 4H,
2×CH2), 3.27 (broad s, 4H, 2×CH2), 3.27 (broad s, 1H, OH), 3.38 (s, 3H, OCH3), 3.47
(dd, 1H, J4,5 = 9.4 Hz, H-4), 3.83 (m, 1H, H-5), 4.21 – 4.51 (m, 7H, H-6a, 6b, Ser-CβH2,
Ser-CαH, CH2Fmoc), 4.86 (m, 1H, H-2), 4.90 (broad s, 1H, H-1), 5.31 (dd, 1H, J3,4 = 9.1
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Hz, H-3), 5.96 (broad s, 1H, Ser-NH), 7.27 – 7.42 (m, 4H, aromatic), 7,61 (d, 2H, J = 6.9
Hz, aromatic), 7.76 (d, 2H, J = 7.5 Hz, aromatic) ppm; 13C NMR (75 MHz, CDCl3): δ =
25.03, 25.08, 28.93, 29.26, 29.30, 29.44, 29.54, 29.66, 29.83, 29.86, 32.10, 34.24, 34.47,
47.20, 55.46, 62.91, 64.33, 67.64, 69.36, 69.57, 69.89, 71.16, 72.73, 77.42, 96.84, 114.10,
120.18, 124.95, 125.29, 127.28, 127.95, 141.44, 143.83, 143.89, 171.67, 171.78, 174.31,
174.58, 175.10 ppm; HR FAB MS [M+Na]+ calcd for C57H85NO15Na 1046.5817, found
1045.5822. (See Appendix; Figure A-24, and A-25)

6.3.2

Biological assays

The biological activity testings of Lipid A analogues were performed by Geeta
Paranajape, Shana E. Terrill, and Maria L. D. Udan in the laboratory of Dr. MR Nichols
with the standard experiments.

Preparation of compounds for cellular treatment. Synthetic compounds in solid form
were dissolved in tetrahydrofuran (THF), aliquotted in small volumes, vacuumcentrifuged for 1 hour and stored at −80°C as dry compounds. For cellular treatment, an
aliquot was dissolved in an appropriate volume of dimethylsulfoxide (DMSO) (Fisher
Sci) to give a concentrated working stock solution. This stock solution was further diluted
in DMSO to give the desired concentration range. The final concentration of DMSO was
always maintained at 0.6%.

Cell culture. THP-1 cells were obtained from ATCC (Manassas, VA) and maintained in
RPMI-1640 culture medium (HyClone, Logan, UT) containing 2 mM L-glutamine, 25
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mM HEPES, 1.5 g/L sodium bicarbonate, 10% fetal bovine serum (FBS) (HyClone), 50
units/mL penicillin, 50 μg/mL streptomycin (HyClone), and 50 μM β-mercaptoethanol at
37°C in 5% CO2. For cellular assay, THP-1 monocytes were centrifuged and resuspended
in a fresh growth medium to a cell density of 5 x 105 cells/ml. Cell were then seeded in a
48-well plate and differentiated into adherent macrophages by treatment with 10 ng/ml
phorbol 12-myristate 13-acetate (PMA) (Sigma) for 24 hours at 37°C in5% CO2. The non
adherent cells were removed and the adherent cells were washed and replenished with
reduced FBS growth medium. For the two wells set aside for calculating percent
differentiation, the cells were washed with PBS (Hyclone) prior to removal by 0.25%
trypsin-EDTA. The adherent cells were counted under the microscope using
hemocytometer. Percentage of adherent cells was determined by dividing the number of
adherent cells by the number of plated cells. For the remaining wells, the cells were preincubated with LPS antagonist at different concentrations for 30 minutes followed by by
addition of 10 nM ultra pure LPS for 6 h at 37°C in 5% CO2. DMSO was used as a
negative control. The medium was collected and stores at -20°C until analyzed by ELISA
for TNFα production

XTT cell toxicity assay. Cellular toxicity was monitored using an XTT [2,3-bis(2methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide] cell assay. Estimate of
cellular metabolic activity was obtained by probing mitochondrial reduction of XTT
(Sigma) which in turn reflected the toxicity in response to LPS-antagonists. The cells
treated with LPS antagonists and ultrapure LPS were washed with PBS (Hyclone) and
then further incubated with XTT and phenazine methosulfate (PMS) (Acros, Morris

211

Plains, NJ) to a final concentration of 0.33 mg/mL and 8.3 μM respectively for 2 h at 37C
in 5% CO2. The cellular toxicity was then assessed based on the absorbance
measurement of the reduced XTT at 467 nm.
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Figure A-1: H NMR spectrum of Methyl O-(2,3,4,6-tetra-O-benzoyl-β-Dglucopyranosyl)-(1→6)-O-(2,3,4-tri-O-benzoyl-β-D-galactopyranosyl)-(1→6)-2,3,4-triΟ-benzyl-α-D-glucopyranoside (2.25)

CDCl3 75 MHz

Figure A-2: 13C NMR spectrum of Methyl O-(2,3,4,6-tetra-O-benzoyl-β-Dglucopyranosyl)-(1→6)-O-(2,3,4-tri-O-benzoyl-β-D-galactopyranosyl)-(1→6)-2,3,4-triΟ-benzyl-α-D-glucopyranoside (2.25)
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Figure A-3: 2-D NMR COSY spectrum of Methyl O-(2,3,4,6-tetra-O-benzoyl-β-Dglucopyranosyl)-(1→6)-O-(2,3,4-tri-O-benzoyl-β-D-galactopyranosyl)-(1→6)-2,3,4-triΟ-benzyl-α-D-glucopyranoside (2.25)
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Figure A-4: H NMR spectrum of 2-Thiazolinyl 2,3,4-tri-O-benzoyl-6-O-(2,3,4-tri-Obenzoyl-6-O-(2,3,4,6-tetra-O-benzoyl-β-D-glucopyranosyl)-β-D-glucopyranosyl)-1-thioβ−D-glucopyranoside (3.17c).
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Figure A-5: 13C NMR spectrum of 2-Thiazolinyl 2,3,4-tri-O-benzoyl-6-O-(2,3,4-tri-Obenzoyl-6-O-(2,3,4,6-tetra-O-benzoyl-β-D-glucopyranosyl)-β-D-glucopyranosyl)-1-thioβ−D-glucopyranoside (3.17c).
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Figure A-6: 2-D NMR COSY spectrum 2-Thiazolinyl 2,3,4-tri-O-benzoyl-6-O-(2,3,4-triO-benzoyl-6-O-(2,3,4,6-tetra-O-benzoyl-β-D-glucopyranosyl)-β-D-glucopyranosyl)-1thio-β−D-glucopyranoside (3.17c).

218

BzO
BzO

OBz
O
O
BzO BzO
BzO

O
O
BzO BzO
BzO
3.17d

O

N
S

BzO

O

CDCl3 500 MHz

Figure A-7: 1H NMR spectrum of Benzoxazol-2-yl 2,3,4-tri-O-benzoyl-6-O-(2,3,4-tri-Obenzoyl-6-O-(2,3,4,6-tetra-O-benzoyl-β-D-glucopyranosyl)-β-D-glucopyranosyl)-1-thioβ−D-glucopyranoside (3.17d).
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Figure A-8: 13C NMR spectrum of Benzoxazol-2-yl 2,3,4-tri-O-benzoyl-6-O-(2,3,4-triO-benzoyl-6-O-(2,3,4,6-tetra-O-benzoyl-β-D-glucopyranosyl)-β-D-glucopyranosyl)-1thio-β−D-glucopyranoside (3.17d).

219

BzO
BzO

OBz
O
O
BzO BzO
BzO

O
O
BzO BzO
BzO
3.17d

O

N
S

BzO

O

ppm
3.5

4.0

4.5

5.0

5.5

6.0

6.5

6.0

5.5

5.0

4.5

4.0

3.5

ppm

CDCl3 300 MHz

Figure A-9: 2-D NMR COSY spectrum of Benzoxazol-2-yl 2,3,4-tri-O-benzoyl-6-O(2,3,4-tri-O-benzoyl-6-O-(2,3,4,6-tetra-O-benzoyl-β-D-glucopyranosyl)-β-Dglucopyranosyl)-1-thio-β−D-glucopyranoside (3.17d).
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Figure A-10: 1H NMR spectrum of 2,3,4-Tri-O-benzoyl-β-D-glucopyranosyl-(1→6)-O2,3,4,6-tetra-O-benzoyl-β-D-glucopyranosyl)-(1→6)-O-(2,3,4-tri-O-benzoyl-β-Dglucopyranosyl)-(1→6)-2,3,4-tri-O-benzoyl-β-D-glucopyranosyl fluoride (3.20).
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Figure A-11: 13C NMR spectrum of 2,3,4-Tri-O-benzoyl-β-D-glucopyranosyl-(1→6)-O2,3,4,6-tetra-O-benzoyl-β-D-glucopyranosyl)-(1→6)-O-(2,3,4-tri-O-benzoyl-β-Dglucopyranosyl)-(1→6)-2,3,4-tri-O-benzoyl-β-D-glucopyranosyl fluoride (3.20).
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Figure A-12: 2-D NMR COSY spectrum of 2,3,4-Tri-O-benzoyl-β-D-glucopyranosyl(1→6)-O-2,3,4,6-tetra-O-benzoyl-β-D-glucopyranosyl)-(1→6)-O-(2,3,4-tri-O-benzoyl-βD-glucopyranosyl)-(1→6)-2,3,4-tri-O-benzoyl-β-D-glucopyranosyl fluoride (3.20).
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Figure A-13: 1H NMR spectrum of Ethyl O-(2,3,4-tri-O-benzoyl-β-D-glucopyranosyl)(1→6)-O-2,3,4,6-tetra-O-benzoyl-β-D-glucopyranosyl)-(1→6)-O-(2,3,4-tri-O-benzoyl-βD-glucopyranosyl)-(1→6)-O-(2,3,4-tri-O-benzoyl-β-D-glucopyranosyl)-(1→6)-2,3,4-triO-benzoyl-β-thio-D-glucopyranoside (3.22).
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Figure A-14: 13C NMR spectrum of Ethyl O-(2,3,4-tri-O-benzoyl-β-D-glucopyranosyl)(1→6)-O-2,3,4,6-tetra-O-benzoyl-β-D-glucopyranosyl)-(1→6)-O-(2,3,4-tri-O-benzoyl-βD-glucopyranosyl)-(1→6)-O-(2,3,4-tri-O-benzoyl-β-D-glucopyranosyl)-(1→6)-2,3,4-triO-benzoyl-β-thio-D-glucopyranoside (3.22).
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Figure A-15: 2-D NMR COSY spectrum of Ethyl O-(2,3,4-tri-O-benzoyl-β-Dglucopyranosyl)-(1→6)-O-2,3,4,6-tetra-O-benzoyl-β-D-glucopyranosyl)-(1→6)-O(2,3,4-tri-O-benzoyl-β-D-glucopyranosyl)-(1→6)-O-(2,3,4-tri-O-benzoyl-β-Dglucopyranosyl)-(1→6)-2,3,4-tri-O-benzoyl-β-thio-D-glucopyranoside (3.22).
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Figure A-16: H NMR spectrum of 4-Pentenyl O-(2,3,4-tri-O-benzoyl-β-Dglucopyranosyl)-(1→6)-O-2,3,4,6-tetra-O-benzoyl-β-D-glucopyranosyl)-(1→6)-O(2,3,4-tri-O-benzoyl-β-D-glucopyranosyl)
(1→6)-O-(2,3,4-tri-O-benzoyl-β-Dglucopyranosyl)-(1→6)-O-(2,3,4-tri-O-benzoyl-β-D-glucopyranosyl)-(1→6)-2,3,4-tri-Obenzoyl-β-D-glucopyranoside (3.24).

CDCl3 125 MHz

Figure A-17: 13C NMR spectrum of 4-Pentenyl O-(2,3,4-tri-O-benzoyl-β-Dglucopyranosyl)-(1→6)-O-2,3,4,6-tetra-O-benzoyl-β-D-glucopyranosyl)-(1→6)-O(2,3,4-tri-O-benzoyl-β-D-glucopyranosyl)
(1→6)-O-(2,3,4-tri-O-benzoyl-β-Dglucopyranosyl)-(1→6)-O-(2,3,4-tri-O-benzoyl-β-D-glucopyranosyl)-(1→6)-2,3,4-tri-Obenzoyl-β-D-glucopyranoside (3.24).
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Figure A-18: 2-D NMR COSY spectrum of 4-Pentenyl O-(2,3,4-tri-O-benzoyl-β-Dglucopyranosyl)-(1→6)-O-2,3,4,6-tetra-O-benzoyl-β-D-glucopyranosyl)-(1→6)-O(2,3,4-tri-O-benzoyl-β-D-glucopyranosyl)
(1→6)-O-(2,3,4-tri-O-benzoyl-β-Dglucopyranosyl)-(1→6)-O-(2,3,4-tri-O-benzoyl-β-D-glucopyranosyl)-(1→6)-2,3,4-tri-Obenzoyl-β-D-glucopyranoside (3.24).
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Figure A-19: 1H NMR monitoring of the conversion of thioglycoside 5.12b into
5.5a/5.5b.
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Figure A-20: 1H NMR monitoring of the conversion of thioglycoside 5.14a into
5.1a/5.1b.
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Figure A-21: 1H NMR monitoring of the conversion of thioglycoside 5.14b into
5.1a/5.1b.
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Figure A-22: 1H NMR spectrum of Lipid A analog 6.11.
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Figure A-23: 13C NMR spectrum of Lipid A analog 6.11.
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Figure A-24: H NMR spectrum of Lipid A analog 6.19.
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Figure A-25: 13C NMR spectrum of Lipid A analog 6.19.
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